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ABSTRACT 
The glucose transport protein, GLUT1, is highly expressed in rapidly proliferating cells, 
including cancer cells, while decreased GLUT1 levels are found in diseases such as 
GLUT1 deficiency syndrome and Alzheimer’s. There is increased interest in developing 
GLUT1 inhibitors as novel anticancer therapeutics, and the discovery of compounds that 
directly stimulate GLUT1 function. This work investigates how small molecules stimulate 
and/or inhibit GLUT1-mediated glucose transport, either directly or through the AMPK 
pathway. 
Using sugar transport assays and docking analyses to explore Ligand–GLUT1 interactions 
and specificity of binding, we show that: 1) Ligands inhibit GLUT1 by competing with 
glucose for binding to the exofacial or endofacial sugar binding sites; 2) Subsaturating 
inhibitor concentrations stimulate sugar uptake; 3) Ligands inhibit GLUT1–, GLUT3– and 
GLUT4–mediated sugar uptake in HEK293 cells; and 4) Inclusion of a benzonitrile head 
group on endofacial GLUT1 inhibitors confers greater inhibitory potency. 
Furthermore, we investigated AMPK-regulated GLUT1 trafficking in cultured blood-brain 
barrier endothelial cells, and show that inhibition of GLUT1 internalization is not 
responsible for increased cell surface levels of GLUT1 observed with AMPK activation in 
these cells. 
This study provides a framework for screening candidate GLUT1 inhibitors for specificity, 
and for optimizing drug design and delivery. Our data on transport stimulation at low 
inhibitor concentrations support the idea that GLUT1 functions as a cooperative oligomer 
of allosteric alternating access subunits.  
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CHAPTER I 
Introduction 
Solute transport across cell membranes 
The plasma membrane encloses all living cells and acts as a physical barrier that limits 
the movement of substances in and out of cells. This barrier function allows a cell to define 
and distinguish the contents of its interior, from the extracellular environment (1). The 
plasma membrane, like all other biological membranes, is a complex, dynamic non-
covalent macromolecular structure comprising a lipid bilayer containing embedded and 
membrane-spanning proteins. The lipid bilayer comprises amphipathic phospholipids 
arranged in such a way that the nonpolar fatty acid tails self-associate to form a 
hydrophobic interior of about 2 – 3 nm in thickness, shielded from the polar interstitial and 
cytoplasmic environments by their hydrophilic phosphate head groups (1). 
Simple diffusion 
Given enough time, virtually all substances will diffuse across an artificial lipid bilayer down 
an electrochemical gradient (1). The ability of a molecule to diffuse across the plasma 
membrane and enter into the cell depends on its size and relative hydrophobicity (1,2). 
Small nonpolar molecules (e.g. carbon dioxide, oxygen, benzene, and steroid hormones) 
cross lipid membranes readily by simple diffusion. Small uncharged polar molecules (e.g. 
ethanol, water and glycerol) also diffuse across lipid membranes but slowly. In contrast, 
larger uncharged polar substrates (e.g. glucose, amino acids and nucleotides) and 
charged ions (e.g. H+, Na+, K+, and Cl-) are unable to cross lipid membranes by simple 
diffusion (1,2). 
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Protein-mediated transport 
Cells utilize specialized membrane proteins which span the membrane to facilitate the 
rapid transbilayer movement of hydrophilic molecules and ions, which otherwise could not 
cross the cell membranes by simple diffusion at physiologically meaningful rates. This 
protein-mediated transport system creates a path for polar solutes to cross cells 
membranes without interacting directly with the hydrophobic interior of the lipid bilayer 
(1,3). Membrane transport proteins can be classified into 2 major classes: 1) channels and 
2) transporters. 
Channels form narrow and highly selective hydrophilic pores across cell membranes 
which allow rapid passage of specific solutes in the order of tens of millions per second 
(4). The most characterized channels include: 1) ion channels, that transport specific 
inorganic ions (e.g. Na+, K+, Ca2+ and Cl-), and 2) aquaporins, water channels, which allow 
rapid transport of water but exclude ions (2). Unlike the aquaporins, ion channels are 
gated, and they open and close rapidly in response to signals such as voltage, mechanical 
stress or binding of a ligand (1). Transporters, on the other hand, move specific substrates 
or a class of substrates across cell membranes by undergoing substrate-induced 
conformational changes that shuttle substrates between either side of the membrane. 
Unlike most transporters, channels interact with transported solutes with low affinity but 
are able to transport solutes at much faster rates, typically more than 1,000-fold greater 
than transporters (5). This may simply reflect selective pressure to transport cations at 
prevailing substrate levels (high mM) and at rates compatible with function (e.g. allow the 
conduction of action potentials). Another striking difference between transporters and 
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channels is that channels can only mediate passive transport of solutes, while transporters 
facilitate both passive and active transport (1,3,6). 
Passive versus active transport 
Passive transport describes the net movement of solutes down a concentration gradient 
(or electrochemical gradient for charged solutes), while active transport describes the net 
transport of solutes against a concentration or electrochemical gradient and requires 
energy input (1,6). The free energy source for active transport is either derived directly 
from transporter-catalyzed ATP hydrolysis (primary active transport; e.g., Na+–K+ ATPase) 
or indirectly (secondary active transport) by coupling the uphill transport of substrate to 
the downhill transport of a second solute (usually a cation) down an electrochemical 
gradient established by the action of a primary active transporter (7). Secondary active 
transporters can either mediate the cotransport of 2 different solutes in the same direction 
(symporters; e.g., Na+–dependent glucose cotransporters [SGLTs]) or in different 
directions (antiporters; e.g., Na+–Ca2+ and Na+–H+ exchangers). Symporters and 
antiporters dependent on the electrochemical gradients created and maintained by 
primary active transporters (e.g., Na+ gradients generated by Na+–K+ ATPase). 
Transporters that catalyze passive transport of a single solute down its concentration 
gradient are referred to as uniporters (e.g., glucose transporter proteins [GLUTs]) (1,6). 
Clinical relevance of membrane transport proteins 
The biological significance of membrane transport proteins is revealed in various inherited 
human diseases caused by mutations that impair transport of specific solutes by their 
transporters. Mutations in the glucose transporter 1 (GLUT1), stymies the import of 
 4 
glucose into the brain, resulting in GLUT1–deficiency syndrome, characterized by retarded 
mental development with manifestations such as abnormally small head, ataxia and 
seizures (8-10). Mutations in the genes (SLC7A9 and SLC3A1) encoding transporter 
proteins responsible for cysteine transport from urine to the blood causes accumulation of 
cysteine in urine (cystinuria), which results in the formation of cysteine stones in kidneys 
and ultimately kidney damage if not properly treated (11). Point mutations in the 
membrane transport protein cystic fibrosis membrane conductance regulator protein 
(CFTR), which mediates chloride ion transport across plasma membranes of epithelial 
cells, cause reduced transporter activity or prevent CFTR expression at the cell surface 
and give rise to cystic fibrosis (12). 
Glucose transport across cell membranes 
Three families of glucose transport proteins have been identified in humans: 1) the 
facilitative glucose transporters, GLUTs (SLC2); 2) the secondary active sodium– 
dependent glucose transporters, SGLTs (SLC5); and 3) the recently identified sugars will 
eventually be exported transporters, SWEETs (SLC50) (13-16). GLUTs catalyze the 
passive, facilitative transport of glucose down its concentration gradient, and mediate 
sugar transport in almost all mammalian cells (5). SGLTs couple the energy released from 
the flow of Na+ down its concentration gradient to the uphill transport of glucose across 
cell membranes, and are primarily responsible for the absorption and reabsorption of 
glucose at the mucosal membranes of the small intestine and kidney respectively (16,17). 
SWEETs, found in animals, plants and bacteria, have been shown to catalyze the 
facilitative diffusion of sugars across the plasma membrane and endoplasmic reticulum 
membrane in plants, but their physiological role in mammals is still uncharacterized 
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(15,18). Figure 1.1 shows a model for cellular transport of glucose in humans, depicting 
the roles (or possible roles, as in the case of SWEETs) of each of these glucose transport 
proteins. 
The glucose transporter (GLUT) proteins 
The GLUT proteins belong to the major facilitator superfamily (MFS) of proteins which are 
ubiquitously expressed in living organisms, and transport a wide range of substrates 
including sugars, ions, drugs and toxins (19,20). There are 14 members of the GLUT 
protein family (GLUT1 – 12, 14 and HMIT) – each containing ~500 amino acids, and 
sharing an overall sequence identity of 25% – 68% (13,21). Hydropathy plot analysis 
reveals that GLUT proteins, like other members of the MFS superfamily, contain 12 
transmembrane (TM) domains, with intracellular N– and C–termini and a single exofacial 
glycosylation site at either loop 1 (between TM1 and TM2) or loop 9 (between TM9 and 
TM10) (5,22). Like the rest of the MFS transporter proteins, GLUTs are divided into 2 
symmetrical halves connected by a large intracellular loop between TM6 and TM7 (22,23). 
The GLUT proteins contain a highly conserved RXGRR/K motif between TM2 and TM3, 
which is thought to maintain their proper topology within the membrane (24). Additionally, 
the GLUTs contain sugar-transporter signature motifs which appear to be important for 
substrate/inhibitor sensitivity and selectivity. These include: PMY (in TM4), PESPRY/FLL 
(in loop 6), QQLSGIN (in loop 7), GXXXXP (in TM10), and VPETKG (in the C-terminus) 
(25). Based upon sequence similarity analysis, GLUTs are subdivided into 3 classes. 
Class 1 comprises GLUT1–4 and GLUT14; Class 2 comprises GLUT5, 7, 9 and 11; and 
Class 3 comprises GLUT6, 8, 10, 12 and HMIT1 (21). Table 1.1  
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Figure 1.1: A model for cellular glucose transport mediated by different glucose transport 
proteins in human intestinal epithelial cells 
 
Glucose (glc) from the small intestinal lumen is taken up into the cytoplasm of enterocytes by 
the Na+–dependent glucose transporter, SGLT1. Cytoplasmic glc is either transported out of the 
cell by passive diffusion mediated by the facilitative glucose transporter, GLUT2 or  
phosphorylated by hexokinase to form glucose-6-phosphate (Glc-6-P). Glc-6-P, especially in the 
liver, and during gluconeogenesis can be shuttled into the endoplasmic reticulum (ER) lumen by 
the antiporter, glucose-6-phosphate translocase (26), where Glc-6-P is dephosphorylated and 
glucose shuttled back into the cytoplasm by GLUTs, probably by GLUT8 (27). Although the role 
of SWEETs in mammalian cells is still unclear, SWEET proteins are localized to the Golgi in 
mammalian cells, suggesting a possible role for this glc transporter in the Golgi (18). 
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shows the classification of human GLUTs, their characteristics and their tissue distribution. 
With the exception of HMIT (a H+/myo-inositol symporter), all GLUTs transport glucose, 
fructose, or both sugars (13). The crystal structures of human GLUT1 (28,29) and GLUT3 
(30) were recently reported. These, together with the crystal structures of Bos taurus and 
Rattus norvegicus GLUT5 (31), and their bacterial homologs XylE (32-34) and GlcP (35), 
provide structural insights to the transport mechanisms of the GLUT proteins. 
The Na+–dependent glucose cotransporter (SGLT) proteins 
SGLTs belong to the amino acid-polyamine-organocation (APC) superfamily of 
transporter proteins containing 5+5 or 7+7 inverted repeat folds (36). Unlike the GLUTs, 
SGLTs are secondary active glucose transporters that cotransport the uphill flow of 
glucose and downhill flow of Na+ in the same direction, by harnessing the free energy of 
the Na+ electrochemical gradient to transport of glucose against its concentration gradient 
(17). The favorable Na+ electrochemical gradient exploited by SGLTs is created and 
maintained by Na+–K+ ATPase (1). Six SGLT proteins (SGLT1–6) have been identified in 
humans which share amino acid sequence identity of 21% – 70% with SGLT1 (14,17). 
SGLTs contain 580 – 718 amino acid residues and are predicted to have 14 
transmembrane helices (37). The best-characterized members of the SGLT proteins are 
SGLT1 and SGLT2 (16). SGLT1, a high affinity glucose and galactose transporter (Km = 
0.5 – 1 mM) (38,39), is primarily expressed in the small intestine where it mediates the 
absorption of glucose and galactose from the intestinal lumen (17). Relative to SGLT1, 
SGLT2 is a low affinity glucose transporter (Km for glucose = 5 mM (39)) and is 
predominantly expressed in the kidney cortex where it facilitates the concentrative 
reabsorption of glucose from the glomerular filtrate (17). Unlike SGLT1, SGLT2 does not  
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Table 1.1: Classification, tissue distribution and characteristics of GLUT proteins 
Isoform Class 
Amino acid 
residues & 
(molecular 
weight) 
Substrate 
Km 
(mM) 
Tissue 
distribution 
Ref. 
GLUT1 1 492 (54 kDa) 
Glucose 
Galactose 
Glucosamine 
DHA 
Mannose 
3–7 
17 
2.5 
1.1 
20 
Ubiquitous 
expression 
(40-42) 
GLUT2 1 524 (55 kDa) 
Glucose 
Fructose 
Galactose 
Glucosamine 
Mannose 
17 
76 
92 
0.8 
125 
Liver, kidney, small 
intestine, pancreas 
(40,43-
45) 
GLUT3 1 496 (45 kDa) 
Glucose  
Galactose 
1.4 
8.5 
Brain, testis, 
leukocytes 
(44,46,47) 
GLUT4 1 509 (55 kDa) 
Glucose 
Glucosamine 
DHA 
5 
3.9 
0.98 
Muscle, fat, heart (48,49) 
GLUT5 2 501 (55 kDa) 
Fructose 6 Kidney, intestine, 
testis 
(50-52) 
GLUT6 3 507 (46 kDa) 
Glucose  Brain, spleen, 
leukocytes 
(53,54) 
GLUT7 2 524 (53 kDa) 
Fructose 
Glucose 
0.2 
0.3 
Small intestine, 
testis, colon, 
prostate 
(54,55) 
GLUT8 3 477 (51.5 kDa) 
Glucose 2 Brain, testis, liver, 
lung, fat, spleen,  
(56) 
GLUT9 2 
511 (66 kDa) 
540 (46 kDa) 
Urate 
Fructose 
Glucose 
0.9 
0.42 
0.61 
Kidney, liver, 
pancreas, placenta 
(57,58) 
GLUT10 3 541 (57 kDa) 
Glucose 
Galactose 
0.3 Brain, liver, heart, 
lung, pancreas, 
muscle, kidney, 
placenta 
(59,60) 
GLUT11 2 496 (54 kDa) 
Fructose 
Glucose 
0.16 
0.16 
Kidney, heart, fat, 
muscle, placenta, 
pancreas 
(61-64) 
GLUT12 3 617 (67 kDa) 
Glucose  Heart, fat, muscle, 
small intestine, 
placenta, prostate 
(65) 
HMIT 3 618 (69 kDa) Myoinositol 0.1 Brain (66) 
GLUT14 1 497 (N/A) 
520 (N/A) 
N/A  Testis (67) 
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transport galactose efficiently (Km for galactose > 100 mM) (39). Mechanistically, SGLT1 
couples the transport of 2 Na+ ions with the transport of 1 glucose molecule, while SGLT2 
couples the transport of 1 Na+ ion to each transported glucose molecule (17). Only one 
SGLT crystal structure is available and this structure is of the bacterial homolog vSGLT 
(68,69) 
SWEET proteins 
The SWEET protein family is a recently discovered, diverse family of glucose transport 
proteins, belonging to the transporter-opsin-G protein-coupled receptor (TOG) superfamily 
(70). Eukaryotic SWEETs have 7 transmembrane domains arranged in a 3+1+3 repeat 
(70), whereas most bacterial SWEETs (commonly referred to as SemiSWEETs) contain 
only 3 TMs (15). While an average of 20 SWEET paralogs are found in plants, only 1 
SWEET gene has been identified in animals (except for Caenorhabditis elegans with 7 
SWEET paralogs) (15). In plants, SWEETs are localized to different cellular 
compartments, including: the plasma membrane (71-74), Golgi (73,74), and tonoplast 
(75,76) where they mediate the transport of sucrose and hexose (15). Although animal 
SWEETs have been shown to transport glucose (18), the physiological role of SWEET in 
mammals is yet to be characterized (15). No mammalian crystal structures of SWEETs 
have been resolved yet, but different crystal structure conformations of their bacterial 
homologs have recently been reported (77-79). These structures reveal that a single 
protomer of SemiSWEET is incapable of forming a functional transporter by itself, so two 
protomers dimerize in these crystal structures, suggesting that the dimer is the basic 
functional unit of SemiSWEETs (77-79). 
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Kinetic and structural characteristics of GLUT1 
The kinetics of GLUT1–mediated sugar transport are analogous to those of enzyme 
catalyzed reactions. Accordingly, enzyme kinetics principles, such as Michaelis–Menten 
kinetics, are used to define the catalytic properties of GLUT1-mediated sugar transport 
(6). Being a passive transporter, GLUT1 mediates both unidirectional sugar uptake and 
exit. Net transport is a vector – the sum and net direction of unidirectional uptake and exit. 
Thus, if net transport is positive, unidirectional uptake is greater than exit. If net transport 
is negative, unidirectional uptake is less than exit. At equilibrium, when intracellular 
[glucose] = extracellular [glucose], net transport is zero because unidirectional uptake and 
exit are identical. 
Affinity for substrate 
GLUT proteins have affinities for sugars (measured as apparent Km for transport (Km(app))), 
that are commensurate with the extracellular sugar concentration of their respective 
environments. Km(app) for GLUT1 (3–7 mM) and GLUT4 (5 mM) is comparable to serum 
glucose concentration of 4–6 mM under normal physiologic conditions (25,80). Neuronal 
GLUT3 has a Km of 1.4 mM, consistent with the brain interstitial fluid glucose concentration 
of 1–2 mM (81). The glucose concentration in human liver is > 10 mM (82), which 
rationalizes why the Km for hepatic GLUT2 is ~ 17 mM (25). 
Although GLUT1 also transports galactose, glucosamine and L-dehydroascorbic acid 
(DHA) (40,83-85), the main physiological substrate of GLUT1 is glucose (21). Biochemical 
studies have demonstrated that GLUT1 sugar binding sites interact with hydroxyl groups 
on glucose through hydrogen bonding (86-88). Hydrogen bonds with C1 and C3 hydroxyls 
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of glucose are required for binding to the exofacial sugar site. Hydrogen bonding with C4 
hydroxyl group enhances affinity for the exofacial sugar site, while C6 hydroxyl group is 
not important for substrate interaction at the exofacial sugar binding site (86-88). 
Conversely, hydrogen bonding with C3 and C6 hydroxyl groups of glucose are needed for 
interaction with the endofacial sugar site, while C1 hydroxyl is not required (86-88). 
Asymmetry of GLUT1-mediated glucose transport 
Sugar transport is described as asymmetric when Km and Vmax, for sugar influx into sugar-
free cells (zero-trans uptake) and sugar efflux into sugar-free medium (zero-trans exit) are 
different. Transport asymmetry is observed with GLUT1-mediated glucose transport in 
human red blood cells where Km and Vmax for glucose exit are 5 – 10 times greater than 
Km and Vmax for uptake (89,90). Asymmetry is pronounced at low temperatures. At 4ºC, 
the Vmax for exit is 10-fold greater than Vmax for uptake, but as temperature increases Vmax 
and Km for uptake increase, and asymmetry falls (91). Cytoplasmic ATP has been shown 
to contribute to transport asymmetry observed with GLUT1 (92). Depletion of intracellular 
ATP results in loss of transport asymmetry with Km and Vmax for sugar uptake approaching 
the values for sugar exit (92). The physiological relevance of GLUT1 asymmetry may be 
that it allows cells to equilibrate more rapidly with extracellular sugar (93). 
Trans-acceleration 
Trans-acceleration or accelerated exchange transport describes a phenomenon whereby 
the presence of sugar at the opposite (trans) side of the membrane increases the rate of 
unidirectional sugar transport from the other (cis) side of the membrane (6,93). Trans-
acceleration has been shown in human erythrocytes where intracellular glucose stimulates 
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the rate of unidirectional glucose uptake, and extracellular glucose increases the rate of 
unidirectional glucose exit (94,95). Unlike GLUT1, GLUT4 does not show trans-
acceleration (96). By swapping transmembrane (TM) domains between GLUT1 and 
GLUT4 using homology scanning mutagenesis, Vollers and Carruthers show that TM6 in 
GLUT1 is important for trans-acceleration (97). Trans-acceleration, just as with asymmetry 
can accelerate the rate at which a cell equilibrates with extracellular glucose (97). 
Structure of GLUT1 
GLUT1 comprises 492 amino acid residues (molecular weight = 54 kDa), and forms 12 
transmembrane α-helices (TMs) with both the N– and C–termini located within the 
cytoplasm (13,21,98). Like other class I GLUTs, GLUT1 has a single N-glycosylation site 
(Asn45) in loop 1, which is heterologously glycosylated causing the protein to appear as 
a smeared band running from 45 – 65 kDa when resolved by SDS-PAGE and Western 
blot (99). Deglycosylation does not interfere with GLUT1 targeting to the plasma 
membrane but reduces glucose uptake and affinity for glucose (100). 
The crystal structure of human GLUT1, capturing the inward–open conformation, was first 
reported in 2014 (28). This structure confirms the following predictions of GLUT structure 
based on the structures of prokaryotic MFS homologs, XylE, GlpT and LacY (32,101,102): 
1) GLUT1 contains 12 TMs; 2) These TMs are divided into 2 symmetrical halves 
connected by a large intracellular loop (now referred to as intracellular helices, ICH); 3) 
TMs in GLUT1 are organized in a similar way as XylE; and 4) GLUT1 also share the MFS 
fold with its bacterial homologs. TM arrangement and GLUT1 structure is shown in figure 
1.2. Since 2014, the number of GLUT crystal structures has been steadily growing, with 3   
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Figure 1.2: Structure of human GLUT1 
 
A, Arrangement of the 12 transmembrane helices (TM) of GLUT1, as refined by the recent crystal 
structure shown in B. The 12 TMs are divided into 2 symmetrical halves, N–domain (cyan) and 
C–domain (grey), and connected by the intracellular helices (ICH; gold) domain. B, Crystal 
structure of human GLUT1 (PDB code: 4PYP) 
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more inward–open human GLUT1 structures, 3 human GLUT3 crystal structures captured 
in the outward–open and outward–occluded conformations, and bovine and rat GLUT5 
captured in the inward–open and outward–open conformations respectively (29-31). 
Mechanisms of GLUT1–mediated sugar transport 
Two prevailing models have been proposed for how GLUT1 mediates sugar transport: 1) 
Alternating access transporter (AAT) model, and 2) Fixed-site transporter (FST) model. 
The alternating access transporter model argues that the transporter alternately presents 
either the exofacial or endofacial sugar binding site at any instant (95,103-105). 
Accordingly, the carrier must undergo cycles of reversible conformational change between 
the exofacial and endofacial states whether sugar is bound or absent. Thus, sugar bound 
to the transporter at one side of the membrane is translocated to the other side via this 
alternating access mechanism. Conformational reorientations of the carrier between the 
two sides of the membrane in the presence of bound sugar is termed “translocation,” and 
in the absence of sugar is called “relaxation” ((3,5); figure 1.3A). 
The fixed-site transporter model depicts a carrier that simultaneously exposes the 
exofacial and endofacial sugar binding sites (89,106,107). Hence, the transporter must 
allow sugars bound at both sugar binding sites to bypass each other as they translocate 
in opposite directions ((5); figure 1.3B). 
Early biochemical evidence to support the AAT model came from equilibrium ligand 
binding experiments to purified GLUT1 isolated from human erythrocytes in the presence 
of reducing agents. These studies showed that the stoichiometry of binding between 
GLUT1 and cytochalasin B (CB; an endofacial GLUT1 ligand) is 1:1, and the carrier   
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Figure 1.3: The Alternating Access Transporter (AAT) and the Fixed Site Transporter (FST) 
 
A, The AAT. The carrier alternates between conformations exposing an exofacial sugar binding 
site (e2) and an endofacial sugar binding site (e1). Extracellular inhibitor (L2) and extracellular 
sugar (S2) compete for binding to e2. Intracellular inhibitor (L1) and intracellular sugar (S1) 
compete for binding to e1. Conformational changes between e2 and e1 are called "translocation" 
when sugar is bound and "relaxation" when no sugar is bound. B, The FST. The carrier, e, 
presents exofacial and endofacial sugar binding sites simultaneously. Extracellular sugar (S2) 
and inhibitor (L2) compete for binding at the exofacial site. Intracellular sugar (S1) and inhibitor 
(L1) compete for binding at the endofacial site. The carrier can form ternary complexes with intra- 
and extracellular sugars (S2.e.S1, intra- and extracellular inhibitors (L2.e.L1), or with sugars and 
inhibitors (L2.e.S1, S2.e.L1). 
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presents no exofacial ligand binding site in the presence of saturating CB concentrations 
(108-110). This observation is refuted by CB binding studies to purified human erythrocyte 
GLUT1 isolated in the absence of reductants, which show that 2 molecules of GLUT1 are 
needed to bind 1 molecule of CB, consistent with the FST model (111-115). Additionally, 
equilibrium binding of CB to intact human erythrocytes in the presence of exofacial 
inhibitors (maltose, phloretin, and ethylidene glucose) reveal a behavior consistent with 
the FST model (116). 
Sugar transport measurements in the presence of both endofacial and exofacial GLUT1 
inhibitors provided another biochemical strategy to test the GLUT1 sugar transport 
models. By performing glucose efflux experiments in human red blood cells, in the 
presence of CB and phloretin (an exofacial GLUT1 inhibitor), Krupka and Deves (104) 
demonstrated that the exofacial and endofacial sugar binding sites in GLUT1 are mutually 
exclusive, and concluded (provided that binding of endofacial and exofacial ligands is not 
characterized by negative cooperativity) that GLUT1 functions as a simple carrier (104). If 
the AAT model is correct, then CB and phloretin should compete with each other for 
binding to GLUT1, such that the presence of another inhibitor acting at the opposite side 
of the membrane increases the apparent inhibitory constant (Ki(app)) for glucose transport 
by the first inhibitor (117,118), but this was not observed by Krupka and Deves (104). On 
the basis that phloretin behavior deviates from that of a simple exofacial inhibitor (117), 
Carruthers and Helgerson performed glucose uptake by human RBCs in the presence of 
maltose (an exofacial GLUT1 inhibitor) and CB and showed these ligands simultaneously 
bind to GLUT1, but that the binding of these ligands displays negative cooperativity (118). 
This was exactly the finding required to negate the conclusions of Krupka & Deves (104) 
and affirms the FST model (118). 
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The aforementioned biochemical data lend support to the FST model, by revealing that 
the exofacial and endofacial sugar binding sites coexist in GLUT1 at any instant. However, 
recent crystal structures of human GLUT1 and GLUT3, the mammalian homologs of 
GLUT5, as well as the bacterial homologs, XylE, LacY and GlcP all suggest that GLUT1 
functions as a simple, alternating access transporter (28-32,101). Put together, these 
crystal structures demonstrate that GLUT1 cycles between at least 4 different 
conformations including the outward-open, outward-occluded, inward-occluded and 
inward-open conformations (30,119). These structural data, together with the biochemical 
data obtained with purified GLUT1, strongly suggest that each monomer of GLUT1 is a 
functional unit, capable of binding substrates and functions as an alternating access 
transporter. However, the biochemical evidence obtained from membrane-bound GLUT1 
suggests that GLUT1 functions as a more complex carrier than what the alternating 
access transporter model proposes. 
A unifying model that incorporates evidence for both the AAT and FST models, views 
GLUT1 as a homotetramer of alternating access carriers which simultaneously presents 
2 exofacial and 2 endofacial sugar binding sites (120-122). This conclusion is reinforced 
by the observations that, cell membrane GLUT1 exists as homodimers and tetramers 
(113-115,123) and that GLUT1 exhibits trans- and cis-allostery (121,122,124). 
Regulation of GLUT1 function 
Glucose uptake is rate limiting in cells (e.g. adipocytes, cardiomyocytes, astrocytes and 
neurons) where rates of glucose metabolism can exceed rates of basal glucose transport. 
In these cells, the rate of net glucose uptake is rapidly stimulated in response to increased 
glucose utilization (125-127). For instance, GLUT4–mediated glucose uptake in muscle 
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and fat is stimulated by up to 50-fold in response to insulin or cellular metabolic depletion 
(96,125,126,128,129). 
GLUT1–mediated glucose transport in mature human erythrocytes and endothelial cells 
occur at rates 50– to 500–fold greater than glucose utilization rates (130,131). In spite of 
this, erythrocytes and endothelial cell GLUT1 are subject to physiologic regulation by 
factors including ATP, hypoglycemia, hypoxia and growth factors (132-135). Control of 
GLUT1-mediated glucose transport can occur by modulation of GLUT1 intrinsic activity, 
as observed in human erythrocytes (111,136,137), and/or by modulating cell surface 
content of GLUT1 as seen in endothelial cells (132,133). 
Regulation of GLUT1 activity by ATP 
GLUT1 is an ATP–binding protein with no ATPase activity (138,139). ATP depletion 
enhances the sugar-import capacity of human erythrocyte GLUT1 or GLUT1 
heterologously expressed in cultured cells, by increasing the Km and Vmax of sugar uptake 
(111,137,140-143). Conversely, cytoplasmic ATP inhibits GLUT1–mediated glucose 
transport by decreasing Vmax and Km for net sugar uptake, Vmax for net sugar exit, and Km 
for equilibrium exchange transport (144,145). ATP regulates GLUT1–mediated glucose 
transport by interacting at an intracellular nucleotide binding site located within the 
cytoplasmic loop 8 in GLUT1 (138,146). ATP modulation of GLUT1 is competitively 
inhibited by AMP, ADP and H+ (139,140). 
Regulation of GLUT1 activity by cellular metabolic state and AMPK 
Mature human erythrocytes lack the machinery to regulate GLUT1 expression and cell 
surface translocation, but GLUT1 in endothelial cells is subject to control by the metabolic 
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status of the cell (5). Conditions of cellular energy (ATP) depletion, including 
hypoglycemia, hypoxia and mitochondrial poisoning, increase the Vmax of GLUT1-
mediated glucose uptake, without altering the cell’s affinity for glucose (Km for transport is 
unchanged) (132,147,148). This increased glucose uptake results from increasing cell 
surface content of GLUT1 and is dependent on activation of AMP-activated kinase 
(AMPK) (149-152). AMPK is a cellular energy-sensing kinase that becomes activated by 
an increase in intracellular AMP:ATP ratio (153). When activated, AMPK phosphorylates 
many targets in different metabolic pathways to decrease active ATP consumption and 
replenish depleted cellular energy (154). AMPK activation controls the cell surface 
localization of GLUT1 in endothelial cells during acute metabolic stress (151), and has 
been shown to upregulate increased GLUT1 mRNA transcription and protein expression 
under chronic metabolic stress conditions (155,156). 
Mechanisms of AMPK-regulated GLUT4 trafficking in insulin-sensitive tissues, including 
fat and skeletal muscle, have been extensively studied. Reports indicate that AMPK 
inhibits GLUT4 endocytosis in adipocytes (157), whereas in skeletal muscle AMPK inhibits 
endocytosis (157) and stimulates exocytosis of GLUT4 (158,159). AMPK appear to 
stimulate GLUT4 exocytosis by directly phosphorylating the Rab–GAP proteins, TBC1D1 
and TBC1D4 (160,161). It is not clear if AMPK regulates endothelial cell GLUT1 via 
mechanisms previously described in fat and skeletal muscle. A recent report showed that 
AMPK inhibits GLUT1 endocytosis in primary rat hepatocytes and in the liver 
hepatocellular carcinoma cell line, HepG2 cells, through a TXNIP-dependent mechanism 
(162). 
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Small molecule modulation of GLUT1 activity 
A wide range of structurally unrelated compounds have been shown to inhibit GLUT1–
mediated glucose transport. These include naturally-occurring, and extensively 
characterized compounds, such as cytochalasin B (CB) (117,163), phloretin (117,164) and 
maltose (118), as well as recently reported synthetized small molecules such as WZB117 
(165), STF-31 (166) and BAY-876 (167). CB, for example, is a cell membrane permeable 
endofacial GLUT1 inhibitor (apparent inhibitory constant, Ki(app) = 140 – 300 nM) (117), 
and until recently, was the most potent inhibitor of GLUT1 known. CB, phloretin and 
maltose have been used as tools to extensively study the structure, function and regulation 
of GLUT1. The observation that GLUT1 expression is highly upregulated in various forms 
of cancer, has made GLUT1 an attractive target for the development of novel anticancer 
therapeutics. CB and phloretin cannot be used as anticancer therapeutics because of their 
numerous off target effects. CB, for instance, interferes with actin filament polymerization, 
cell division, as well as blood clotting (168,169). In addition to characterizing the new 
generation of GLUT1 inhibitors, they can be used as tools to further understand the 
function and regulation of GLUT1. 
Physiological and pathological roles of GLUT1 
GLUT1 is ubiquitously expressed, usually at low levels, in virtually all mammalian cells, 
and is thought to facilitate basal glucose transport needed for respiration in mammalian 
tissues (170). 
GLUT1 plays a crucial role in distributing absorbed glucose to peripheral tissues and the 
central nervous system. GLUT1 is expressed at the highest levels in erythrocytes of 
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primates and in other species with high brain to body mass ratios (171). It is possible, 
therefore, that the physiological role of the erythrocyte not only includes O2 and CO2 
transport but also glucose transport to and from metabolically active tissues like the brain 
and placenta (93,172). For glucose to enter the brain, it must first transverse the 
endothelial cells of the blood-brain barrier, through a process mediated by GLUT1 (127). 
GLUT1 is also involved in regulating blood glucose in humans. GLUT1 is the major 
glucose transporter expressed in the α- and ß-cells of human pancreas (173-175). This is 
in contrast to rodent pancreatic α- and ß-cells, which express GLUT2 (173). These cells 
are responsible for hormone secretion in response to changes in blood glucose levels – 
α-cells secrete glucan in response to reduction of blood glucose, while ß-cells release 
insulin during hyperglycemia, to increase glucose uptake by fat and muscle. As the major 
GLUT in α- and ß-cells, GLUT1 indirectly regulates glucose levels in the blood (176,177). 
Elevated expression of GLUT1 in proliferating cells and activated immune cells may play 
a physiological role in reprogramming glucose metabolism by enabling these cells to 
switch to, and sustain aerobic glycolysis which is essential, not only for ATP production 
but also for the supply of carbon needed for biosynthesis in the growing cells, and NADPH 
production important for proinflammatory responses by immune cells (178-181). 
Elevated GLUT1 expression also plays a pathological role in many cancer types. As with 
other rapidly proliferating cells, tumor cells metabolize glucose through aerobic glycolysis 
to generate ATP, NADPH and biomass needed for new cells (181). This over-reliance on 
glucose makes cancer cells more sensitive to reductions in extracellular glucose 
concentration than normal differentiated cells (182). Targeting GLUT1 is currently being 
explored as a novel strategy to develop novel anticancer therapeutics. 
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Mutations in the gene encoding GLUT1 as reported in GLUT1 deficiency syndrome 
(GLUT1DS), reduces GLUT1 expression in the patient (10). The most deleterious 
consequences of GLUT1DS arise from the impaired glucose transport across the blood-
brain barrier (BBB) into the brain, resulting in stunted brain development and other 
manifestations such as seizures and ataxia (9,183). Reduced BBB GLUT1 expression and 
a corresponding reduction in brain glucose metabolism are also observed at the onset of 
Alzheimer’s disease (80,184). The role of glucose metabolism in Alzheimer’s disease is 
an active area of research, and increasing evidence suggests that early interventions 
targeted towards stimulating or restoring GLUT1 activity at the BBB may help prevent, or 
at least, delay the progression of Alzheimer’s disease (80). 
GLUT1 as a novel therapeutic target 
GLUT1 inhibition and stimulation are promising therapeutic strategies in diseases 
characterized by dysfunctional regulation of GLUT1. GLUT1 expression is highly 
upregulated in cancers, while decreased GLUT1 levels at the blood-brain barrier (BBB) is 
found in GLUT1DS and Alzheimer’s disease. Accordingly, there is an increased interest 
in developing GLUT1 inhibitors as novel anticancer therapeutics and in the discovery of 
compounds that directly stimulate GLUT1 function that will ameliorate GLUT1DS and 
Alzheimer’s disease. Additionally, BBB GLUT1 is considered as a potential route for 
delivery of drugs into the brain for treating neurological disorders (80). 
 Characterizing candidate small molecule inhibitors of GLUT1 
Several small molecules have been reported to inhibit GLUT1 and as a result, kill cancer 
cells and/or inhibit tumor growth in mice (165,166). Figure 1.4 shows the chemical   
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Figure 1.4: Chemical structures of candidate small molecule inhibitors of GLUT1 
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structures of a wide range of structurally unrelated candidate small molecule inhibitors of 
GLUT1. These include naturally occurring flavonoids (quercetin, EGCG and ECG) 
abundant in the human diet, as well as synthesized molecules discovered from high 
throughput screening (e.g., WZB117 (165) , BAY-876 (167) and NV-5440 developed by 
Navitor Pharmaceuticals, MA) and by computational methods (PUG1–8) (185). 
In this study, we used a combination of sugar transport assays and molecular biology 
techniques in human erythrocytes and cultured mammalian cells, as well as in silico ligand 
docking, to define the mechanism of GLUT1 inhibition by these small molecules. Our 
approach included the following: 
 Validation of small molecules as GLUT1 inhibitors by testing their effects on sugar 
uptake by human erythrocytes. 
 Determination of sidedness of action of inhibitors on GLUT1. Taking advantage of the 
fact that GLUT1 exhibits Michaelis-Menten kinetics (104,118,186), we tested the 
effects of inhibitors on the Vmax and Km of sugar transport in human erythrocytes. Based 
on Michaelis–Menten kinetics of sugar transport, as well as radioactive ligand binding 
assays, we defined each compound as either an exofacial (acting on the outside) or 
endofacial (acting on the inside) inhibitor of GLUT1. Figure 1.4 illustrates the different 
modes of glucose transport assays used and the graphical representation and 
interpretation of data obtained. 
 Tested isoform specificity of inhibition by assessing the effects of these compounds 
on sugar uptake in cultured mammalian cells stably expressing GLUT1, GLUT3 or 
GLUT4.  
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Figure 1.5: Determination of sidedness of action of GLUT1 inhibitors 
 
A. Procedure for determining the sidedness of action of GLUT1 inhibitors in human erythrocytes. 
Experiments are designed to measure radioactive sugar: 1) uptake into sugar–depleted cells 
(zero-trans entry), 2) exit into sugar-free medium (zero-trans exit), and 3) exchange in cells 
loaded with equal concentrations of non-radioactive sugar as their medium (equilibrium 
exchange). Data from these experiments are analyzed by Michaelis–Menten kinetics and 
provide the Km and Vmax of sugar transport. B. Analysis of transport data by Michaelis–Menten 
kinetics. A plot of the rate of transport versus substrate concentration yields the Michaelis–
Menten parameters, Km and Vmax. If an inhibitor competes with glucose for binding at the sugar 
binding site on the side of the membrane where sugar transport is initiated, we will observe an 
increase in Km with no change in Vmax (red curve). If inhibitor does not compete with glucose for 
binding at the side of the membrane where transport is initiated, it will reduce Vmax without 
changing Km (blue curve). Any deviation from competitive or noncompetitive inhibition will 
suggest that inhibitor interaction with GLUT1 is more complex, and that inhibitor binds GLUT1 
at a site different from the sugar binding site. 
 
  
[S]
ra
te
 o
f 
tr
a
n
s
p
o
rt
Noncompetitive
Inhibition
Competitive
Inhibition
No inhibition
Vmax
Km Km
Vmax
A
B
 26 
 Guided by our biochemical data, we used homology modeling and ligand docking 
analyses to computationally predict the molecular interactions between these 
compounds and GLUT1. 
In addition to uncovering the mechanisms of GLUT1 inhibition by these small molecules, 
the GLUT1 inhibitors served as molecular probes that revealed valuable insights for the 
mechanism of GLUT1 function. 
Significance of study 
This study provides a framework for screening candidate GLUT1 inhibitors for specificity, 
and optimizing drug design and delivery. The human erythrocyte robustly expresses 
GLUT1 as its only glucose transport protein. Therefore, the ability of a compound to inhibit 
human erythrocytes glucose transport should be a “gold standard” for confirming a 
potential GLUT1 inhibitor. Furthermore, understanding the sidedness of action of an 
inhibitor on GLUT1 will help in drug delivery. For instance, exofacial GLUT1 inhibitors do 
not need to cross cell membranes, which potentially simplifies the drug delivery process, 
and alleviates concerns about off target interaction of drugs with cellular targets. Also, 
testing a wide range of structurally diverse compounds, reveals functional groups essential 
for greater inhibitory potency, and these can be used to optimize drug design. 
Finally, this study provides further experimental evidence concerning the function and 
regulation of GLUT1, supporting the idea that GLUT1 functions as a cooperative oligomer 
of allosteric alternating access subunits.  
 27 
CHAPTER II 
Preface 
Chapter II of this dissertation was published in the Journal of Biological Chemistry, as: 
Ojelabi, O. A., Lloyd, K. P., Simon, A. H., De Zutter, J. K., and Carruthers, A. (2016) 
WZB117 (2-Fluoro-6-(m-hydroxybenzoyloxy) Phenyl m-Hydroxybenzoate) inhibits 
GLUT1-mediated sugar transport by binding reversibly at the exofacial sugar binding site. 
Journal of Biological Chemistry 291, 26762-26772 
Author contributions: OAO and AC designed experiments, analyzed results and co-wrote 
the manuscript. OAO conducted most of the experiments. KPL undertook the molecular 
docking studies. AHS assisted with quantitative analysis of data. JKD conducted 
experiments on the isoform specificity of transport inhibition 
  
 28 
WZB117 inhibits GLUT1-mediated sugar transport by binding reversibly at the 
exofacial sugar binding site 
Introduction 
Most cancer cells use anaerobic metabolism (glycolysis) to generate the ATP required for 
cellular processes and proliferation (181). This contrasts with normal, differentiated cells, 
which mostly use mitochondrial oxidative phosphorylation to sustain cellular function 
(187). The transition from aerobic to anaerobic metabolism is termed “the Warburg effect” 
and is driven by growth conditions, by mutations of proto-oncogenes and tumor-
suppressor genes (187,188). Vander Heiden et al. (181) have proposed that the 
metabolism of all proliferating cells (including cancer cells) is adapted to enhance nutrient 
uptake and nutrient incorporation into the biomass needed to produce a new cell. This 
would explain why the developing central nervous system is so susceptible to glucose 
deprivation resulting from glucose transport-deficiency at the blood-brain barrier (189) and 
why cancer cells are so sensitive to limited glucose availability (190). 
This has prompted several groups to propose that suppressing anaerobic metabolism may 
offer an effective anticancer strategy. Three approaches have been used to limit glycolysis 
in cancer cells; that is glucose deprivation in vitro (191,192), the in vitro and in vivo use of 
glycolysis inhibitors (193), and cellular glucose transport inhibition in vitro and in vivo 
(165,193). All three approaches cause cancer cell death. 
Glucose transport in most mammalian cells is catalyzed by one or more members of the 
GLUT (SLC2A) family of passive glucose transporters (194). GLUT1 (the blood brain 
barrier/erythroid glucose transporter) and, in some instances, GLUT3 (the neuronal 
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glucose transporter) or GLUT12 expression is significantly increased in proliferating cells 
(195). 
Successful strategies for passive glucose transport inhibition have exploited a range of 
molecules that bind at or close to either the exofacial (e.g. maltose, ethylidene glucose) 
or the endofacial sugar binding site (e.g. cytochalasin B; (86,117,196)). A number of 
unrelated inhibitory molecules react with the GLUT1 purine binding site (e.g. ATP, AMP, 
caffeine; (197)) or at other, less well defined sites (e.g. androgens, quercetin; (198) and 
(199)). These and related molecules have been suggested as potential scaffolds for 
designing inhibitors of glucose uptake in cancer cells or cancer stem cells (193,200-202). 
Using such an approach, Zhang et. al. (203) identified a class of polyphenolic compounds 
with sugar transport inhibitory potency. Among these, WBZ117 (2-fluoro-6-(m-
hydroxybenzoyloxy)phenyl m-hydroxybenzoate) showed the highest affinity for sugar 
transport inhibition and inhibited tumor growth in a nude mouse model (165). 
Although a promising strategy for cancer cell elimination, glucose transport inhibition in 
vivo may present several attendant complications. These include impaired insulin 
secretion, elevated blood glucose, diuresis, elevated glycation, impaired glucose transport 
across the blood-brain barrier, and reduced metabolic capacity in healthy cells that depend 
upon glycolysis for normal function. We, therefore, undertook a systematic analysis of 
WZB117 inhibition of glucose transport. 
We found that WZB117 interacts with GLUT1 at the exofacial sugar binding site and thus 
acts as a reversible, competitive inhibitor of net glucose uptake and exchange glucose 
transport but as a noncompetitive inhibitor of sugar efflux from cells. WZB117 inhibits the 
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insulin-sensitive glucose transport (GLUT4) with greater potency than its inhibition of 
either GLUT1 or GLUT3. 
Materials & Methods 
Reagents 
[3H]-Cytochalasin B ([3H]-CB) and 3-O-[3H]-methylglucose ([3H]-3MG) were purchased 
from American Radiolabeled Chemicals (St. Louis, MO). Unlabeled 3MG, CB, and 
phloretin were purchased from Sigma. WZB117 was purchased from EMD Millipore 
(Billerica, MA). 
Solutions 
KCl medium was composed of 150 mM KCl, 5 mM HEPES, 4 mM EGTA, 5 mM MgCl2, 
pH 7.4. Solubilization buffer was composed of KCl medium with 0.5% Triton X-100. 
Phosphate-buffered saline was composed of 140 mM NaCl, 10 mM Na2HPO4, 3.4 mM 
KCl, 1.84 mM KH2PO4, pH 7.3. Stop solution was composed of ice-cold KCl medium plus 
CB (CB; 10 µM) and phloretin (100 µM). Sample buffer contained 0.125 M Tris-HCl, pH 
6.8, 4% SDS, 20% glycerol, and 50 mM DTT. Transfer buffer was composed of 12 mM 
Tris base, 96 mM glycine, 20% methanol. 
Cells 
De-identified whole human blood was purchased from Biological Specialty Corporation 
(Colmar, PA). HEK293 cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 µg/ml 
streptomycin in a 37 °C humidified 5% CO2 incubator. 
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Heterologous Expression of GLUTs 
GLUT1, GLUT3, and GLUT4 heterologous expression in HEK293 cells was as described 
previously (97,123). Both GLUT1 and GLUT3 contain a myc-epitope in exofacial loop 1 
(97). GLUT1, GLUT3, GLUT4, and NaKATPase expression in whole cell lysates was 
analyzed by Western blotting as previously described (97,123). 
Erythrocyte Sugar Transport Measurements 
All human red cell sugar transport experiments were performed at 4 °C as previously 
described (197,204,205). 
Zero-trans Uptake—Five volumes (100 µl) of 3MG uptake medium ± WZB117 or CB were 
added to 1 volume (20 µl) of sugar-depleted, 50% hematocrit (Ht) red cells, and sugar 
uptake allowed to proceed for 0.5–1 min at 4 °C. Uptake was stopped by adding 50 
volumes (1 ml) of ice-cold stop solution containing 100 µM phloretin and 10 µM CB. Cells 
were washed in stop solution and lysed in 3% perchloric acid, and centrifugation-clarified 
lysates were assayed for radioactivity in duplicates using liquid scintillation counting. 
Zero-trans Exit—Sugar-depleted packed RBCs were loaded with 10 mM 3MG by 
incubating with 20 mM 3MG (containing 10 µCi [3H]-3MG/10 ml of cold 3MG for 1 hr at 37 
°C). One volume (0.5 ml) of sugar-loaded RBCs was added to 50 volumes of KCl ± 
medium CB or WBZ117 on a shaker with magnetic stirrer. Aliquots (0.5 ml) of the 
suspension were withdrawn at the indicated time intervals, washed in ice-cold stop 
solution, lysed, and assayed for remaining radioactivity. 
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Equilibrium Exchange Transport—Sugar-depleted RBCs were preloaded with 2.5–50 mM 
3MG at 25 °C for 30 min. These cells were collected by centrifugation, incubated in 10 
volumes of 3MG ± WZB117 or CB for 10 min at 4 °C, centrifuged again, and resuspended 
to 50% Ht in the appropriate 3MG and inhibitor medium. 3MG uptake medium (100 µl) ± 
WZB117 or CB was added to 20 µl of sugar-loaded cells (50% Ht), and the experiment 
was allowed to proceed for 0.5–1 min at 4 °C. Uptake was arrested by adding 50 volumes 
(1 ml) of ice-cold stop solution. Cells were centrifuged, and the pellet was washed in 1 ml 
of stop solution, collected by centrifugation, lysed in 3% perchloric acid, clarified, and 
assayed for radioactivity in duplicates using liquid scintillation counting. 
HEK293 Cell Sugar Transport Measurements 
All HEK293 cell sugar transport experiments were performed at 37 °C using 0.1 mM 2-
deoxy-D-glucose as previously described (97,123). 
CB Binding 
Equilibrium CB binding to red cells was performed as previously described (116). Briefly, 
1 volume of sugar-depleted red cells (50% Ht) was suspended in one volume of ice-cold 
wash buffer 150 mM KCl, 5 mM HEPES, pH 7.4, containing 0.5 µM [3H]-CB, 10 µM 
cytochalasin D, and varying concentrations of WZB117 (1–60 µM) for 15 min at 4 °C with 
constant end-over-end rotation. For total CB, 2 x 10 µl of the cell suspension were lysed 
in 100 µl of 3% perchloric acid and clarified by centrifugation, and the associated 
radioactivity was assayed by liquid scintillation counting. For free CB, the cell suspension 
was centrifuged at 10,000 x g for 30 s, and 10 µl of clarified supernatant were assayed in 
duplicate by scintillation counting. Bound CB was obtained as: total CB – free CB. 
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Quantitative RT-PCR 
Expression levels of hGLUT3 mRNA were measured by qPCR using the QuaniTect SYBR 
Green PCR kit (Qiagen). Reactions were performed according to the manufacturer’s 
protocol. Total RNA was isolated from HEK293 cells stably overexpressing hGLUT1 or 
hGLUT4 using the RNeasy kit and Qiashredder (Qiagen). cDNA was synthesized using 
the QuantiTect Reverse Transcriptase kit (Qiagen). qPCR reactions contained 100 ng of 
the indicated cDNA and 0.3 µM each human GLUT3-specific qPCR primers (G3, 5’-qF-
AGCTCTCTGGGATCAATGCTGTGT and G3 3’ qR-
ATGGTGGCATAGATGGGCTCTTGA, where qF denotes qPCR forward and qR denotes 
qPCR reverse). Samples were run in triplicate on a Research PTC-200 Peltier Thermal 
Cycler with a Chromo4 real time PCR detector running Opticon Monitor 3 software (Bio-
Rad). Results were analyzed by using the ΔΔCt method and normalized to an internal 
GAPDH marker. 
Data Analysis 
Linear and nonlinear regression analysis of data sets and statistical tests were 
accomplished using GraphPad Prism (Version 7.0a; La Jolla, CA). 
Michaelis-Menten inhibition of sugar transport is assumed to be described by: 
 
𝑣 =  𝑣𝑜 – 
𝑣𝑜[𝐼]
𝐾𝑖(𝑎𝑝𝑝) + [𝐼]
 
 
(equation 2.1) 
Where vo is v measured in the absence of inhibitor I, [I] is the concentration of inhibitor 
and Ki(app) is that [I] producing 50% inhibition of uptake. 
Michelis-Menten transport is assumed to be described by: 
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𝑉 =  
𝑉𝑚𝑎𝑥[3𝑀𝐺]
𝐾𝑚(𝑎𝑝𝑝) + [3𝑀𝐺]
 
 
(equation 2.2) 
Where Vmax is the maximum rate of 3MG transport, [3MG] is the concentration of 3MG, 
and Km(app) is that [3MG] where the rate of uptake is Vmax/2. 
Hanes-Woolf analysis of transport assumes Michelis-Menten kinetics, and when data are 
plotted as [3MG]/v versus [3MG], the results fall on a straight line described by: 
Where Vmax is the maximum rate of 3MG transport, [3MG] is the concentration of 3MG, 
and Km(app) is [3MG], where the rate of uptake is Vmax/2. 
Transport stimulation followed by inhibition by inhibitors was approximated first by 
normalizing all uptake to vo and then using the following model. 
 𝑣
𝑣𝑜
= 1 + 
[𝐼]∆1
𝐾1 + [𝐼]
 – [𝐼]
1 + ∆1
𝐾2 + [𝐼]
 
 
 
(equation 2.4) 
Homology Modeling 
The homology models of the e2 (open) state of GLUT1 and GLUT4 were generated using 
the maltose-bound human GLUT3 (PDB code 4ZWC) structure (30). GLUT1 and GLUT3 
have 65% sequence identity and 88% sequence similarity (194). Ligands were removed, 
and chain A was used as the template for each modeled structure. Sequence alignments 
were generated using ClustalX. Homology models were built using Modeler-9.9 and 
analyzed using PROCHECK. The GLUT1-e1 structure (PDB code 4PYP; Ref. (28)) was 
used directly. 
  
 [3𝑀𝐺]
𝑉
=  
[3𝑀𝐺]
𝑉𝑚𝑎𝑥
 +  
𝐾𝑚(𝑎𝑝𝑝)
𝑉𝑚𝑎𝑥
 
 
(equation 2.3) 
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Stochastic Docking 
The GLUT1 crystal structure was obtained from the protein data bank using PDB code 
4PYP. The structures for D-glucose and CB were obtained from ZINC. The WZB117 
structure was generated using the three-dimensional structure generator Corina from 
Molecular Networks GmbH. Docking was performed using the Schrodinger software suite. 
The protein structure was preprocessed with the Protein Preparation Wizard, bond orders 
were assigned, hydrogens were added, and the H-bond network was optimized. The 
system was energy-minimized using the OPLS 2005 force field. Ligand structures were 
prepared with the LigPrep module, and the pKa of the ligands was calculated using the 
Epik module. Computational docking was performed by the GLIDE module in standard 
precision (SP) mode and default values for grid generation. Cavities for docking were 
calculated using the CastP server, and the grid was centered on the residues forming the 
cavity. No restraints were used during the docking. 
Results 
Sugar transport in human erythrocytes is catalyzed by GLUT1 (98). Transport theory 
states that ligands binding reversibly at the exofacial sugar binding site act as competitive 
inhibitors of sugar uptake and as noncompetitive inhibitors of exit. Conversely, ligands 
binding reversibly at the endofacial sugar binding site act as noncompetitive inhibitors of 
sugar uptake and as competitive inhibitors of exit (104,118,186). To understand whether 
WZB117 inhibits GLUT1 by binding at the exofacial or endofacial sugar binding site, we 
examined its effects on three modes of erythrocyte sugar transport: zero-trans 3MG 
uptake (uptake into cells lacking sugar), zero-trans 3MG exit (efflux from cells into medium 
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lacking sugar), and equilibrium exchange 3MG uptake (unidirectional uptake of 3MG in 
cells where [3MG]i = [3MG]o). 
Concentration dependence of WZB117 and CB inhibition of sugar uptake by human 
erythrocytes 
WZB117 inhibits zero-trans 3MG (0.1 mM) uptake by erythrocytes in a dose-dependent 
manner with Ki(app) = 0.23 ± 0.04 µM (figure 2.1A). CB (a known GLUT1 endofacial site 
ligand) inhibits 0.1 mM 3MG zero-trans uptake with Ki(app) = 0.21 ± 0.02 µM (figure 2.1B). 
Inhibition of human RBC sugar transport by WZB117 is reversible 
We assessed the reversibility of inhibition in two ways. The first method involved exposing 
RBCs to buffer containing or lacking WZB117 (3 µM) or CB (0.5 µM) for 10 min, then 
removing the inhibitors using a centrifugation/wash cycle and incubating the cells in 
inhibitor-free buffer for a further 15 min. We then measured 0.1 mM 3MG uptake in these 
cells. WZB117 (3 µM) or CB (0.5 µM) inhibit sugar uptake by 50% (figure 2.2). Removing 
the inhibitor before sugar uptake determinations restored sugar uptake to levels of 75% 
or greater of uninhibited controls (figure 2.2). 
WZB117 is a competitive inhibitor of 3MG uptake by human erythrocytes 
The second method of assessing reversibility of inhibition evaluates the type of sugar 
transport inhibition produced by WZB117. Competitive inhibitors act by binding reversibly 
either to the active site of an enzyme or to a site whose occupancy occludes occupancy 
of the active site and vice versa (206). Preincubation with WZB117 (7 µM) before initiation 
of transport measurements increased Km(app) for zero-trans 3MG uptake from 1.0 ± 0.2 mM   
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Figure 2.1: Sensitivity of zero-trans 3MG (0.1 mM) uptake by erythrocytes to inhibition by 
WZB117 (A) and CB (B) 
 
Ordinate: 3MG uptake in mmol/liter of cell water/min. Abscissa: WZB117 or CB in µM. Each data 
point represents the mean ± S.E.M of at least three separate measurements made in duplicate. 
The curves drawn through the points were computed by nonlinear regression assuming uptake 
is inhibited completely by inhibitor in a dose-dependent manner (equation 2.1). The results are: 
A, WZB117-treated cells: Ki(app) = 0.23 ± 0.04 µM, R2 = 0.894, standard error of regression = 
0.011; B, CB-treated cells: Ki(app) = 0.21 ± 0.02 µM, R2 = 0.933, standard error of regression = 
0.007. 
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Figure 2.2: Reversibility of transport inhibition by WZB117 and by CB 
 
Ordinate: 3MG uptake in mmol/liter of cell water/min. Abscissa: experimental treatment. Control 
cells saw no inhibitor during sugar uptake; WZB117 and CB cells were exposed to inhibitor (3 
µM WZB117 and 0.5 µM CB respectively) for 15 min on ice before measurement of 3MG uptake 
in the presence of inhibitor. WZB117-washout and CB-washout cells were exposed to inhibitor 
(3 µM WZB117 and 0.5 µM CB, respectively) for 15 min on ice followed by inhibitor removal and 
exposure to inhibitor-free medium for 15 min on ice and finally measurement of 3MG uptake in 
the absence of inhibitor. Each symbol (●) represents the mean of duplicate measurements. The 
horizontal line and error bars represent the mean ± SEM of each condition. Unpaired t test 
analysis indicates: *, transport under all treatments is significantly lower (p < 0.005) than in 
control cells; **, transport after washout treatment is significantly greater (p < 0.005) than in the 
corresponding non-washout treatment. 
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to 2.8 ± 0.4 mM, but Vmax for 3MG uptake (0.59 ± 0.03 mmol/liter of cell water/min) was 
unaffected (figure 2.3). This result indicated that WZB117 is a competitive inhibitor of 
human erythrocyte sugar uptake. If WZB117 bound irreversibly to the active site, 
preincubation with the inhibitor would most likely have reduced Vmax for transport in 
addition to increasing Km(app). Conversely, CB (0.7 µM) reduces Vmax for 3MG uptake (0.29 
± 0.05 mmol/liter of cell water/min) but has no effect on Km(app) (figure 2.3). This result 
confirms that CB is a noncompetitive inhibitor of uptake and is expected for an inhibitor 
which binds reversibly to the endofacial active site (118). 
WZB117 is a noncompetitive inhibitor of net sugar exit 
Because WZB117 competes for 3MG binding at or close to the exofacial sugar entry site, 
we hypothesized that WZB117 would act as a noncompetitive inhibitor of sugar exit (118). 
To this end, we performed sugar exit experiments where we measured the time course of 
zero-trans sugar exit from pre-loaded red cells into sugar-free external medium. The time 
course of exit was analyzed by simulating sugar exit by numerical integration using 
Berkeley Madonna software assuming Michaelis-Menten exit kinetics then adjusting 
simulated Michaelis-Menten parameters using the Levenberg-Marquardt algorithm until 
the fits between simulated and experimental exit data were optimal. Our analysis shows 
that WZB117 (0.7 µM) reduces Vmax for 3MG exit from 2 mmol/liter of cell water/min to 0.8 
mmol/liter of cell water/min, whereas Km(app) for exit (15 mM) was unaffected (figure 2.4A). 
Consistent with published data (117), CB (0.7 µM) was competitive for sugar exit, 
increasing Km(app) to 47 mM with no effect on Vmax (figure 2.4B).  
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Figure 2.3: Effects of WZB117 and CB on Michaelis-Menten kinetics of zero-trans 3MG 
uptake 
 
Results are shown for control cells (○), WZB117-treated cells (●), and for CB-treated cells (△
). Each data point is the mean ± S.E. of three duplicate measurements. A, ordinate: 3MG uptake 
in mmol/liter of cell water/min. Abscissa: [3MG]o in mM. Curves drawn through the points were 
computed by nonlinear regression assuming Michaelis-Menten uptake kinetics (equation 2.2) 
and have the following results: control cells (○), Vmax = 0.59 ± 0.03 mmol/liter of cell water/min, 
Km(app) = 1.05 ± 0.16 mM, R2 = 0.992, standard error of regression = 0.018; WZB117 treatment 
(●): Vmax = 0.68 ± 0.04 mmol/liter of cell water/min, Km(app) = 2.77 ± 0.35 mM, R2 = 0.997, 
standard error of regression = 0.018 mmol/liter of cell water/min; CB treatment (△): Vmax = 0.29 
± 0.05 mmol/liter of cell water/min, Km(app) = 1.67 ± 0.63 mM, R2 = 0.966, standard error of 
regression = 0.010. 
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Figure 2.4: Effects of WZB117 (A) and CB (B) on Michaelis-Menten kinetics of zero-trans 
3MG 
 
Ordinates: [3MG]i in mmol/liter of cell water. Abscissa: time in minutes. Curves drawn through 
the points were computed by nonlinear regression and numerical integration assuming 
Michaelis-Menten exit kinetics and have the following results: Control cells (○): Vmax = 2 
mmol/liter of cell water/min, Km(app) = 15 mM; WZB117 treatment (●): Vmax = 0.8 mmol/liter of cell 
water/min, Km(app) = 15 mM; CB treatment (△): Vmax = 2 mmol/liter of cell water/min, Km(app) = 47 
mM. 
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WZB117 is a competitive inhibitor of equilibrium exchange sugar transport 
Equilibrium exchange 3MG transport in human red blood cells ([3MG]i = [3MG]o) was 
competitively inhibited by WZB117. WZB117 (7 µM) increased Km(app) for 3MG exchange 
transport from 40.25 ± 3.57 mM to 82.25 ± 15.30 mM but had no effect on Vmax (13.39 ± 
0.79 mmol/liter of cell water/min; figure 2.5). CB (0.7 µM), however, was a mixed-type 
inhibitor of equilibrium exchange 3MG transport reducing Vmax (8.87 ± 0.33 mmol/liter of 
cell water/min) and increasing Km(app) (49.85 ± 2.56 mM; figure 2.5). 
Subsaturating levels of CB and WZB117 stimulate sugar uptake in human erythrocytes 
Previous studies have shown that subsaturating concentrations of CB or exofacial 
inhibitors of GLUT1 produce a modest stimulation of erythrocyte sugar uptake (122,124). 
Subsaturating levels of WZB117 (≤ 10 nM) and CB (≤ 50 nM) significantly (p < 0.05) 
stimulate zero-trans 3MG uptake in human erythrocytes by up to 40% above untreated 
cells (figure 2.6). 
Effect of WZB117 on CB Binding 
CB is membrane-permeant and rapidly crosses the cell membrane to interact with the 
GLUT1 endofacial sugar binding site (118,186). The simple carrier hypothesis for 
facilitated diffusion predicts that CB and WZB117 binding to GLUT1 are mutually exclusive 
(104,118,186). Accordingly, CB should competitively inhibit WZB117 inhibition of and 
binding to GLUT1. The Ki(app) for CB inhibition of 3MG uptake is increased by more than 
4-fold when WZB117 (200 nM) is present (figure 2.7A), suggesting that WZB117 interferes 
with CB inhibition of sugar uptake. Similarly, WZB117, as well as nonradioactive CB, 
inhibits the binding of [3H]-CB to human RBCs in a dose-dependent manner (figure 2.7B).   
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Figure 2.5: Effects of WZB117 and CB on Michaelis-Menten kinetics of equilibrium 
exchange 3MG uptake 
 
Hanes-Woolf plot of equilibrium exchange transport. Ordinate: [3MG]/rate of equilibrium 
exchange 3MG uptake in minutes. Abscissa: intracellular and extracellular [3MG] in mM. Lines 
drawn through the points were computed by nonlinear regression assuming that each line is 
described by equation 2.3. The results are: control cells (○): Vmax = 13.39 ± 0.79 mmol/liter of 
cell water/min, Km(app) = 40.25 ± 3.57 mM, R2 = 0.990, standard error of regression = 0.17 min; 
WZB117 treatment (●): Vmax = 13.36 ± 2.02 mmol/liter of cell water/min, Km(app) = 82.25 ± 15.30 
mM, R2 = 0.936, standard error of regression = 0.43 min; CB treatment (△): Vmax = 8.87 ± 0.33 
mmol/liter of cell water/min, Km(app) = 49.85 ± 2.55 mM, R2 = 0.996, standard error of regression 
= 0.16 min 
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Figure 2.6: CB and WZB117 stimulate 3MG uptake at subsaturating inhibitor 
concentrations 
 
Ordinate: Relative 3MG uptake. Abscissa: Inhibitor concentration in M (axis expressed in log 
scale). Results are shown for   WZB117-treated cells (●) and for CB-treated cells (△). Each 
data point is the mean S.E. of three or more duplicate measurements. The curves drawn through 
the points were computed by nonlinear regression according to equation 2.4 and have the 
following constants: WZB117-treated cells (●) ∆1 = 0.42 ± 0.15, K1 = 2.8 x 10-9 ± 3.6 x 10-9, K2 
= 2.4 x 10-7 ± 6.3 x 10-7, R2 = 0.985, standard error of regression = 0.07; CB-treated cells (△) ∆1 
= 0.46 ± 0.14, K1 = 4.7 x 10-9 ± 5.4 x 10-9, K2 = 3.0 x 10-7 ± 6.0 x 10-8, R2 = 0.988, standard error 
of regression = 0.06. Differences between transport in the absence and presence of each 
concentration of inhibitor were analyzed by one-tailed t-test.) WZB117 (≤10 nM) and CB (≤ 50 
nM significantly increased 3MG uptake (p < 0.05). 
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Together these results are consistent with the simple carrier alternating access 
hypothesis, suggesting that binding of WZB117 at the exofacial sugar binding site of 
GLUT1 prevents CB binding at the endofacial site. 
Isoform specificity of transport inhibition 
The GLUT (SLC2A) family of passive glucose transporters can show distinct, isoform-
specific affinities for inhibitors. For example, the insulin-sensitive glucose transporter of fat 
and muscle (GLUT4) is inhibited by HIV protease inhibitors, but GLUT1 is not (207), 
whereas GLUT1, GLUT3, and GLUT4 are inhibited by CB and the intestinal fructose 
transporters GLUT5 and GLUT7 are not (55). We, therefore, stably transfected HEK293 
cells with GLUT1, GLUT3, or GLUT4 and measured the concentration dependence of 
WZB117 inhibition of 2-deoxy-D-glucose (2DG, 0.1 mM) uptake at 37 °C. WZB117 inhibits 
GLUT1- and GLUT3-mediated 2DG uptake with Ki(app) ≈ 10 µM (figure 2.8A) but is a more 
potent inhibitor of GLUT4-mediated uptake (Ki(app) = 0.2 µM; figure 2.8A). 
GLUT12 has been reported to be the most abundant endogenous GLUT in HEK293 cells 
(97). Endogenous GLUT3 mRNA content is about 50% of GLUT12 mRNA, while there are 
only trace levels of GLUT1 and GLUT4 mRNAs in HEK293 cells (97). Heterologous 
expression of human GLUT1 or GLUT4 (figure 2.8E) significantly reduced endogenous 
GLUT3 mRNA (figure 2.8B) and protein (figure 2.8, C and D) levels in HEK293 cells as 
judged by qPCR and Western blotting analyses. This explains why high affinity, WZB117 
inhibition of transport in GLUT4-transfected cells reduced transport more effectively than 
observed in untransfected cells (figure 2.8A). We hypothesize that endogenous GLUT3 
expression is reduced in GLUT4- and GLUT1-transfected cells as a compensatory 
response to increased cellular sugar uptake.  
 46 
 
Figure 2.7: WZB117 inhibits endofacial CB binding to human red blood cells 
 
A, WZB117 interferes with CB inhibition of 3MG uptake by human RBCs. Ordinate: 3MG uptake 
in mmol/L cell water/min. Abscissa: Concentration of inhibitors in µM (expressed in log scale). 
Results are shown for CB-treated cells (△), and CB-treated cells plus 200 nM WZB117 (●). 
Each data point represents the mean ± SEM of at least 3 duplicate measurements. The curves 
drawn through the data points were computed by nonlinear regression using equation 2.1 and 
have the following results: CB only treatment (△): Ki(app) = 0.323 ± 0.042 µM, R2 = 0.966, standard 
error of regression = 0.005; CB + 200 nM WZB117 (●): Ki(app) = 1.376 ± 0.355 µM, R2 = 0.734, 
standard error of regression = 0.004. B, Inhibition of [3H]-CB binding to human RBCs. Ordinate: 
Normalized ratio of bound [3H]-CB to free [3H]-CB. Abscissa: Concentration of WZB117 (●) or 
nonradioactive CB (△) in µM (expressed in log scale). Each data point represents the mean ± 
SEM of duplicate measurements of 3 separate experiments. The curves drawn through the data 
points were computed by nonlinear regression using equation 2.4, with the following results: 
WZB117 treatment (●): Ki(app) = 0.140 ± 0.010 µM, R2 = 0.981, standard error of regression = 
0.046; nonradioactive CB treatment (△): Ki(app) = 0.098 ± 0.006 µM, R2 = 0.989, standard error 
of regression = 0.036. 
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Figure 2.8: WZB117 inhibition of sugar transport is GLUT isoform-specific 
 
A, Dixon plot of transport inhibition by WZB117 in untransfected HEK293 cells (○) and in cells 
transfected with and expressing hGLUT1 (●), hGLUT3 (△), or hGLUT4 (▲). Ordinate: 1/2DG 
uptake in min•µg protein/mol. Abscissa: WZB117 in µM. Lines drawn through the points were 
computed by linear regression and Ki(app) for WZB117 inhibition of transport computed as -x-
intercept. The results are: untransfected cells (○), Ki(app) 2.45 ± 0.66 µM, R2 = 0.975, standard 
error of regression = 3.66 x 1010; hGLUT1-transfected cells (●), Ki(app) = 5.71 ± 0.95 µM, R2 = 
0.974, standard error of regression = 7.59 x 109; hGLUT3-transfected cells (△), Ki(app) = 13.32 ± 
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5.12 µM, R2= 0.862, standard error of regression 8.82 x 109; hGLUT4-transfected cells (▲), 
Ki(app) = 0.23 ± 0.47 µM, R2 = 0.977, standard error of regression = 1.09 x 1011. B, effect of 
heterologous GLUT1 or GLUT4 expression on parental GLUT3 mRNA levels as detected by 
qPCR. For each condition, the symbols (●) show the results of six separate measurements, and 
the horizontal lines plus error bars show their mean ± SEM. The conditions are untransfected 
(Control), GLUT1-transfected, and GLUT4-transfected cells. Results are normalized to one of 
the six GLUT3 message levels measured in untransfected cells. Ordinary one-way ANOVA 
shows that GLUT3 mRNA expression is significantly reduced in GLUT1-transfected and GLUT4-
transfected cells relative to control cells (+++, p = 0.0001; ++, p = 0.0025). C, effect of 
heterologous GLUT1 or GLUT4 expression on parental GLUT3 expression. Results are shown 
for untransfected (UTF), GLUT1-transfected (G1), and GLUT4-transfected (G4) cells. Total 
GLUT3 and NaKATPase expression were assayed by obtaining whole cell lysates followed by 
SDS-PAGE of protein load-normalized samples and immunoblotting using protein-directed 
antibodies. Molecular mass markers are shown. D, quantitation of the effect of heterologous 
GLUT1 or GLUT4 expression on parental GLUT3 protein levels. Results (normalized to parental 
GLUT3 levels in untransfected cells as in figure 2.8C) are shown for untransfected (Control), 
GLUT1-transfected (G1) and GLUT4-transfected (G3) cells. For each condition, the symbols (●
) show the results of four separate measurements, and the horizontal lines plus error bars show 
their mean ± SEM. Ordinary one-way ANOVA (+) shows that GLUT3 expression is significantly 
reduced in G1 and G4 cells relative to control cells (p = 0.0014). E, heterologous expression of 
GLUT1 and GLUT4 in HEK293 cells. Results are shown for untransfected (UTF), GLUT1-
transfected (G1), and GLUT4-transfected (G4) cells. The GLUT1, GLUT4, and NaKATPase 
contents of protein load-normalized, whole cell lysates were assayed by immunoblot analysis 
using transporter specific (peptide-directed) antibodies (α-GLUT1, α-GLUT4, or α-NaKATPase 
IgGs) or with GLUT1 and GLUT4 by using-myc IgGs. Molecular mass markers are shown. 
Heterologous expression of GLUT1 increased HEK293 cell GLUT1 expression over 
untransfected cells by 47.5- and 30.8-fold using-fold α-GLUT1 and α-myc IgGs, respectively. 
Heterologous expression of GLUT4 increased HEK293 cell GLUT4 expression over 
untransfected cells by 58.7- and 3.6-fold using α-GLUT4 and α-myc IgGs, respectively. 
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Molecular Docking Studies 
We undertook molecular docking studies of D-glucose, WZB117, and CB binding to a 
homology model of the exofacial (e2) open conformation of GLUT1 (hm-GLUT1-e2). We 
used the ligand-depleted chain A of the maltose-bound human GLUT3 (PDB code 4ZWC) 
structure (30) as the template to generate the homology model of the GLUT1-e2 (open) 
state. GLUT1 and GLUT3 share 65% sequence identity and 88% sequence similarity 
(194). ß-D-glucose docks at three high affinity sites in hm-GLUT1-e2 (figure 2.9a; figure 
2.9, a–f). We term these sites peripheral, intermediate, and core based upon their location 
within the exofacial, interstitium–exposed cavity of the GLUT1-e2 conformer. Eighteen ß-
D-glucose binding configurations were obtained at the core site. The affinity of binding 
(∆G) ranged from –6 to –4kcal/mol. Of these 18 possibilities, only 4 match the known 
stereospecificity of sugar inhibition of GLUT1-mediated L-sorbose entry in human 
erythrocytes (87). We illustrate one such complex in figure 2.10 e and f. ß-D-glucose 
binding at this site is coordinated by hydrogen bonds to Gln161, Gln282, Asn317, and 
Glu380. Two additional ß-D-glucose binding sites were detected in the exofacial cavity. ß-
D-glucose binding at the peripheral site (figure 2.10a and b) and at the intermediate site 
(figure 2.10c and d) presents fewer configurations, and in both instances C1 and its 
hydroxyl are solvent-exposed, whereas C6 and its hydroxyl are not. ß-D-glucose binding 
at the intermediate site is coordinated by hydrogen bonds to Thr30, Asn34, Val69, Ser73, 
and Asn415. This orientation of sugar is incompatible with the stereochemistry of L-
sorbose uptake inhibition described by Barnett et al. (87). 
WZB117 docking studies indicate that WZB117 can assume three positions in the 
exofacial cavity of hm-GLUT1-e2. When binding at its highest affinity site, WZB117   
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Figure 2.9: Molecular docking studies of ligand binding to hm-GLUT1 and hm-GLUT4.  
 
a, hm-GLUT1-e2 complexed with peripheral, intermediate, and core -D-glucose molecules (red). 
GLUT1 is shown in transparent, schematic representation normal to the bilayer plane (horizontal 
yellow lines), membrane spanning -helices (H1, H5, H6, H8, H9, and H10) are indicated, and 
locations of the interstitium and cytoplasm are highlighted. b, hm-GLUT1-e2 complexed with ß-
D-glucose molecules (red) and WZB117 (green). c, human GLUT1-e1 conformation complexed 
with intermediate and core ß-D-glucose molecules (red) and WZB117 (green). d, human GLUT1-
e1 conformation complexed with ß-D-glucose molecules (red), WZB117 (green), and CB 
(yellow). e, hm-GLUT1-e2 conformation complexed with WZB117. The majority of computed 
binding sites (28 of 30) overlap with intermediate and core Glc binding sites. f, hm-GLUT4 e2 
conformation complexed with WZB117. 30 potential binding sites are indicated; all overlap with 
peripheral and core Glc binding sites. 
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Figure 2.10: ß-D-glucose (a–f) and WZB117 (g and h) binding to hm-GLUT1-e2 
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The perspective is looking into the exofacial cavity of hm-GLUT1-e2 from the interstitium. The 
identities of several membrane spanning α helices (H1, H2, H4, H5, H7, H9, H11, and H12) are 
indicated in magenta in a. ß-D-glucose (in red) is shown docked to the peripheral (a and b), 
intermediate (c and d), and core (e and f) sites. Computed ∆G for ligand binding: peripheral, D-
Glc binding site ∆G = – 5.1 kcal/mol; intermediate D-Glc binding site ∆G = –5.1 kcal/mol; core 
binding site = 4.9 kcal/mol. WZB117 is shown in green (g), and its docking site overlaps with 
intermediate and core-D-Glc binding sites. ∆G for WZB117 binding = –8.22 kcal/mol. Note that 
two additional configurations of WZB117-hm-GLUT1-e2 interactions were observed: one in 
which WZB117 interacts with and spans peripheral and core-D-glucose binding sites (∆G = –
7.37 kcal/mol) and a second where WZB117interacts only with the peripheral and intermediate-
D-glucose binding sites (∆G = –6.74 kcal/mol). Binding is shown as two representations: 1) three-
dimensional in which GLUT1 is represented in transparent schematic format, Glc and WZB117 
is in stick format, and H-bonds are represented as dashed lines (a, c, e, and g); 2) two-
dimensional format in which Glc and WZB117 are shown as two-dimensional structures, 
coordinating GLUT1 residues are shown as circles, GLUT1 backbones are shown as ribbons, 
solvent-exposed regions of-D-Glc and WZB117 are indicated by gray-shaded circles, and H-
bonds and their directionality are represented as red arrows (b, d, f, and h). 
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spanned the core and intermediate ß-D-glucose binding sites (figure 2.9b and figure 2.10g 
and h). Phenol ring 1 occupied the intermediate glucose binding site and was coordinated 
by hydrogen bonds to GLUT1 residues Val69 and Asn415. Phenol ring 2 occupied the 
core glucose binding site and was coordinated by hydrogen bonds to GLUT1 residues 
Asn317 and Glu380 (figure 2.10g and h). The two lower affinity WZB117 binding sites 
comprise one in which WZB117 docks to and spans the peripheral and core D-Glc binding 
sites and a second where WZB117 interacted with the peripheral 
 and intermediate D-Glc binding sites (not shown). CB did not dock at any high affinity 
sites in hm-GLUT1-e2 but did dock to the endofacial, GLUT1-e1 conformer (GLUT1-e1; 
figure 2.9d). The e1 GLUT1 conformation presented overlapping endofacial WZB117 and 
D-glucose sites that partially overlapped with the benzene ring of CB (figure 2.9c and d). 
Discussion 
WZB117, a prototypic anticancer drug, inhibited human erythrocyte sugar transport by 
acting as a competitive inhibitor of sugar uptake and as a noncompetitive inhibitor of sugar 
exit. This suggests that WZB117 and extracellular glucose compete for binding to the 
same site on the erythrocyte sugar transporter. Molecular docking and ligand binding 
studies support this hypothesis by showing that extracellular D-glucose and WZB117 
binding sites comprise overlapping amino side chains distinct from those involved in 
binding CB, an inhibitor that acts at the endofacial sugar binding site. 
Several studies have demonstrated (regardless of the assumed carrier model) that 
reversible transport inhibitors binding at the exofacial sugar binding site of the passive 
glucose transporters serve as competitive inhibitors of net sugar uptake and equilibrium 
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exchange transport and as noncompetitive inhibitors of net sugar exit (104,118,186). 
Conversely, reversible transport inhibitors binding at the endofacial sugar binding site are 
competitive inhibitors of net sugar exit and equilibrium exchange transport and are 
noncompetitive inhibitors of net sugar uptake (104,118,186). WZB117, therefore, fits the 
profile of a reversible inhibitor binding at the exofacial sugar binding site. CB behaves as 
a reversible inhibitor that binds at the endofacial sugar binding site, although the mixed-
type inhibition of equilibrium exchange sugar transport and our molecular docking studies 
suggest that CB binding may involve more than a simple interaction with the endofacial 
sugar binding site. 
Although several permutations of D-glucose and WZB117 binding sites were identified in 
GLUT1 docking studies, the highest affinity binding sites are consistent with the transport 
and ligand binding studies presented here and with previous studies of ligand binding to 
GLUT1 (30,62,86,116,118,208,209). Three exofacial D-glucose docking sites are present 
in the interstitium exposed exofacial cavity of hm-GLUT1-e2, peripheral, intermediate, and 
core. The stereochemistry of sugar binding at the peripheral and intermediate sites is 
incompatible with the findings of previous studies describing the stereochemistry of sugar 
transport inhibition by D-glucose analogs (87), whereas several configurations of sugar 
binding at the core site are compatible with the earlier studies. We, therefore, propose that 
the core D-glucose binding site may be the site at which hexose binding subsequently 
gives rise to sugar translocation. 
WZB117 occupies three envelopes in GLUT1-e2. Envelope 1 comprises peripheral and 
core Glc binding sites, envelope 2 comprises intermediate and core Glc binding sites, and 
envelope 3 comprises peripheral and intermediate Glc sites. A majority (93%) of computed 
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WZB117:GLUT1 complexes correspond to WZB117 binding within envelope 2. The 
remaining 7% are equally distributed between envelopes 1 and 3. WZB117 geometry is 
fully extended (linear) in envelope 1 but is “L” shaped in envelopes 2 and 3. Although each 
envelope would leave one available Glc binding site available for extracellular hexose, it 
is easy to see how Glc and WZB117 would compete for binding to GLUT1. 
CB does not dock to hm-GLUT1-e2 but can be docked with high affinity to GLUT1-e1. D-
Glucose and WZB117 also dock to GLUT1-e1 but bind at overlapping (and presumably 
mutually exclusive) sites deeper within the e1 cavity. These sites do overlap with the CB 
binding site, and the observed competitions between sugar, intracellular WZB117, and CB 
for binding to GLUT1 suggest that mutually exclusive binding could result from steric 
hindrance.  
GLUT1 and GLUT3 are inhibited by WZB117 with Ki(app) of ~ 5–10 µM. GLUT4, the insulin-
sensitive glucose transporter of fat and muscle cells (210-212), is inhibited by WZB117 
with a 30 –100-fold greater potency. 
The GLUT4-e2 conformer also presents peripheral, intermediate, and core Glc binding 
sites. However, the presence of Ile42 in GLUT4 transmembrane helix 1 (Thr30 in GLUT1 
H1) leaves only linear envelope 1 (peripheral and core Glc sites) accessible to WZB117 
(figure 2.9F). Molecular docking, therefore, suggests that WZB117 preferentially occupies 
envelope 2 in GLUT1-e2 and envelope 1 in GLUT4-e2. Km(app) for sugar transport and 
Ki(app) for transport inhibition are products of multiple steps in the catalytic cycle regardless 
of the presumed mechanism of transport (118,213). It is not surprising, therefore, that 
WZB117 occupancy of different binding envelopes in two transporters characterized by 
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very different transport kinetics (97) would result in significantly different Ki(app) for sugar 
transport inhibition. 
Four observations in the present study impact our understanding of glucose transport 
mechanism, and are stated below. While the first 2 observations lend support for the 
simple carrier hypothesis, observation 3 negates the idea that exofacial and endofacial 
sugar binding sites cannot coexist. Our observations are as follows. 1) As is the case for 
extracellular maltose (118), extracellular WZB117 inhibits CB binding to GLUT1. Hence, 
the transporter’s exofacial WZB117 binding site and the endofacial CB binding site are 
mutually exclusive. If CB binds only to the GLUT1-e1 conformer, which presents an 
endofacial sugar binding site, this behavior is consistent with the simple (alternating 
conformer) carrier model for sugar transport which predicts that inhibitor binding to the 
exofacial sugar binding site should competitively inhibit CB binding (95,105,214). 2) 
Extracellular WZB117 increases Ki(app) for CB noncompetitive inhibition of sugar uptake. 
Again, this observation supports the simple (alternating conformer) carrier model for sugar 
transport (95,105,214). 3) Like extracellular maltose and intracellular CB (122,124), 
subsaturating extracellular WZB117 modestly stimulates sugar uptake. Transport 
stimulation by exofacial and endofacial transport inhibitors has been ascribed to 
cooperative interactions between co- existent exofacial and endofacial sugar binding sites 
present in the tetrameric GLUT1 transporter complex (122,124). The transporter is 
proposed to comprise four subunits (GLUT1 proteins) in which each subunit behaves as 
an alternating conformer carrier but where intersubunit cooperativity results in two 
subunits presenting exofacial (e2) orientations and 2 subunits presenting endofacial (e1) 
conformations at any instant (115,215). At subsaturating WZB117, there is a greater 
probability that only one of the two available GLUT1-e2 conformers is occupied by 
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WZB117, and its occupancy is proposed to allosterically activate sugar uptake via the 
remaining, inhibitor-free e2 subunit (124). As WZB117 is further increased, the probability 
that inhibitor occupies both e2 subunits increases and leads to sugar uptake inhibition. An 
alternative hypothesis is that exofacial ligand-induced allostery is an intra-subunit 
phenomenon in which occupancy of the exofacial cavity by polyphenolic WZB117 
increases GLUT1 affinity for, or transport of, the transported sugar through the same 
GLUT1 subunit (216). 4) Molecular docking studies reveal three exofacial D-glucose 
binding sites in the hm-GLUT1-e2 cavity, peripheral, intermediate, and core. This is 
consistent with previous observations that GLUT1 binds ≥ 2 mol of transported sugar per 
mol GLUT1 (140). Each envelope would leave one Glc binding site available for substrate. 
The results of this docking analysis, therefore, do not permit resolution of the mechanism 
of exofacial allostery (i.e. inter- or intrasubunit interactions). 
Although a promising strategy for cancer cell elimination, glucose transport inhibition using 
WZB117 could perturb organismal carbohydrate homeostasis in several important ways. 
Blood-brain and blood-tissue barrier GLUT1-dependent glucose transport will be 
depressed, perturbing peripheral and central neuro-metabolic function (127). Human, 
GLUT1-dependent, pancreatic beta cell insulin secretion in response to hyperglycemia will 
be diminished (217), and insulin-dependent, GLUT4-mediated skeletal muscle and 
adipose glucose transport will be prone to high affinity WZB117 inhibition thereby further 
compounding hyperglycemia. The net effects will include acute hyperglycemia and 
perturbations of neurometabolic function and insulin-dependent lipogenesis. These 
predictions are consistent with the reported hyperglycemia and lipodystrophy in mice after 
WZB117 treatment (165) and suggest that WZB117-treatment could induce metabolic 
syndrome/insulin resistance in individuals undergoing therapy. 
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The current study demonstrates that WZB117 inhibits facilitative sugar transport by 
competing with sugars for occupancy of the exofacial substrate binding site of the 
transporter. GLUT1, GLUT3, and GLUT4 are sensitive to transport inhibition, suggesting 
that sugar transport across the blood brain barrier in CNS astrocytes and neurons and in 
insulin-sensitive tissues is susceptible to inhibition (5). Most cancer cells rely on anaerobic 
glycolysis to generate the ATP and substrates required for cellular processes and 
proliferation (181). This contrasts with normal, differentiated cells, which mostly use 
mitochondrial oxidative phosphorylation to sustain cellular function (187). This could 
explain why sugar transport inhibition is a successful anticancer strategy in mice (165). 
However, human CNS development and function are especially dependent on glucose 
transport and metabolism (127), and the consequences of inhibition of glucose transport 
into and within the CNS could be catastrophic. We suggest, therefore, that a combination 
therapy of ketogenic diet (such as is used to manage GLUT1 deficiency; Refs. (189) and 
(218-220)) plus sugar transport inhibition might be more successful. 
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Ojelabi, O. A., Lloyd, K. P., De Zutter, J. K., and Carruthers, A. (2017) Red wine and green 
tea flavonoids act as cis-allosteric GLUT1 activators at low concentrations but are 
competitive inhibitors of glucose uptake at higher concentrations 
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the manuscript. OAO conducted all experiments except isoform specificity of transport 
inhibition. KPL contributed to the molecular docking studies. JKD conducted experiments 
on the isoform specificity of transport inhibition 
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Red wine and green tea flavonoids act as cis-allosteric GLUT1 activators at low 
concentrations but are competitive inhibitors of glucose uptake at higher 
concentrations 
Introduction 
Moderate consumption of red wine or green tea is associated with protection against 
cancer, cardiovascular disease and diabetes (221-224). These benefits are hypothesized 
to result from the flavonoid-rich content of the beverages (225). 
The flavonoids are a large group of polyphenolic secondary metabolites with over 4000 
types identified in fruits, flowers, vegetables and leaves (225,226). The general structure 
of flavonoids is a flavan backbone consisting of 2 benzene rings linked together by a 
heterocyclic pyran ring (227). Substitutions in the flavan structure by hydroxyls, methyl 
groups and sugars creates the wide range of flavonoid derivatives (225). Quercetin, 
epigallocatechin gallate (EGCG) and epicatechin gallate (ECG) are present in red wine 
and green tea and are among the most extensively characterized flavonoids. Each cup of 
green tea is estimated to contain up to 300 mg EGCG, 49 mg ECG and 14 mg quercetin 
(228-230). Red wine contains 4–16 mg/L quercetin (231,232) and although EGCG and 
ECG are known to be present in red wine (229) their levels are not well defined. The health 
benefits of flavonoids have been attributed to their strong antioxidant capacity. Flavonoids 
chelate metal ions such as Fe3+, and trap reactive species including singlet oxygen, 
superoxide radicals, nitric oxide, and peroxynitrite (225,233,234). 
Some studies, however, have shown that the red wine and green tea flavonoids quercetin, 
EGCG and ECG inhibit GLUT1-mediated facilitative glucose transport (198,199,235-237) 
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raising the possibility that the interaction of these molecules with GLUT1 and their 
downstream effects on carbohydrate metabolism contribute to their impact on health. 
While this could make sense in cancer cells where GLUT1 expression and non-oxidative 
glucose metabolism are upregulated (238), it is harder to understand how glucose 
transport inhibition would ameliorate diabetes and cardiovascular disease. 
Recent studies have suggested that GLUT1 functions as an oligomeric complex of 
interacting, allosteric, alternating access transporters (120) and that low concentrations of 
GLUT1 inhibitors acting at exofacial or endofacial sugar binding sites stimulate sugar 
transport (120,239). The present study explores the detailed structure/function 
relationships of flavonoid-GLUT1 interactions in an effort to explicate flavonoid action on 
cellular function. We find that the flavonoids act as heterotropic, cis-allosteric activators of 
sugar uptake at low concentrations and as competitive inhibitors of sugar uptake at higher 
concentrations. Low concentrations of flavonoids could, therefore, be protective against 
diabetes and Alzheimer’s, by stimulating GLUT1-mediated glucose uptake while higher 
concentrations of, flavonoids could be anti-tumorigenic by inhibiting GLUT1. 
Methods 
Reagents 
Tritium-labeled 3-O-methylglucose ([3H]-3MG), 2-deoxy-D-glucose ([3H]-2DG) 
cytochalasin B ([3H]-CB) and quercetin ([3H]-quercetin) were purchased from American 
Radiolabeled Chemicals (St. Louis, MO). Unlabeled 3MG, CB, quercetin, (-)-
epigallocatechin gallate (EGCG), (-)-epicatechin gallate (ECG) and phloretin were 
purchased from Sigma-Aldrich (St. Louis, MO). Phosphate-buffered saline (PBS) was 
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purchased from Thermo Fisher Scientific (Waltham, MA). WZB117 was purchased from 
EMD Millipore (Billerica, MA). 
Solutions 
KCl medium comprised 150 mM KCl, 5 mM HEPES, 0.5 mM EDTA, pH 7.4. Stop solution 
comprised ice-cold KCl medium plus 50 µM WZB117 and 100 µM phloretin. Sugar 
uptake/exit medium was made up in KCl medium containing 0 – 20 mM 3MG ± inhibitors 
and contained [3H]-3MG or [3H]-quercetin as indicated. HEK293 solubilization buffer 
comprised KCl medium with 1% Triton X-100. 
Cells 
De-identified whole human blood was purchased from Biological Specialty Corporation 
(Colmar, PA). HEK293 cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 
µg/mL streptomycin in a 37 °C humidified 5% CO2 incubator. 
Heterologous Expression of GLUT Isoforms 
Heterologous expression of hGLUT1, hGLUT3 and hGLUT4 in HEK293 cells was as 
previously described (97,123). Both hGLUT1 and hGLUT4 contain a myc-epitope in 
exofacial loop 1 (97), while the 13 C-terminal amino acids in hGLUT3 are replaced by the 
corresponding residues of hGLUT4 (123) to facilitate detection of heterologous 
expression. 
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Red blood Cell Transport Measurements 
All human erythrocytes sugar transport experiments were performed at 4 ºC as previously 
described (205,239). Red blood cells were isolated from whole blood, and glucose-
depleted as described previously (204,205). One volume of glucose-depleted RBCs was 
pre-incubated in 50 – 400 volumes of ice-cold KCl medium ± inhibitors at 4 ºC for 10 – 15 
min, to ensure optimal equilibration of inhibitor with GLUT1 before performing transport 
measurements. 
Zero-trans Uptake: Zero-trans [3H]-3MG or [3H]-quercetin uptake (uptake into cells lacking 
intracellular sugar or quercetin) was initiated by adding 10 volumes (100 µL) of uptake 
medium ± inhibitor to 1 volume (10 µL) of sugar-depleted, 50% hematocrit (Ht) red cells, 
and sugar uptake allowed to proceed for 30 – 60 seconds at 4 ºC. Uptake was stopped by 
adding 50 volumes (1 mL) of ice-cold stop solution containing 50 µM WZB117 and 100 
µM phloretin. Cells were washed one more time in stop solution, lysed in 3% perchloric 
acid, and radioactivity assayed in clarified lysates using liquid scintillation counting. 
Radioactivity measurements were done in duplicates. 
Zero-trans Exit: Glucose-depleted, packed RBCs were loaded with 10 mM 3MG by 
incubating 1 volume of cells with 20 volumes of 20 mM 3MG (containing 1 µCi [3H]-
3MG/mL of cold 3MG) for 1 hour at 37 ºC. Immediately following 3MG loading, cells were 
transferred to 4 ºC and pre-incubated with or without inhibitors for 10 – 15 min. Cell 
suspension were spun at 10,000 x g for 1 min, and supernatant discarded. One volume 
(0.5 mL) of sugar-loaded RBCs were added to 50 volumes of KCl medium ± inhibitor on a 
shaker with magnetic stirrer. Aliquots (0.5 mL) of the suspension were withdrawn at 
indicated time intervals, and immediately added to 1 mL ice-cold stop solution. Cells were 
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washed again in stop solution, lysed in 3% perchloric acid and assayed in duplicate for 
radioactivity. 
HEK-293 Cell Sugar Uptake 
All HEK293 cell sugar uptake measurements were performed at 37 ºC, using 100 µM 2-
deoxyglucose (2DG plus [3H]-2DG) as described previously (97,143). 
Equilibrium CB Binding 
CB binding to human red cells was performed as previously described (116,239). Briefly, 
50 µL of sugar-depleted RBC (50% Ht) ± inhibitors were mixed with 50 µL of ice-cold KCl 
medium containing 40 nM [3H]-CB and 10 µM cytochalasin D for 15 min at 4 ºC, with 
constant end-over-end rotation. Total [CB] was obtained from 2 x 10 µL of the cell 
suspension lysed in 100 µL of 3% perchloric acid, and radioactivity assayed for by liquid 
scintillation counting. To obtain free [CB], cell suspension was centrifuged at 10,000 x g 
for 30 s, and 2 x 10 µL of clarified supernatant were assayed for radioactivity. Bound [CB] 
was calculated as Total [CB] – Free [CB]. 
Homology Modeling 
The homology models of the outward-open (e2) conformations of GLUT1 and GLUT4 
were generated using the maltose-bound human GLUT3 structure (PDB code: 4ZWC) 
(30). Maltose was removed from the GLUT3 structure and chain A was used as the 
template for modeled structures.  Sequence alignments were generated using ClustalX 
(240). Homology models were built using Modeller-9.9 (241) and analyzed using 
PROCHECK (242). 
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Stochastic docking 
The crystal structure of outward-open hGLUT3-e2 (4ZWC) (30) was obtained from the 
protein databank (http://www.rcsb.org/pdb/home/home.do). The structures for β-D-
Glucose, quercetin, EGCG and ECG were obtained from Pubchem 
(https://pubchem.ncbi.nlm.nih.gov). Docking was performed using the Schrodinger 
software suite. The protein structure was preprocessed with the Protein Preparation 
Wizard, bond orders were assigned, hydrogens added and the H-bond network was 
optimized. The system was energy minimized using the OPLS 2005 force field. Ligand 
structures were prepared with the LigPrep module and the pKa of the ligands was 
calculated using the Epik module. Molecular docking was performed by the GLIDE module 
in standard-precision (SP) mode and default values for grid generation. Cavities for 
docking were calculated using the CastP server (http://sts.bioe.uic.edu/castp/) and the grid 
was centered on the residues forming the cavity. No restraints were used during the 
docking. 
Data analysis 
Linear and nonlinear regression analysis of data sets and statistical tests were performed 
using GraphPad Prism (Version 7.0a; La Jolla, CA). 
Michaelis-Menten inhibition of sugar transport is assumed to be described by: 
 
𝑉 = 𝑉𝑐–
𝑉𝑐[𝐼]
𝐾𝑖(𝑎𝑝𝑝) + [𝐼]
 (equation 3.1) 
where Vc is V measured in the absence of inhibitor I, [I] is the concentration of inhibitor 
and Ki(app) is that [I] producing 50% inhibition of uptake. 
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Michaelis-Menten transport is assumed to be described by: 
 
𝑉 =
𝑉𝑚𝑎𝑥[3𝑀𝐺]
𝐾𝑚(𝑎𝑝𝑝) + [3𝑀𝐺]
 (equation 3.2) 
where Vmax is the maximum rate of 3MG transport, [3MG] is the concentration of 3MG and 
Km(app) is the [3MG] where the rate of uptake is Vmax/2. Sugar exit was analyzed by 
nonlinear regression analysis using Mathematica 10.4.1.0 (Wolfram Research) assuming 
that exit follows Michaelis-Menten kinetics and that the first derivative of the exit progress 
curve represents d[S]/dt at any given [S] (239). 
Transport stimulation followed by inhibition by inhibitors was approximated first by 
normalizing all uptake to Vc and then using the following model: 
 𝑉𝑖
𝑉𝑐
=
𝐶𝑜𝑛𝑠𝑡1 + [𝐼](𝐶𝑜𝑛𝑠𝑡2 + [𝐼])
𝐶𝑜𝑛𝑠𝑡1 + [𝐼](𝐶𝑜𝑛𝑠𝑡3 + [𝐼]𝐶𝑜𝑛𝑠𝑡4)
 (equation 3.3) 
where Vc is uptake measured in the absence of inhibitor I, Vi is uptake measured in the 
presence of inhibitor, [I] is the concentration of inhibitor and Const1 through Const4 are 
model dependent (120). 
Inhibition of [3H]-CB binding to GLUT1 by ligands was analyzed by simple competitive 
inhibition using the model: 
 [𝐶𝐵]𝑏
[𝐶𝐵]𝑓
=
𝐾𝑖(𝑎𝑝𝑝)(𝐾𝐶𝐵 + [𝐶𝐵])
[𝐼]𝐾𝐶𝐵 + 𝐾𝑖(𝑎𝑝𝑝)(𝐾𝐶𝐵 + [𝐶𝐵])
 (equation 3.4) 
where [CB]b = bound [CB], [CB]f = free [CB], Ki(app) is the apparent inhibitory constant for 
inhibition of CB binding by inhibitor, I, and KCB is dissociation constant for CB binding to 
GLUT1. 
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CB binding was also analyzed using a variation of Michaelis-Menten equilibrium binding 
kinetics in which the transporter is allowed to bind more than one molecule of competing 
ligand, I 
 [𝐶𝐵](𝑏/𝑓)𝑖
[𝐶𝐵](𝑏/𝑓)𝑐
= 1 −
𝐾[𝐼]𝑛
𝐾𝐼 + [𝐼]𝑛
 (equation 3.5) 
where [CB](b/f)I = the ratio of bound to free [CB] measure in the presence of inhibitor I, 
[CB](b/f)c = the ratio of bound to free [CB] measure in the absence of inhibitor, K is a number 
where 0 ≤ K ≤ 1, KI is Kd(app) for I binding to GLUT1 and n is the number of inhibitor binding 
sites. 
Results 
Dose-dependent inhibition of human erythrocyte sugar transport by dietary flavonoids 
Dietary flavonoids are reported to impair cellular sugar transport to varying degrees in 
different cell types (199,236,243-246). Here we tested the effect of quercetin, EGCG and 
ECG on GLUT1-mediated zero-trans sugar uptake (uptake in the absence of intracellular 
sugar) in human red blood cells. Figure 3.1A–D shows the chemical structures of the 
quercetin, EGCG and ECG, as well as the general backbone (flavan nucleus) of all 
flavonoids. Quercetin, EGCG and ECG inhibit uptake of 0.1 mM 3-O-methylglucose (3MG) 
in a dose-dependent manner, with Ki(app) = 1.882 ± 0.3324 µM, 9.631 ± 1.947 µM, and 
1.902 ± 0.315 µM respectively (figure 3.1E). 
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Figure 3.1: Chemical structures and dose-dependent inhibition of human erythrocytes 
zero-trans 3MG (0.1 mM) uptake by quercetin, EGCG and ECG 
 
A, Flavan skeleton which provides the basic backbone for over 4000 identified flavonoids, 
including quercetin (B), epigallocatechin gallate (EGCG) (C), and epicatechin gallate (ECG) (D). 
E, Ordinate: 3MG uptake in mmol/L cell water/min; Abscissa: [Inhibitor] in µM. Results are shown 
for quercetin (●), EGCG (△), and ECG (▲). Each point represents the mean ± SEM of at least 
3 duplicate measurements. The points were fitted by nonlinear regression assuming that uptake 
is completely inhibited by inhibitors in a dose-dependent manner (equation 3.1), with the 
following results: quercetin-treated cells (●): Ki(app) = 1.882 ± 0.332 µM, R2 = 0.915, standard 
error of regression = 0.012 mmol/L cell water/min; EGCG-treated cells (△): Ki(app) = 9.631 ± 
1.947 µM, R2 = 0.873, standard error of regression = 0.012 mmol/L cell water/min; ECG-treated 
cells (▲): Ki(app) = 1.902 ± 0.315 µM, R2 = 0.929 standard error of regression = 0.008 mmol/L cell 
water/min. 
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Quercetin, EGCG and ECG competitively inhibit net sugar uptake, but are noncompetitive 
inhibitors of net sugar exit by human erythrocytes 
We determined the sidedness of flavonoid action on GLUT1 by examining their effects on 
2 modes of red cell sugar transport: 1) zero-trans 3MG uptake (influx into sugar-free cells), 
and 2) zero-trans 3MG exit (efflux from sugar-loaded cells into medium lacking sugar). 
Transport theory informs us (117,118) that a ligand competing with sugar for binding at 
the exofacial sugar binding site serves as a competitive inhibitor of sugar uptake and as a 
noncompetitive inhibitor of sugar exit. Conversely, a ligand competing with sugar for 
binding at the endofacial sugar binding site serves as a noncompetitive inhibitor of sugar 
uptake and as a competitive inhibitor of sugar exit. 
The flavonoids increase Km(app) for sugar uptake from 2.39 ± 0.356 mM to 11.07 ± 5.03 
mM (quercetin), 10.64 ± 2.63 mM (EGCG) and 7.14 ± 2.63 mM (ECG), without significantly 
affecting Vmax for uptake (1.202 ± 0.082 mmol/L cell water/min; figure 3.2A). This suggests 
that quercetin, EGCG and ECG inhibit GLUT1-mediated sugar uptake by binding at the 
exofacial 3MG binding site or at a site whose occupancy is mutually exclusive with 3MG 
occupancy of the exofacial sugar binding site. Consistent with this idea, the flavonoids act 
as noncompetitive inhibitors of net 3MG exit: they are without effect on Km(app) (12.9 mM) 
for exit, but decrease Vmax for exit by more than 2-fold from 2.03 mmol/L cell water/min to 
0.89 (quercetin), 0.72 (EGCG), and 0.60 mmol/L cell water/min (ECG; figure 3.2B). 
Subsaturating concentrations of Quercetin, EGCG, and ECG stimulate GLUT1-mediated 
sugar uptake in human red blood cells 
We have previously shown that low concentrations of exofacial inhibitors (e.g. WZB117   
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Figure 3.2: Effects of quercetin, EGCG and ECG on Michaelis-Menten kinetics of zero-
trans 3MG uptake (A) and zero-trans 3MG exit (B) 
 
Results are shown for control cells (○), quercetin-treated cells (●), EGCG-treated cells (△), 
and ECG-treated cells (▲). Each data point represents the mean ± SEM of at least 3 
experiments measured in duplicates. A, Ordinate: 3MG uptake in mmol/L cell water/min; 
Abscissa: [3MG] in mM. Curves drawn through the points were computed by Michaelis-Menten 
uptake kinetics as in equation 3.2. The results are: Control cells (○): Vmax = 1.202 ± 0.082 
mmol/L cell water/min, Km(app)  = 2.39 ± 0.36 mM, R2 = 0.934, standard error of regression = 
0.072; quercetin-treated cells (●): Vmax = 1.976 ± 0.663 mmol/L cell water/min, Km(app)  = 11.07 
± 5.03 mM, R2 = 0.893, standard error of regression = 0.074; EGCG-treated cells (△): Vmax = 
2.137 ± 0.387 mmol/L cell water/min, Km(app) = 10.64 ± 2.63 mM, R2 = 0.965, standard error of 
regression = 0.046; ECG-treated cells (▲): Vmax = 1.717 ± 0.292 mmol/L cell water/min, Km(app)  
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= 7.14 ± 1.85 mM, R2 = 0.937, standard error of regression = 0.065. B, Ordinate: [3MG]i in 
mmol/L cell water; Abscissa: Time in minutes. Curves drawn through the points were computed 
by numerical integration and nonlinear regression assuming Michaelis-Menten exit kinetics 
(equation 3.2) with the following results: Control cells (○): Vmax = 2.033 mmol/L cell water/min, 
Km(app) = 12.90 mM, R2 = 0.999, standard error of regression = 0.014 mmol/L cell water/min; 
quercetin treatment (●): Vmax = 0.894 mmol/L cell water/min, Km(app)  = 12.10 mM, R2 = 0.989, 
standard error of regression = 0.050; EGCG treatment (△): Vmax = 0.720 mmol/L cell water/min, 
Km(app) = 12.30 mM, R2 = 0.972, standard error of regression = 0.075; ECG treatment (▲): Vmax 
= 0.600 mmol/L cell water/min, Km(app) = 12.10 mM, R2 = 0.999, standard error of regression = 
0.016. 
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Figure 3.3: Subsaturating concentrations of quercetin, EGCG, and ECG stimulate 3MG 
uptake 
 
Relative 3MG uptake. Abscissa: Concentration of inhibitors in M (expressed in log scale). Results 
are shown for cells treated with quercetin (●), EGCG (△), and ECG (▲). Each data point 
represents the mean ± SEM of at least 3 duplicate measurements. The curves drawn through 
the data points were computed by nonlinear regression using equation 3.3 and have the following 
constants: quercetin treatment (●): Const1 = 4.69 x 10-5 ± 2.05 x 104, Const2 = 2.59 x 104 ± 1.13 
x 1013, Const3 = 1.80 x 104 ± 7.83 x 1012, Const4 = 1.17 x 1010 ± 5.08 x 1018, R2 = 0.966, standard 
error of regression = 0.101; EGCG treatment (△): Const1 = 3.02 x 102 ± 5.13 x 106, Const2 = 
1.27 x 104 ± 2.14 x 1012, Const3 = 2.60 x 103 ± 4.40 x 1011, Const4 = 2.19 x 109 ± 3.71 x 1017, R2 
= 0.923, standard error of regression = 0.135; ECG treatment (▲): Const1 = 4.44 x 102 ± 9.49 x 
107, Const2 = 9.86 x 102 ± 2.11 x 1012, Const3 = 1.74 x 104 ± 3.72 x 1013, Const4 = -4.46 x 107 ± 
9.53 x 1016, R2 = 0.866, standard error of regression = 0.167. 
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and maltose) or endofacial inhibitors (e.g cytochalasin B) of GLUT1-mediated sugar 
transport modestly stimulate red cell sugar uptake (122,124,239). Consistent with these 
reports, quercetin (≤ 0.5 µM), EGCG (≤ 2.5 µM) and ECG (≤ 0.5 µM) reproducibly stimulate 
erythrocyte zero-trans 3MG uptake by up to 35% (p < 0.05; figure 3.3). These results 
suggest that GLUT1 presents at least 2 exofacial flavonoid binding sites – one that 
stimulates sugar uptake and a second site that inhibits uptake (120). 
Quercetin, EGCG and ECG interfere with cytochalasin B (CB) binding to human 
erythrocytes 
CB is a membrane-permeant, GLUT1 inhibitor which binds to the endofacial glucose 
binding site (117,118). Extracellular maltose, but not glucose, inhibits equilibrium binding 
of the CB to the endofacial glucose binding site of GLUT1 (124,247). We asked if exofacial 
binding of quercetin, EGCG, or ECG interfere with equilibrium binding of 3H-CB to GLUT1. 
Quercetin, EGCG, ECG, and nonradioactive CB inhibit [3H]-CB binding to GLUT1 with 
Ki(app) of 0.637 ± 0.071 µM, 6.097 ± 0.726 µM, 0.871 ± 0.103 µM, and 0.064 ± 0.003 µM 
respectively (figure. 3.4A). While these curve fits produce good correlation coefficients (R2 
> 0.91 in all cases), the standard deviation of residuals of the fit (0.09) is greater than 20% 
of the standard deviation of the y values suggesting that the fit is poor. 
Closer examination reveals that inhibition by quercetin and EGCG increases more steeply 
while inhibition produced by ECG increases less steeply than is expected for simple 
Michaelis-Menten inhibition. Inhibition of radiolabeled CB binding by unlabeled CB is well-
described by simple Michaelis-Menten inhibition. We therefore asked if the quercetin, 
EGCG and ECG data are better approximated by inhibition involving multiple, cooperative 
ligand binding sites and applied a simple, Hill-type model to analyze these results (figure   
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Figure 3.4: Exofacial interaction of flavonoids with GLUT1 interfere with CB binding to 
human red blood cells 
 
A, Inhibition of [3H]-CB binding to human RBCs. Ordinate: Normalized ratio of bound [3H]-CB 
to free [3H]-CB. Abscissa: Concentration of inhibitors in µM (expressed in log scale). Results 
are shown for cells treated with quercetin (●), EGCG (△), ECG (▲) and non-radioactive CB (
○). Each data point represents the mean ± SEM of duplicate measurements of 3 separate 
experiments. The curves drawn through the data points were computed by nonlinear regression 
using equation 3.4, with the following results: quercetin treatment (●): Ki(app) = 0.637 ± 0.071 
µM, R2 = 0.948, standard error of regression = 0.087; EGCG treatment (△): Ki(app) = 6.097± 
0.726 µM, R2 = 0.949, standard error of regression = 0.089; ECG treatment (▲): Ki(app) = 0.871 
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± 0.103 µM, R2 = 0.910, standard error of regression = 0.094; nonradioactive CB treatment (○
): Ki(app) = 0.064 ± 0.003 µM, R2 = 0.988, standard error of regression = 0.036. The residuals of 
the fits (for quercetin, EGCG and ECG data) are plotted beneath the inhibition plot. B, 
Reanalysis of the same data set assuming multiple binding sites for competing ligand using the 
Hill-equation (equation 3.5). The results are: quercetin treatment (●): Ki(app) = 0.89 ± 0.14 µM, 
n = 1.53 ± 0.14, R2 = 0.974, standard error of regression = 0.064; EGCG treatment (△): Ki(app) 
= 21.75 ± 7.80 µM, n = 1.51 ± 0.16, R2 = 0.976, standard error of regression = 0.063; ECG 
treatment (▲): Ki(app) = 1.34 ± 0.30 µM, n = 0.75 ± 0.08, R2 = 0.94, standard error of regression 
= 0.083; nonradioactive CB treatment (○): Ki(app) = 0.074 ± 0.014 µM, n = 1.08 ± 0.07, R2 = 
0.991, standard error of regression = 0.034. The residuals of the fits (for quercetin, EGCG and 
ECG data) are plotted beneath the inhibition plot. C, Ordinate: 3MG uptake in mmol/L cell 
water/min. Abscissa: Concentration of inhibitors in µM (expressed in log scale). Results are 
shown for CB-treated cells (○), and CB-treated cells plus 2 µM quercetin (●), 20 µM EGCG 
(△), or 5 µM ECG (▲). Each data point represents the mean ± SEM of at least 3 duplicate 
measurements. The curves drawn through the data points were computed by nonlinear 
regression using equation 3.1 and have the following results: CB only treatment (○): Ki(app) = 
0.240 ± 0.003 µM, R2 = 0.936, standard error of regression = 0.007; CB + 2 µM quercetin 
treatment (●): Ki(app) = 0.619 ± 0.175 µM, R2 = 0.831, standard error of regression = 0.004; CB 
+ 20 µM EGCG treatment (△): Ki(app) = 0.619± 0.123 µM, R2 = 0.897, standard error of 
regression = 0.004; CB + 5 µM ECG treatment (▲): Ki(app) = 0.713 ± 0.119 µM, R2 = 0.941, 
standard error of regression = 0.002. 
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3.4B). The analysis produces better fits with residuals that do not deviate from zero and 
the standard error of the residuals is significantly reduced. The analysis indicates that 
quercetin, EGCG, ECG and CB interact with 1.53 ± 0.14, 1.51 ± 0.16, 0.75 ± 0.08 and 
1.08 ± 0.07 sites per CB binding site respectively with inhibitory constants of 0.89 ± 0.14, 
21.75 ± 7.80, 1.34 ± 0.30 and 0.17 ± 0.02 µM respectively (figure 3.4B). 
To further test the effects of flavonoids on CB binding to erythrocyte GLUT1, we measured 
the concentration dependence of CB inhibition of 3MG (0.1 mM) uptake ± flavonoids in 
human red cells. The presence of quercetin (2 µM), EGCG (20 µM) or ECG (5 µM) 
increases the Ki(app) for CB inhibition of 3MG uptake by at least 2.5-fold (figure 3.4C). 
Assuming simple competition between the flavonoids and CB for binding to GLUT1 (but 
see figure 3.4B), the computed Ki(app) for quercetin (2 µM), EGCG (20 µM) and ECG (5 
µM) inhibition of CB inhibition (Ki(app) = 0.24 ± 0.03 µM) of transport are 1.88 ± 0.33, 9.63 
± 1.95 and 1.90 ± 0.32 µM respectively. These results indicate that exofacial inhibitors 
impair CB binding to the GLUT1 endofacial sugar binding site and thereby reduce the 
potency of CB inhibition of sugar transport. 
Quercetin does not cross the cell membrane via a GLUT1-dependent pathway 
To act as potent cytoplasmic antioxidants, the flavonoids must first cross the cell 
membrane. Previous studies have suggested that dietary flavonoids permeate cell 
membranes both by protein-independent transbilayer diffusion (248,249), and via carrier 
proteins, including GLUT1, GLUT4, SGLT1 and MCT (198,235,250-252). If GLUT1 
transports quercetin, as suggested by Cunningham et al (198), [3H]-quercetin uptake by 
human erythrocytes should be inhibited by high concentrations of CB (figure 3.5A). CB 
(20 µM) almost completely inhibits [3H]-3MG uptake, but is without effect on [3H]-quercetin   
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Figure 3.5: Quercetin is not transported by GLUT1 
 
A, Effect of CB on [3H]-quercetin and [3H]-3MG uptake by human erythrocytes. Ordinate: 
Relative substrate uptake. Abscissa: Radiolabeled substrate. Results are shown for control (□) 
and 20 µM CB-treated cells (■). Each bar represents the mean ± S.E.M of 3 separate 
experiments measured in duplicates. Analysis by unpaired t test indicates: ***, significant [3H]-
3MG uptake inhibition by CB (p < 0.0005), n.s., no significant difference in [3H]-quercetin 
uptake with or without CB treatment (p > 0.05). B, Relative [3H]-3MG and [3H]-quercetin spaces 
of RBCs. Ordinate Equilibration relative to the equilibrated 3MG space of the cell. Time course 
analysis indicates that [3H]-quercetin achieves equilibrium uptake within 5 minutes of exposure 
to cells. Each bar represents the mean ± S.E.M of 3 separate experiments measured in 
duplicates. Analysis by unpaired t test indicates: **, significant difference between the 3MG 
and quercetin cell volume (p = 0.0044). 
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influx into human RBCs (figure 3.5A). Analysis of [3H]-quercetin binding normalized to the 
RBC equilibrium 3MG space (i.e. accessible cell water) reveals that quercetin achieves 
up to 70% equilibration with human RBC cell water (figure 3.5B). 
Molecular docking of quercetin, EGCG and ECG to GLUT1 
We investigated potential interactions of ß-D-glucose, quercetin, EGCG and ECG with the 
exofacial sugar binding site by molecular docking using a homology modeled GLUT1 
outward-open (GLUT1e2) structure (120). The exofacial, interstitium-exposed cavity of 
GLUT1e2 presents 3 potential ß-D-glucose docking sites – peripheral, intermediate and 
core (120,239). Benzene ring A (figure 3.1A–D) in quercetin, EGCG and ECG overlaps 
with the proposed core ß-D-glucose docking site (ref. (239); and figure 3.6A–D) while 
benzene ring B in quercetin interacts with intermediate and peripheral sites via hydrogen 
bonding and/or hydrophobic interactions (figure 3.6B). In EGCG and ECG, benzene ring 
B is flipped 45º, and makes additional interactions with core ß-D-glucose docking site, 
while their gallate group overlaps with the intermediate ß-D-glucose docking site (figure 
3.6C & D). 
The residues contributing to ß-D-glucose docking at core, intermediate, and peripheral ß-
D-glucose have been previously described (239). Figure 3.6E–H illustrates the putative 
hydrogen bond and hydrophobic contacts of core ß-D-glucose, quercetin, EGCG and ECG 
with GLUT1-e2. All ligands form 5 common hydrophobic interactions (Ile164, Val165, 
Ile168, Phe291 & Phe379), and 1 hydrogen bond interaction at Glu380 (figure 3.6E-H). 
Additionally, each inhibitor forms hydrogen bonds with Asn34 and Gln283 (figure 3.6F–
H), but quercetin forms 3 additional hydrogen bonds (Gln283, Glu380 and Asn415; figure 
3.6F). EGCG and ECG form more hydrophobic contacts with GLUT1-e2 than does   
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Figure 3.6: Molecular docking of ß-D-glucose, quercetin, EGCG and ECG to homology-
modeled exofacial GLUT1 conformation 
A–D, Homology-modeled exofacial GLUT1 (hm-GLUT1-e2) is shown in cartoon representation, and 
membrane spanning helixes are indicated. Ligands – peripheral, intermediate and ß-D-glucose (red); 
quercetin (cyan); EGCG (sky blue); ECG (light blue) – are shown as spheres complexed with hm-
GLUT1-e2, and as sticks in the zoomed in sections. E–G, Interactions between ligands and hm-
GLUT1-e2, showing residues that form hydrogen bonds and hydrophobic interactions. Color scheme 
is the same as in A–D, and hydrogen bonds are represented by yellow dashed lines. 
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quercetin (figure 3.6G & H). 
Isoform specificity of transport inhibition 
Neuronal GLUT3, and the insulin-sensitive GLUT4 share 93% and 85% sequence 
similarity with GLUT1 respectively (29). We therefore asked if Ki(app) for quercetin, EGCG 
and ECG inhibition of GLUT3 and GLUT4 resemble Ki(app) for their inhibition of GLUT1 or 
if they present an unanticipated selectivity towards these proteins. We stably expressed 
hGLUT1, hGLUT3 or hGLUT4 into HEK293 cells and assayed for the dose-dependent 
inhibition of 100 µM 2-deoxy-D-glucose uptake (2DG) at 37 ºC. Quercetin, EGCG and 
ECG inhibit GLUT1-, GLUT3- and GLUT4-mediated 2DG uptake in HEK-293 cells (figure 
3.7A–C). Ki(app) for quercetin-inhibition of GLUT1, GLUT3 and GLUT4 are 2.00 ± 0.98, 
17.68 ± 1.71 and 1.70 ± 0.25 µM respectively, suggesting that quercetin may have 
reduced affinity for GLUT3 relative to GLUTs 1 and 4. Ki(app) for EGCG-inhibition of GLUT1, 
GLUT3 and GLUT4 are 9.09 ± 4.99, 14.44 ± 8.19 and 8.45 ± 5.47 µM respectively, 
suggesting that EGCG may interact with GLUTs 1, 3 and 4 with similar affinities. Analysis 
of ECG inhibition of transport does not converge as successfully because these 
experiments demonstrate significant allosteric activation of transport at subsaturating 
inhibitor concentration. Assuming simple saturable inhibition of transport, Ki(app) for ECG-
inhibition of GLUT1, GLUT3 and GLUT4 are 22.7 ± 17.3, 199.4 ± 333.4 and 126.2 ± 106.3 
µM respectively. The large errors associated with these estimates indicate that additional 
measurements are needed to confirm any suggested isoform-specific differences in 
affinity for ECG. 
Docking of quercetin, EGCG and ECG to exofacial GLUT3 and GLUT4 reveal that these 
ligands coordinate with equivalent residues when docked to the same GLUT isoform, but   
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Figure 3.7: Isoform specificity of sugar transport inhibition by quercetin, EGCG and ECG 
 
Results are shown for transport inhibition by quercetin (A), EGCG (B) and ECG (C), in 
untransfected (○), and in transfected HEK293 cell stably expressing hGLUT1 (●), hGLUT3 (△
), or hGLUT4 (▲). Ordinate: 2–deoxyglucose uptake in mol/µg protein/min; Abscissa: inhibitor 
concentration in µM (axis shown in log scale). The curves drawn through the data points were 
computed by nonlinear regression using equation 3.1, with results shown in table 3.1. 
 
Table 3.1: Inhibition of GLUT1-, GLUT3- and GLUT4-mediated 2DG uptake in HEK293 cells 
by quercetin, EGCG and ECG 
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Figure 3.8: 2-dimensional representation of ligands interactions with hm-GLUT1-e2, GLUT3-e2 and 
hm-GLUT4-e2 interactions 
 
Residues within 4Å distance to docking ligand are shown for quercetin (A), EGCG (B) and ECG (C). 
Residues and contacts are shown in the following color codes: Polar, blue; hydrophobic, green; negatively 
charged, orange; positively charged, violet; hydrogen bond; purple arrow. 
  
 83 
differ significantly when their interactions are compared across GLUT1, GLUT3 and 
GLUT4 (figure 3.8). 
Discussion 
The major dietary flavonoids in red wine and green tea inhibit the facilitative glucose 
transporter, GLUT1, by interacting with its exofacial sugar binding site. Quercetin, EGCG 
and ECG competitively inhibit net sugar uptake by human erythrocytes but are 
noncompetitive inhibitors of sugar exit from cells. This finding is supported by homology 
modeling and molecular docking studies which reveal that quercetin, EGCG and ECG 
overlap with extracellular D-glucose for binding to GLUT1. Additionally, we show that 
quercetin does not cross cell membranes via a GLUT1-dependent pathway. 
Our data on the sidedness of action of quercetin, EGCG and ECG are consistent with 
previous reports suggesting that quercetin (236,246), and EGCG (199) compete with 
extracellular glucose for  binding to the exofacial sugar binding site of GLUT1. Consistent 
with this conclusion, quercetin, EGCG and ECG all dock within the same binding pocket 
in the central cavity of GLUT1-e2 overlapping with the previously defined core ß-D-glucose 
docking site ((239), and figure 3.6), and form hydrogen bonds and/or hydrophobic 
interactions with the intermediate and peripheral ß-D-glucose docking sites. ß-D-glucose 
coordination by our homology model of GLUT1-e2 involves the same residues as those 
reported in the ß-D-glucose-bound human GLUT3-e2 crystal structure (30), lending further 
support to the present molecular docking analyses. Core ß-D-glucose, quercetin, EGCG 
and ECG all form hydrophobic interactions with Ile164, Val165, Ile168, Phe291 and 
Phe379; and hydrogen bonds with Glu380, suggesting that these residues are important 
for exofacial ligand binding to GLUT1. 
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Quercetin and ECG inhibit GLUT1 with a Ki(app) of ~ 2 µM but EGCG (Ki(app) ~ 10 µM) has 
a 5-fold lower inhibitory potency. There are no striking differences in the docking of EGCG 
and ECG to GLUT1-e2 that explain the difference in potency. It is not surprising that EGCG 
and ECG interact with the same residues in GLUT1-e2, since their chemical structures 
are almost identical (the only difference is the presence of a hydroxyl group at C3’ in 
EGCG, which is absent in ECG). According to our docking analysis, C3’–OH is not 
involved in EGCG interaction with GLUT1. The similarity in computed ECG–GLUT1 and 
EGCG–GLUT1 interactions stands in contrast to the 5-fold greater transport inhibitory 
potency of ECG versus EGCG (figure 3.1E) and serves to emphasize the current 
limitations of docking analysis. 
Consistent with previous equilibrium CB binding studies exploring the effects of 
extracellular maltose on CB binding (118,124), exofacial quercetin, EGCG or ECG, inhibit 
intracellular binding of CB to GLUT1. Ki(app) for inhibition of CB binding is 1.6 – 3 fold lower 
than Ki(app) for transport inhibition. This is not explained by competition between inhibitor 
and transported sugar for binding to the exofacial site because saturation of GLUT1 by 
0.1 mM 3MG is less than 5% (Km(app) for 3MG = 2.4 mM; see figure 3.2A). Curve fit analysis 
indicates that Sy.x (square root of the sum of the squared residuals, divided by the number 
of measurements-number of fitted parameters) for nonlinear fits to equation 3.4 are poor 
(0.04 - 0.1). Fitting the data to a model comprising multiple cooperative binding sites 
(equation 3.5) produces significantly better fits (figure 3.4B; Sy.x = 0.03 - 0.08). These 
results suggest that GLUT1 presents at least 2 positively cooperative binding sites each 
for quercetin and EGCG and, because Hill analysis revealed n < 1 for ECG, two or more 
negatively cooperative binding sites for ECG. Our docking analyses do not reveal the 
possibility of a second binding site for these ligands in GLUT1-e2, suggesting that the 
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cooperativity effects observed with these ligands is due to GLUT1 oligomerization. 
We considered the possibility that the flavonoids also compete directly with CB for binding 
at the endofacial sugar binding site. This would explain their competitive displacement of 
CB from GLUT1 and would also be consistent with previous demonstrations of 
cooperativity between endofacial ligand binding sites present on adjacent GLUT1 subunits 
forming the membrane-resident GLUT1 tetramer  (115,121,122,124). Molecular docking 
of CB and quercetin to the endofacial orientation of GLUT1 (GLUT1-e1; (28)) supports the 
hypothesis that CB and quercetin could compete for high affinity binding to GLUT1 (not 
shown). However, inhibition of transport by a molecule that can bind with equal avidity to 
both exo- and endofacial sugar binding sites should produce noncompetitive inhibition of 
both net uptake or net exit (reduced Vmax) and competitive inhibition of equilibrium-
exchange transport (117,118). Flavonoid inhibition of net uptake is, however, observed to 
be competitive (figure 3.2A). If such an inhibitor were to bind with 500-fold lower affinity to 
the endofacial binding site versus the exofacial site, it would increase Km(app) for net sugar 
uptake but Vmax for uptake would also be reduced by > 65% (117,118) and this is not 
observed. This complex cooperativity (positive and negative) in flavonoid inhibition of CB 
binding to GLUT1 reinforces the conclusion that analyses of ligand binding to GLUT1 
which assume simple, saturable equilibrium binding represent a significant 
oversimplification of the behavior. 
The actions of the flavonoids on GLUT1-mediated sugar transport demonstrate an 
additional form of cooperativity which we have termed cis-allostery (120). Quercetin, 
EGCG and ECG, like other exofacial GLUT1 inhibitors (e.g WZB117; (239) and maltose 
(122)), stimulate GLUT1-mediated sugar uptake at low inhibitor concentrations then inhibit 
 86 
transport as their concentration is raised further. This observation reinforces the idea that 
GLUT1 presents at least 2 exofacial ligand binding sites at any given time (122,124). 
Binding of ligand at a high affinity site stimulates glucose uptake via a catalytic sugar 
binding site. As ligand concentration is then raised further, ligand and sugar now compete 
for binding at the active site and transport is inhibited. 
Inhibition of GLUT1 by high flavonoid concentrations (≥ 2 µM for quercetin and ECG; ≥ 10 
µM for EGCG) could explain, at least in part, the anticancer action of flavonoids. GLUT1 
inhibition studies have demonstrated that small molecule inhibition of GLUT1 results in a 
cascade of downstream events including downregulation of glycolytic enzymes, cell cycle 
arrest, and ultimately, cell death (165). Whereas, stimulation of GLUT1-mediated glucose 
uptake by low concentrations of flavonoids (≤ 0.5 µM for quercetin and ECG; ≤ 2.5 µM for 
EGCG), could explain the protective effects of flavonoids against diseases, such as 
diabetes (253-255) and neurodegenerative diseases (256-259), where enhanced glucose 
uptake from the blood could be ameliorative. 
Flavonoids have been shown to modulate several cellular targets including MAP kinase, 
CDKs, HIF-1α, and vimentin (260). Whether flavonoids interact directly or indirectly with 
their cytoplasmic targets is still unclear. There are suggestions, however, that flavonoids 
may not readily cross the plasma membrane, with studies showing that less than 1% of 
orally-ingested flavonoids make it into the bloodstream (261). It has been proposed that 
flavonoids are transported into cells by carrier proteins including 
SGLT1(251,252,262,263), MCT(250), GLUT1(198) and GLUT4 (235), while others have 
suggested that flavonoids interact with membrane phospholipids to cross cell membranes 
(248,249). This current study indicates that, while quercetin may cross the plasma 
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membrane, it does so via a GLUT1-independent pathway. This is contrary to the 
conclusion by Cunningham et. al. (198) that quercetin is transported into cells by GLUT1, 
but is consistent with the failure of GLUT1 inhibitors, phloretin (in their study; (198)), and 
CB (figure 3.5A) to inhibit quercetin uptake. 
Our isoform specificity data reveal that quercetin, EGCG and ECG also inhibit GLUT3 and 
GLUT4. Quercetin inhibits GLUT1 and GLUT4 with similar avidity but is up to 9-fold less 
potent against GLUT3. EGCG shows similar inhibitory potency towards GLUT1, GLUT3 
and GLUT4. The inhibitory concentrations obtained for quercetin and EGCG inhibition of 
GLUT1 in HEK293 cells are identical to those observed in human erythrocytes. ECG, 
however, inhibits sugar uptake in GLUT1-expressing HEK293 cells with a Ki(app) that is 10-
fold greater than that observed in human erythrocytes, and is 5 – 8 times less potent 
against GLUT3 and GLUT4 expressed in HEK293 cells. The disparity between the Ki(app) 
for ECG inhibition of GLUT1 in human red blood cells versus HEK293 suggests a 
reduction in the effective concentration of ECG available for inhibiting GLUT1 in HEK293 
cells probably because ECG interacts with other unknown targets more readily than 
GLUT1. Molecular docking supports the hypothesis that the flavonoids interact with 
equivalent amino acid residues when docked to the same GLUT isoform. However, when 
the docking of each ligand is compared across GLUT1, GLUT3 and GLUT4, there are 
significant differences in the interacting residues, which may account for the different 
inhibitory potencies observed, at least, for quercetin and ECG. 
In addition to uncovering the mechanisms of dietary flavonoids inhibition of GLUT1, this 
study provides valuable insights into the mechanisms of GLUT1-mediated sugar transport. 
The two main mechanisms for proposed for how GLUT1 functions are: 1) the simple, 
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alternating access transporter (AAT) model, and 2) the fixed site transporter (FST) model. 
The AAT model argues that GLUT1 alternately presents exofacial and endofacial sugar 
binding sites but cannot present both simultaneously. The AAT model is supported by the 
recent crystal structures of human GLUT1 and GLUT3 which have captured monomeric 
GLUTs in the inward-open, outward-open, or outward-occluded conformations, clearly 
showing that these carriers alternate between the outward-facing and inward-facing 
conformations. Sugar transport studies, however, show that GLUT1 functions as a more 
complex transporter than is predicted by the AAT model, with the ability to simultaneously 
present exofacial and endofacial sugar binding sites, as predicted by the FST model 
(116,118,121,122,124,205,264,265). 
A current model proposed by our group (120,239,266) reconciles the structural data 
(supporting the AAT model) and biochemical and sugar transport studies (which support 
the FST model), and views GLUT1 as an oligomeric complex of allosteric alternating 
access subunits. This idea is supported by the following observations made in this study: 
1) Cis-allostery: as with other exofacial GLUT1 inhibitors such as maltose and WZB117, 
low concentrations quercetin, EGCG and ECG stimulate human erythrocyte sugar uptake, 
followed by sugar transport inhibition as inhibitor concentration increases. 2) Trans-
allostery: the inhibition of CB binding and CB inhibition of sugar transport by these agents 
suggest inter-subunit interactions in GLUT1 where the binding of exofacial ligands at the 
cis side interfere with the binding of endofacial CB at the trans side of the membrane. This 
trans-allostery observation is consistent with previous studies that show that low 
concentrations of the exofacial inhibitors, maltose and ethylidene glucose, stimulate CB 
binding at the endofacial sugar binding site of human erythrocytes but higher 
concentration inhibit CB binding (116,124). These results, however, could also be 
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interpreted to support the monomeric AAT model, by arguing that quercetin, EGCG, and 
ECG, by trapping GLUT1 in the exofacial, outward conformation, competitively inhibit CB 
binding to the endofacial, inward-conformation. This interpretation is, however, improbable 
for several reasons. 1) We observe multiple cooperative binding sites for flavonoids as 
evidenced by transport stimulation followed by transport inhibition and, 2) Multiple 
cooperative, flavonoid binding sites are also evidenced by inhibition of CB binding where 
quercetin and EGCG binding to GLUT1 displays positive cooperativity whereas ECG and 
WZB117 binding displays negative cooperativity. Another interpretation of these findings 
is that quercetin, EGCG and ECG inhibit sugar transport and CB binding by entering the 
cell and interacting with the GLUT1 endofacial sugar binding site. If this were true, these 
ligands should function as noncompetitive inhibitors of zero-trans sugar uptake and as 
competitive inhibitors of sugar exit from cells. Future experiments should extend these 
dose response studies of cytochalasin B binding to much lower concentrations of 
quercetin, EGCG and ECG to determine whether subsaturating levels of these exofacial 
ligands, as with the exofacial ligand maltose (124,247) and the endofacial ligand families 
of cytochalasins and forskolins (121,122), enhance cytochalasin B binding to GLUT1.  
 90 
Chapter IV 
Preface 
Chapter IV of this dissertation will be submitted for publication as: 
Ojelabi, O. A., Lloyd, K. P., De Zutter, J. K., and Carruthers, A. (2017) Highly potent 
GLUT1 inhibitors, BAY-876 and NV-5440, inhibit human erythrocyte glucose transport by 
binding at the GLUT1 endofacial glucose binding site 
Author contributions: OAO and AC designed experiments, analyzed results and co-wrote 
the manuscript. OAO conducted all experiments except isoform specificity of transport 
inhibition. KPL contributed to the molecular docking studies. JKD conducted experiments 
on the isoform specificity of transport inhibition 
Navitor Pharmaceuticals provided the Navitor compounds (NV-5440, NV-5770, NV-5902, 
NV-5981, NV-6091 and NV-6346), and funded the Navitor compounds project. I would 
especially like to acknowledge Drs. Sengupta, Saiah and Vlasuk for their support and 
encouragement. 
  
 91 
Highly potent GLUT1 inhibitors, BAY-876 and NV-5440, inhibit human erythrocyte 
glucose transport by binding at the GLUT1 endofacial glucose binding site 
Introduction 
Altered glucose metabolism is a hallmark of cancer, manifesting as abnormally elevated 
expression of the glucose transporter (GLUT) proteins and accelerated aerobic glycolysis 
(267,268). The reprograming of glucose metabolism to favor aerobic glycolysis over 
mitochondrial oxidative phosphorylation (Warburg effect) in cancer cells was first reported 
by Warburg more than 90 years ago (188,269). Warburg was convinced that this effect 
resulted from dysfunctional mitochondria in cancer cells, and that this underlies the 
generation of tumors. However, it is becoming increasingly clear that the Warburg effect, 
rather than being the cause, is in fact a consequence of cancer. 
Cancer cells rely heavily on glucose transport, not only for ATP production, but also to 
generate biomass, including amino acids, DNA and RNA precursors, as well as NADPH, 
needed to support the rapidly proliferating tumor cells (270,271). Unlike cancer cells, 
normal cells, in the presence of oxygen, catabolize glucose by glycolysis and oxidative 
phosphorylation to produce a net total of 36 molecules of ATP compared to 2 ATP 
molecules generated in cancer cells through aerobic glycolysis. While completely breaking 
down glucose to CO2 and water appears to be the most efficient way to generate energy 
from glucose, this process burns up the carbons in glucose which is critical for metabolite 
synthesis in rapidly proliferating cancer cells (7). To compensate for diminished ATP 
production, cancer cells upregulate the expression of glucose transporters, especially 
GLUT1, as well as the glycolytic enzymes (268). Consequently, cancer cells are more 
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sensitive to glucose deprivation than normal cells, and restricting glucose supply will force 
tumor cells to halt proliferation and ultimately die. 
An emerging anticancer strategy is to develop therapeutics targeting glycolysis and 
glucose transport. Several inhibitors of glycolytic enzymes have been reported (reviewed 
in (268)). Similarly, many structurally unrelated compounds have been reported to inhibit 
GLUT1. These include: WZB117 (165) (an exofacial inhibitor of GLUT1 (239)), STF-31 
(166), GLUT-i1 and GLUT-i2 (29) (endofacial GLUT1 inhibitors (29)) and BAY-876 (167). 
Most recently, Navitor Pharmaceuticals developed a novel class of GLUT1 inhibitors, 
referred to here as NV-5440 series. BAY-876 and NV-5440 as well as its analogs, are 
benzonitrile-containing compounds, whose mechanisms of GLUT1 inhibition have not 
been reported. 
A vital part of the on-going development of these anticancer agents, is to understand how 
they interact with, and inhibit GLUT1, as this will ultimately aid in optimizing drug design 
and delivery. This present study explores how BAY-876 and NV-5440 inhibit GLUT1-
mediated glucose transport. 
We show that BAY-876 and NV-5440 inhibit GLUT1 by interfering with glucose binding to 
the endofacial sugar binding site. They, thus act as competitive inhibitors of glucose exit 
from cells, but are noncompetitive inhibitors of net glucose uptake. Additionally, we show 
that benzonitrile groups in BAY-876 as well as in NV-5440 and its analogs confers more 
inhibitory potency to these compounds as compared to their analogs lacking the nitrile 
unit. 
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Methods 
Reagents 
Tritium-labeled 2-deoxy-D-glucose ([3H]-2DG), 3-O-methylglucose ([3H]-3MG) and 
cytochalasin B ([3H]-CB) were obtained from American Radiolabeled Chemicals (St. Louis, 
MO). Unlabeled 3MG, CB, BAY-876, BAY-588 and phloretin were purchased from Sigma-
Aldrich (St. Louis, MO). WZB117 was purchased from EMD Millipore (Billerica, MA). NV-
5440 and its analogs were provided by Navitor Pharmaceuticals (Cambridge, MA). 
Solutions 
KCl medium contained 150 mM KCl, 5 mM HEPES, 0.5 mM EDTA, pH 7.4. Sugar 
transport stop solution contained 50 µM WZB117 and 100 µM phloretin in ice-cold KCl 
medium. RBC sugar uptake/exit medium contained 0 – 20 mM 3MG, [3H]-3MG ± inhibitors. 
[3H]-CB–binding medium contained 40 nM [3H]-CB and 10 µM cytochalasin D in KCl 
medium. 
Cells 
De-identified whole human blood was purchased from Biological Specialty Corporation 
(Colmar, PA). HEK293 cells heterologously expressing human GLUT1, GLUT3 or GLUT4 
were made as previously described (97,123). HEK293 cells were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 
100 units/mL penicillin, and 100 µg/mL streptomycin in a 37 °C humidified 5% CO2 
incubator. 
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Red blood Cell Sugar Transport and Ligand Binding Measurements 
All human RBC sugar transport and ligand binding experiments were performed at 4 ºC 
as previously described (204,205,239). Glucose-depleted RBCs were incubated in 37.5 – 
400 volumes of ice-cold KCl medium ± inhibitors at 4 ºC for 15 minutes before 
measurements. 
Zero-trans Uptake: Zero-trans glucose–depleted RBCs were incubated in 400 volumes of 
ice-cold KCl medium ± inhibitors for 15 minutes. [3H]-3MG uptake into sugar–lacking cells 
was performed by adding 100 µL of uptake medium ± inhibitor to 10 µL of sugar-depleted, 
50% hematocrit (Ht) red cells, for 30 seconds at 4 ºC. Uptake was stopped by adding 1 
mL of ice-cold stop solution. Cells were washed in stop solution, lysed in 3% perchloric 
acid, and radioactivity was measured in clarified lysates by liquid scintillation counting. 
Zero-trans Exit: Glucose-depleted, packed RBCs were loaded with 10 mM 3MG 
(containing 1 µCi [3H]-3MG/mL of cold 3MG) at 37 ºC as previously described (239). 3MG–
loaded cells were transferred to 4 ºC and incubated with or without inhibitors for 15 
minutes. Cell suspension was spun at 10,000 x g for 1 min, and supernatant discarded. 
500 µL of sugar-loaded RBCs were added to 25 mL of KCl medium ± inhibitor on a shaker 
with magnetic stirrer. 2 x 500 µL aliquots of the suspension were withdrawn at indicated 
time intervals, and immediately added to 1 mL ice-cold stop solution. Cells were washed 
again in stop solution, lysed in 3% perchloric acid and radioactivity was measured in 
clarified lysates in duplicates. 
Equilibrium CB Binding: CB binding to human erythrocytes was performed as previously 
described with slight modifications (116,239). Briefly, 1 volume of sugar-depleted packed 
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RBCs was incubated with 400 volumes of ice-cold KCl medium ± 2x of desired [inhibitor] 
for 15 minutes. Cells were spun at 10,000 x g for 1 min and 1 volume of cells was 
resuspended in 2x of desired [inhibitor], to make 50% hematocrit (Ht) red cells. 1 volumes 
of 50% hematocrit (Ht) red cells was mixed with 1 volume of ice-cold [3H]-CB–binding 
medium and incubated at 4 ºC for 15 minutes, with constant mixing. For Total [CB] 2 x 10 
µL of the cell suspension were withdrawn from tube and lysed in 100 µL of 3% perchloric 
acid, and radioactivity measured in duplicates. For free [CB], cell suspension was 
centrifuged at 20,000 x g for 1 minute, and 2 x 10 µL of clarified supernatant were assayed 
for radioactivity. Bound [CB] was estimated as Total [CB] – Free [CB]. 
HEK-293 Cell Sugar Uptake 
All HEK293 cell sugar uptake measurements were performed at 37 ºC, using 100 µM 2-
deoxyglucose (2DG plus [3H]-2DG) as described previously (97,143). 
Homology Modeling 
The crystal structure of inward-open (e1) human GLUT1 (hGLUT1-e1; 4PYP) (28) was 
obtained from the RCSB protein databank (http://www.rcsb.org/pdb/home/home.do). 
Homology models of the e1 conformations of GLUT3 and GLUT4 were generated based 
on the crystal structure of hGLUT1-e1. Sequence alignments were generated using 
ClustalX (240). Homology models were built using Modeller-9.9 (241) and analyzed using 
PROCHECK (242). 
Stochastic docking 
Docking was performed using the Schrodinger software suite. Chemical structure for β-D-
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glucose, BAY-876, BAY-588, NV-5440 (and its analogs) were drawn using the 2D 
sketcher of the Schrodinger software suite. Protein structures were preprocessed with the 
Protein Preparation Wizard, using default settings, and the system was energy minimized 
using the OPLS 2005 force field. Ligand structures were prepared with the LigPrep module 
and the pKa of the ligands was calculated using the Epik module. Grids for docking were 
mapped using the CastP server (http://sts.bioe.uic.edu/castp/) and the grid generation 
feature of the Schrodinger suite. Molecular docking was performed by the GLIDE module 
in standard-precision (SP) mode using default settings with no restraints.  
Data analysis 
Analyses of data and statistical tests were performed using GraphPad Prism (Version 
7.0c; La Jolla, CA). 
Michaelis-Menten inhibition of sugar transport is described by: 
 
𝑉 = 𝑉𝑐–
𝑉𝑐[𝐼]
𝐾𝑖(𝑎𝑝𝑝) + [𝐼]
 (equation 4.1) 
where Vc is V measured in the absence of inhibitor I, [I] is the concentration of inhibitor 
and Ki(app) is that [I] producing 50% inhibition of uptake. 
Sugar transport inhibition by analogs of BAY-876 and NV-5440 was estimated by: 
 
𝑅𝑒𝑙 𝐾𝑖(𝑎𝑝𝑝) =
(𝑉𝑖/𝑉𝑐)[𝐼]
1 – (𝑉𝑖/𝑉𝑐)
 (equation 4.2) 
where Rel Ki(app) is the Ki(app) of inhibitor relative to BAY-876 or NV-5440, Vc is V measured 
in the absence of inhibitor [I] and Vi is V measured in the presence of inhibitor 
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Michaelis-Menten sugar uptake is assumed to be described by: 
 
𝑉 =
𝑉𝑚𝑎𝑥[3𝑀𝐺]
𝐾𝑚(𝑎𝑝𝑝) + [3𝑀𝐺]
 (equation 4.3) 
where Vmax is the maximum rate of 3MG transport, [3MG] is the concentration of 3MG and 
Km(app) is the [3MG] where the rate of uptake is Vmax/2. 
Sugar exit was analyzed by nonlinear regression analysis using Mathematica 10.4.1.0 
(Wolfram Research) with the assumption that exit follows Michaelis-Menten kinetics and 
that the first derivative of the exit progress curve represents d[S]/dt at any given [S] (239). 
Transport stimulation followed by inhibition by inhibitors was approximated first by 
normalizing all uptake to Vc and then using the following model: 
 𝑉𝑖
𝑉𝑐
=
𝐾1 + [𝐼](𝐾2 + [𝐼])
𝐾1 + [𝐼](𝐾3 + [𝐼]𝐾4)
 (equation 4.4) 
where Vc is uptake measured in the absence of inhibitor I, Vi is uptake measured in the 
presence of inhibitor, [I] is the concentration of inhibitor and K1 – K4 are model dependent 
(120). 
Inhibition of [3H]-CB binding to GLUT1 by ligands was analyzed by simple competitive 
inhibition using the model: 
 [𝐶𝐵]𝑏
[𝐶𝐵]𝑓
=
𝐾𝑖(𝑎𝑝𝑝)(𝐾𝐶𝐵 + [𝐶𝐵])
[𝐼]𝐾𝐶𝐵 + 𝐾𝑖(𝑎𝑝𝑝)(𝐾𝐶𝐵 + [𝐶𝐵])
 (equation 4.5) 
where [CB]b = bound [CB], [CB]f = free [CB], Ki(app) is the apparent inhibitory constant for 
inhibition of CB binding by inhibitor, I, and KCB is dissociation constant for CB binding to 
GLUT1. 
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CB binding was also analyzed using a variation of Michaelis-Menten equilibrium binding 
kinetics in which the transporter is allowed to bind more than one molecule of competing 
ligand, I 
 [𝐶𝐵](𝑏/𝑓)𝑖
[𝐶𝐵](𝑏/𝑓)𝑐
= 1 −
𝐾[𝐼]𝑛
𝐾𝐼 + [𝐼]𝑛
 (equation 4.6) 
where [CB](b/f)I = the ratio of bound to free [CB] measure in the presence of inhibitor I, 
[CB](b/f)c = the ratio of bound to free [CB] measure in the absence of inhibitor, K is a 
number where 0 ≤ K ≤ 1, KI is Kd(app) for I binding to GLUT1 and n is the number of 
inhibitor binding sites. 
Results 
Sensitivity of human erythrocyte sugar transport to BAY-876, NV-5440, and their analogs  
GLUT1 is the quantitatively most abundant and sole significant glucose transport protein 
of the human erythrocyte, accounting for 10 – 20% of total plasma membrane protein 
content (197,272). To assess BAY-876 and NV-5440 as GLUT1 inhibitors, we tested their 
effects on zero-trans sugar uptake (influx into sugar-free cells) in freshly isolated human 
red blood cells. BAY-876 and NV-5440 inhibit the zero-trans uptake of 3MG (0.1 mM) by 
human erythrocytes in a dose-dependent manner with Ki(app) of 13.15 ± 1.31 nM, and 12.74 
± 1.60 nM respectively (figure 4.1A). BAY-588, an analog of BAY-876, is marketed as an 
inactive control for BAY-876, for its purported lack of inhibition of GLUT1. However, figure 
4.1B shows that BAY-588 inhibit GLUT1-mediated sugar uptake, although with ~ 50-fold 
less potency than BAY-876. We also tested the effects of 5 analogs of NV-5440 (NV-5770, 
NV-5902, NV-5981, NV-6091, and NV-6346) on 3MG uptake by human RBCs (figure 
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4.1C). Ki(app) for NV-5440 analogs containing a benzonitrile group (just like NV-5440) 
ranged from 4.35 – 15.73 nM (figure 4.1C). However, replacing the benzyonitrile group by 
a benzaldehyde in NV-5981 increases its relative Ki(app) by > 220-fold (figure 4.1C). 
Although BAY-588 (Ki(app) = 0.58 µM) and NV-5981 (Ki(app) = 2.9 µM) are much less potent 
than their respective parent analogs, they are still relatively decent inhibitors of GLUT1 as 
compared to other commercially available inhibitors of GLUT1 (e.g. cytochalasin B, Ki(app) 
= 0.1 – 0.3 µM (117); WZB117, Ki(app) = 0.23 – 10 µM (165,239)). 
BAY-876 and NV-5440 are endofacial inhibitors of GLUT1 
GLUT1 presents endofacial (e1) and exofacial (e2) sugar binding sites. Most known 
inhibitors of GLUT1 inhibit GLUT1-mediated glucose transport by competing with glucose 
for binding at either the e1 or e2 sugar binding site. We term ligands that bind GLUT1 at 
the e2 sugar binding site exofacial GLUT1 inhibitors, and ligands interacting at the e1 
sugar binding site, endofacial GLUT1 inhibitors. The effects of exofacial and endofacial 
GLUT1 inhibitors on Michaelis-Menten kinetics of zero-trans sugar uptake (sugar influx 
into sugar-lacking cells) and zero trans sugar exit (sugar efflux into sugar-lacking medium) 
by human erythrocytes are well documented (104,117,118). Exofacial GLUT1 inhibitors 
increase the Km(app) for zero trans glucose uptake without affecting Vmax for uptake, while 
endofacial inhibitors reduce Vmax for uptake and are without effect on Km(app) for uptake. 
For zero trans glucose exit, exofacial GLUT1 inhibitors reduce Vmax with no change in 
Km(app), whereas endofacial inhibitors increase Km(app) for sugar exit without changing Vmax. 
BAY-876 and NV-5440 reduce the Vmax for zero trans 3MG uptake from 0.939 ± 0.044 
mmol/L cell water/min (control) to 0.394 ± 0.029 mmol/L cell water/min (BAY-876) and   
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Figure 4.1: Sensitivity of human erythrocytes sugar transport to BAY-876, NV-5440, and their analogs 
 
A, Concentration dependence of BAY-876 (△) and NV-5440 (●) inhibition of zero-trans 3MG (100 µM) uptake 
by human red blood cells. Ordinate: 3MG uptake in mmol/L cell water/min; Abscissa: [inhibitor] in nM. Each data 
point represents the mean ± SEM of duplicate measurements of at least 3 separate experiments. The curves 
drawn through the points were computed by nonlinear regression using equation 4.1, and with the assumption 
that sugar uptake is completely inhibited in a dose-dependent manner. The results are: BAY-876–treated cells 
(△): Ki(app) = 13.15 ± 1.31 nM, R2 = 0.905, standard error of mean = 0.011; NV-5440–treated cells (●): Ki(app) = 
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12.74 ± 1.60 nM, R2 = 0.926, standard error of mean = 0.009. B & C, Inhibition of human erythrocytes 3MG 
uptake by analogs of BAY-876 or NV-5440. Ordinate: 3MG uptake in mmol/L cell water/min; Abscissa: Inhibitors 
applied to cells. Each data point represents the mean ± SEM of 3 duplicate measurements. Relative Ki(app), were 
calculated using equation 4.2. Relative Ki(app) and chemical structures are shown for BAY-876 and its analog, 
BAY-588 (B), and NV-5440, and its analogs: NV-5770, NV-5902, NV-5982, NV-6091 and NV-6346 (C). Analysis 
was done by ordinary one-way ANOVA. B, Compared to control, **– significantly different at p = 0.0007; ++ & 
+++ – significantly different at p < 0.001. C, Compared to control, + – significantly inhibited uptake at p < 0.0001, 
++ – significantly simulated uptake at p < 0.0001; ** & *** – significantly different at p < 0.0001. 
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0.544 ± 0.037 mmol/L cell water/min (NV-5440), but do not significantly affect Km(app) for 
uptake (figure 4.2A). Additionally, BAY-876, and NV-5440 increase Km(app) for exit from 
14.3 mM (control) to 39.7 mM and 59.8 mM respectively, but are without effect on Vmax for 
exit (figure 4.2B). These results support the hypothesis that BAY-876 and NV-5440 act as 
endofacial inhibitors of GLUT1. 
Subsaturating concentrations of BAY-876, BAY-588 and NV-5440 stimulate sugar uptake 
by human erythrocytes 
Previous studies have shown that both exofacial and endofacial inhibitors of GLUT1 
stimulate erythrocyte sugar uptake at subsaturating concentrations, followed by inhibition 
of sugar uptake as inhibitor concentration is raised (120,122,124,239). In agreement with 
this observation, low concentrations of BAY-876 (0.01 nM), BAY-588 (≥ 0.1 µM), and NV-
5440 (0.1 nM) significantly stimulate zero-trans 3MG uptake in red cells by up to 20% 
above untreated control cells (p < 0.05; figure 4.3). The ability of an endofacial GLUT1 
ligand to stimulate, and then inhibit GLUT1-mediated sugar uptake strongly supports the 
idea that GLUT1 functions as an allosteric oligomeric carrier, simultaneously exposing 2 
endofacial, and 2 exofacial ligand binding sites (120,122,124,239). 
Molecular docking of ligands to endofacial GLUT1 
Our sugar transport data revealed that BAY-876 and NV-5440 are 50 – 200 fold more 
potent than their respective analogs (BAY-588 and NV-5981) lacking the benzonitrile 
group. We docked these ligands to the crystal structure of the inward-open (e1) 
conformation of hGLUT1 (GLUT1-e1) (PDB code: 4PYP), to test if their interactions with 
GLUT1 would explain their different inhibitory potencies.  
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Figure 4.2: Effects of BAY-876 and NV-5440 on Michaelis-Menten kinetics of zero-trans 
3MG uptake (A) and exit (B) 
 
Results are shown for untreated control cells (○), BAY-876–treated cells (△) and NV-5440–
treated cells (●). Each data point represents mean ± SEM of duplicate measurements of more 
than 3 separate experiments. A, Ordinate: 3MG uptake in mmol/L cell water/min; Abscissa: 
increasing concentration of 3MG in mM. Curves drawn through data points were computed by 
Michaelis-Menten uptake kinetics (equation 4.3), with the following results: Control (○): Vmax = 
0.939 ± 0.044 mmol/L cell water/min, Km(app) = 1.620 ± 0.198 mM, R2 = 0.943, standard error of 
mean = 0.058; BAY-876 treatment (△): Vmax = 0.394 ± 0.029 mmol/L cell water/min, Km(app) = 
1.432 ± 0.276 mM, R2 = 0.868, standard error of mean = 0.039; NV-5440 treatment (●): Vmax = 
0.544 ± 0.037 mmol/L cell water/min, Km(app) = 1.995 ± 0.305 mM, R2 = 0.916, standard error of 
mean = 0.039. B, Ordinate: Concentration of intracellular 3MG in mM; Abscissa: 3MG exit time 
in minutes. Curves drawn through data points were computed by nonlinear regression and 
numerical integration assuming Michaelis-Menten exit kinetics as in equation 4.3. The results 
are: Control (○): Vmax = 2.0 mmol/L cell water/min, Km(app) = 14.3 mM; BAY-876 treatment (△): 
Vmax = 2.0 mmol/L cell water/min, Km(app) = 39.7 mM; NV-5440 treatment (●): Vmax = 2 mmol/L 
cell water/min, Km(app) = 59.8 mM. 
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Figure 4.3: Low concentrations of BAY-876, BAY-588 and NV-5440 stimulate 3MG uptake 
 
Ordinate: 3MG uptake in mmol/L cell water/min; Abscissa: [Inhibitor] in M, axis expressed in log 
scale. Results are shown for cells treated with increasing concentration of BAY-876 (△), BAY-
588 (▲) and NV-5440 (●). Each data point represents mean ± SEM of duplicate measurements 
of 3 experiments. Data points were fitted by nonlinear regression using equation 4.4, and with 
the following constants: BAY-876–treated cells (△): K1 = 5.88 x 10-6 ± 3.98 x 10-6, K2 = 1.19 x 
105 ± 6.16 x 1014, K3 = 9.39 x 104 ± 5.28 x 1014, K4 = 8.95 x 1012 ± 3.34 x 1022, R2 = 0.922, 
standard error of regression = 0.134; BAY-588–treated cells (▲): K1 = 2.65 x 10-3 ± 8.12 x 106, 
K2 = 1.09 x 105 ± 3.35 x 1014, K3 = 7.34 x 104 ± 2.25 x 1014, K4 = 1.99 x 1011 ± 6.11 x 1020, R2 = 
0.991, standard error of regression = 0.044; NV-5440–treated cells (●): K1 = 3.06 x 10-4 ± 1.11 
x 10-4, K2 = 1.89 x 105 ± 7.43 x 1014, K3 = 9.50 x 104 ± 5.71 x 1014, K4 = 2.30 x 1013 ± 5.67 x 1022, 
R2 = 0.967, standard error of regression = 0.085. 
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Our docking studies identified 3 high affinity sites for ß-D-glucose – 1 distinct intermediate 
docking site, and 2 overlapping site core 1 and core 2 (figure 4.4A). We obtained a total 
of 27 docking configurations for ß-D-glucose, with glide scores of –5.6 to –4.0 kcal/mol. 
Six of these correspond to the intermediate docking site, 18 correspond to core 1 site, and 
3 correspond to core 2 site. We selected the docking pose in each configuration with the 
least glide score (GS), and whose hydroxyl groups of C3, C4 and/or C6 form hydrogen 
bonds with GLUT1-e1 (figure 4.4B), consistent with the experimentally demonstrated 
stereospecificity of GLUT1-e1 interaction with cytoplasmic sugars (86). BAY-876, NV-
5440, and NV-5981 sterically clash with all 3 ß-D-glucose docking sites, while BAY-588 
overlaps with the 2 core glucose sites, but not with the intermediate site (figure 4.4C). 
These docking analyses, together with experimental data in human erythrocytes, show 
how BAY-876, NV-5440, and their analogs could compete with glucose for binding at the 
endofacial sugar binding site. Figure 4.4D shows the GLUT1 amino acids residues 
predicted to interact with BAY-876, BAY-588, NV-5440 and NV-5981. Common contact 
residues that appear to be required for inhibitor binding include: Phe379, Trp388, Ile164. 
Although our experimental data show that the presence the benzonitrile group confers 
more inhibitory potency on the endofacial GLUT1 ligand, molecular docking reveal that 
the benzonitrile group does not orient the inhibitors to interact with GLUT1 in a similar 
fashion. The benzonitrile group in BAY-876 is oriented towards the intermediate ß-D-
glucose docking site where it interacts with Pro141 and M142. Whereas, benzonitrile 
group in NV-5440, is oriented towards the core 1 and core 2 ß-D-glucose docking sites 
where it forms hydrogen bonds with Gln282 and Trp388, and hydrophobic interactions 
with Val165. 
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Figure 4.4: Ligand docking to endofacial GLUT1 (GLUT1-e1) 
 
A, GLUT1-e1 (semitransparent grey cartoon) complexed with core 1 (red), core 2 (deep salmon), and 
intermediate (ruby) ß-D-glucose, shown as spheres. B, 2-dimensional representations of GLUT1-e1–
ß-D-glucose interactions. Residues and contacts are shown as: hydrophobic (green); polar (blue); 
negatively charged (orange); hydrogen bond (magenta arrow). C, BAY-876 (blue), BAY-588 (light blue), 
NV-5440 (orange), and NV-5981 (purple) docking to GLUT1-e1–ß-D-glucose. D, 3-dimensional 
representation of GLUT1-e1–ligand contact residues and interactions (color code as in C). Viewing 
perspective is zoomed-in orientation as in C. 
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BAY-876 and NV-5440 interfere with cytochalasin B (CB) inhibition of GLUT1 
CB is a well characterized membrane permeable endofacial inhibitor of GLUT1, which as 
acts a noncompetitive inhibitor of sugar uptake but competitively inhibits net sugar exit 
from cells (117). To further validate BAY-876 and NV-5440 as endofacial GLUT1 
inhibitors, we tested their effects on CB binding to GLUT1 and CB inhibition of sugar 
uptake in human red blood cells. BAY-876, NV-5440 and nonradioactive CB inhibit the 
binding of [3H]-CB to human RBCs in a dose-dependent manner (figure 4.5A). As with 
inhibition of CB binding by the flavonoids, our results suggest that inhibition by BAY-876 
and NV-5440 but not by CB increases more steeply with increasing [inhibitor] than is 
predicted by simple Michaelis-Menten inhibition. We therefore reanalyzed these data 
using a Hill equation and found that the data fits are significantly improved (figure 4.5B). 
The number of BAY-876, NV-5440 and CB binding sites contributing to inhibition of CB 
binding are 1.50 ± 0.12, 1.82 ± 0.13 and 1.07 ± 0.07 respectively. 
Docking analysis indicates that BAY-876 and NV-5440 both overlap with cytochalasin B 
(CB) for binding to GLUT1-e1 (figure 4.5C). This suggests that CB and BAY-876 or CB 
and NV-5440 cannot simultaneously occupy the same GLUT1 molecule. Cooperative 
inhibition of CB binding by BAY-876 and NV-5440 must, therefore, require their interaction 
with multiple, interacting GLUT1 molecules. 
BAY-876 (15 nM) modulates CB inhibition of 3MG uptake by human erythrocytes, by 
doubling Ki(app) for CB inhibition of uptake (figure 4.5D). This inhibition is two-fold less than 
that expected on the basis of BAY-876 inhibition of CB binding (1+[BAY-876]/Ki(app) where 
[BAY-876] = 15 nM and Ki(app) = 6 nM see figure 4.5A). Together, these results reveal that   
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Figure 4.5: BAY-876 and NV-5440 overlap with cytochalasin B (CB) for binding to GLUT1e1  
 
A, BAY-876, NV-5440 and nonradioactive CB inhibits [3H]-CB binding to human RBCs. Ordinate: 
Normalized [CB]bound/[CB]free; Abscissa: [inhibitor] in nM (axis expressed in log scale). Each data 
point represents mean ± SEM of at least 3 duplicate measurements. Results are shown for BAY-
876–treated cells (△), NV-5440–treated cells (●) and nonradioactive CB–treated cells (○). The 
curves drawn through data points were computed by nonlinear regression assuming simple 
competitive inhibition (equation 4.5), with the following results: BAY-876 treatment (△): Ki(app) = 
6.17 ± 0.71 nM, R2 = 0.949, standard error of regression = 0.084; NV-5440 treatment (●): Ki(app) 
= 4.46 ± 0.35 nM, R2 = 0.975, standard error of regression = 0.055; nonradioactive CB treatment 
(○): Ki(app) = 64.06 ± 3.09 n M, R2 = 0.988, standard error of regression = 0.036. The residuals 
of the fits (for BAY-876, NV-5440 and CB data) are plotted beneath the inhibition plot. B, 
Reanalysis of the same data set assuming multiple binding sites for competing ligand using the 
Hill-equation (equation 4.6). The results are: BAY-876 treatment (△): Ki(app) = 70.35 ± 21.03 nM, 
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n = 1.82 ± 0.13, R2 = 0.989, standard error of regression = 0.0415; NV-5440 treatment (●): Ki(app) 
= 19.48 ± 4.79 nM, n = 1.50 ± 0.12, R2 = 0.989, standard error of regression = 0.0387; CB 
treatment (○): Ki(app) = 125.5 ± 37.1 nM, n = 1.077 ± 0.067, R2 = 0.991, standard error of 
regression = 0.0338; The residuals of the fits (for BAY-876, NV-5440 and CB data) are plotted 
beneath the inhibition plot. C, Docking of BAY-876 (blue), NV-5440 (orange) and CB (pale green) 
to GLUT1-e1 (light gray cartoon). D, BAY-876 interferes with the concentration dependence of 
CB inhibition of 3MG uptake. Results are shown for CB–treated cells (○), and CB–treated cells 
plus 15 nM BAY-876 (△). The curves drawn through data points were computed by nonlinear 
regression using equation 1, and with the following results: CB only treatment (○): Ki(app) = 107.7 
± 10.02 nM, R2 = 0.977, standard error of regression = 0.052; CB + 15 nM BAY-876 treatment 
(△): Ki(app) = 191.6 ± 33.06 nM, R2 = 0.923, standard error of regression = 0.041. 
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CB, BAY-876 and NV-5440 binding to GLUT1 are mutually exclusive but that the binding 
of BAY-876 and NV-5440 is cooperative. 
BAY-588, NV-5440 and its analogs, but not caffeine overlap with BAY-876 binding to 
GLUT1 
The presence of BAY-876 (15 nM) increases Ki(app) for BAY-588 inhibition of human 
erythrocytes sugar uptake from 0.668 ± 0.074 µM to 2.264 ± 0.510 µM (figure 4.6A), 
suggesting that BAY-876 and BAY-588 share similar GLUT1 binding sites. This is 
supported by our docking studies showing that BAY-876 overlaps with BAY-588 (its 
analog; figure 4.6B), NV-5440 (figure 4.6C), NV-5981 (less potent NV-5440 analog; figure 
4.6D) and NV-6091 (more potent NV-5440 analog; figure 4.6E). Caffeine, which interacts 
with the endofacial nucleotide binding site of GLUT1, and which has been shown to inhibit 
CB binding to GLUT1 (197), does not appear to interfere with BAY-876 binding to, and 
inhibition of GLUT1 (figure 4.6F and G). 
Comparison between ligand inhibitory potency and docking to GLUT1-e1 
The observed inhibitory constants (Ki(app)) of the endofacial GLUT1 inhibitors tested in this 
study, appear to correlate with the extent of contacts and steric hindrance the inhibitor 
makes with the putative ß-D-glucose docking sites in GLUT1-e1 (figure 4.7A). Ki(app) for 
the ligands follows the order: NV-6091 > NV-5902 > NV-5440 ≈ BAY-876 > NV-6346 > 
NV-5770 >> CB > BAY-588 >> NV-5981 >> caffeine (figure 4.1B and C). Ki(app) reported 
for CB and caffeine are 150–300 nM (117), and 3.5 mM (197) respectively. Our ligand 
docking studies predict that ligand binding at the core 2 ß-D-glucose docking site will 
produce the least inhibition of transport (caffeine; figure 4.7B), followed by binding at both   
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Figure 4.6: BAY-588, NV-5440 and its analogs, but not caffeine, interfere with BAY-876 
binding to GLUT1-e1 
 
A, Docking of BAY-588 (light blue) and BAY-876 (blue) to GLUT1-e1 (light gray cartoon). B, 
Dose-dependent inhibition of human erythrocyte 3MG (0.1 mM) uptake by BAY-588 (▲) or BAY-
 112 
588 plus 15 nM BAY-876 (△). Ordinate: Relative 3MG uptake; Abscissa: Increasing [BAY-588] 
in M (axis expressed in log scale). Each data point represents mean ± SEM of 3 duplicate 
measurements. Curves drawn through data points were computed by nonlinear regression using 
equation 4.1, and with the following results: BAY-588–treated cells (▲): Ki(app) = 6.68 x 10-7 ± 
7.38 x 10-8 M, R2 = 0.971, standard error of mean = 0.073; BAY-588 + 15 nM BAY-876–treated 
cells (△): Ki(app) = 2.26 x 10-6 ± 5.10 x 10-7 M, R2 = 0.834, standard error of mean = 0.036. C–E, 
Docking of NV-5440 (orange; C), NV-5981 (purple; D), and NV-6091 (light orange, E), with BAY-
876 (blue) to GLUT1-e1 (light gray cartoon). F, Docking of caffeine (cyan) and BAY-876 (blue) 
to GLUT1-e1 (light gray cartoon). G, Dose-dependent inhibition of human erythrocyte 3MG (0.1 
mM) uptake by BAY-876 (△) or BAY-876 plus 3.5 mM caffeine (○). Ordinate: Relative 3MG 
uptake; Abscissa: Increasing [BAY-876] in M (axis expressed in log scale). Each data point 
represents mean ± SEM of 3 duplicate measurements. Curves drawn through data points were 
computed by nonlinear regression using equation 4.1, and with the following results: BAY-876–
treated cells (△): Ki(app) = 1.41 x 10-8 ± 2.10 x 10-9 M, R2 = 0.922, standard error of mean = 0.131; 
BAY-876 + 3.5 mM caffeine–treated cells (○): Ki(app) = 1.28 x 10-8 ± 1.35 x 10-9 M, R2 = 0.957, 
standard error of mean = 0.062. 
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Figure 4.7: Ligand interaction with all three putative glucose binding sites of GLUT1-e1 
correlates with greater GLUT1 inhibition 
 
GLUT1-e1 is shown as light gray cartoon (a zoomed in view of the same orientation as in Figure 
4A). Ligands are shown as sticks with the following color code: glucose (red), CB (pale green), 
caffeine (cyan), BAY-876 (blue), BAY-588 (light blue), NV-5440 (orange), NV-6091 (light 
orange); NV-5981 (purple), NV-5770 (light pink), NV-5902 (light brown), NV-6346 (olive green). 
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Figure 4.8: Isoform specificity of sugar transport inhibition by BAY-876 and NV-5440 
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A & B, Ordinate: 2-deoxyglcuose uptake in mol/µg protein/min; Abscissa: inhibitor concentration in µM (axis 
expressed as log scale). Results are shown for transport inhibition by BAY-876 (A) and NV-5440 (B) in 
untransfected (○), and in transfected HEK293 cells stably expressing hGLUT1 (●), hGLUT3 (△) or 
hGLUT4 (▲). The curves drawn through the data points were computed by nonlinear regression using 
equation 4.1, with the following results: BAY-876–treated cells: untransfected cells (○), Ki(app) = 0.089 ± 
0.036 µM, R2 = 0.983, standard error of regression = 2.86 x 10-13; hGLUT1-transfected cells (●): Ki(app) = 
0.061 ± 0.019 µM, R2 = 0.994, standard error of regression = 3.88 x 10-13, hGLUT3-transfected cells (△): 
Ki(app) = 1.726 ± 2.757 µM, R2 = 0.760, standard error of regression = 1.04 x 10-12; hGLUT4-transfected cells 
(▲): Ki(app) = 0.527 ± 0.567 µM, R2 = 0.800, standard error of regression = 1.99 x 10-12; NV-5440–treated 
cells: untransfected cells (○), Ki(app) = 0.014 ± 0.012 µM, R2 = 0.996, standard error of regression = 2.96 x 
10-13; hGLUT1-transfected cells (●): Ki(app) = 0.603 ± 0.238 µM, R2 = 0.969, standard error of regression = 
1.06 x 10-12, hGLUT3-transfected cells (△): Ki(app) = 0.958 ± 0.145 µM, R2 = 0.997, standard error of 
regression = 4.90 x 10-13; hGLUT4-transfected cells (▲): Ki(app) = 3.177 ± 5.544 µM, R2 = 0.844, standard 
error of regression = 1.71 x 10-12. C & D, 2-dimensional representations of interactions between GLUT1-
e1, GLUT3-e1, GLUT4-e1 and BAY-876 (C), and NV-5440 (D). Residues and contacts are shown as: 
hydrophobic (green); polar (blue); negatively charged (orange); hydrogen bond (magenta arrow), Pi–Pi 
stacking (green line); Pi cation (red line). 
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core 2 and intermediate docking sites (NV-5981; figure 4.7C). Ligand binding at both core 
1 and core 2 sites (CB and BAY-588; figure 4.7D and E) will increase transport inhibition 
but the greatest inhibition (Ki(app) ≈ 15 nM) is observed with ligands interacting with all 3 
putative ß-D-glucose binding sites (figure 4.7F – K). 
Isoform specificity of sugar transport inhibition by BAY-876 and NV-5440 
Siebeneicher et al (167) used a cell-based assay, with an indirect ATP read-out, to show 
that BAY-876 is GLUT1-specific. They reported that BAY-876 has an inhibitory potency 
for GLUT1 that is more than 100-fold greater than its affinity for GLUT2, GLUT3 and 
GLUT4 (167). Here, we assayed for the dose-dependent inhibition of 2-deoxy-D-glucose 
(2DG) uptake at 37 ºC by BAY-876 and NV-5440 in HEK293 cells stably expressing 
hGLUT1, GLUT3 or GLUT4, and show that BAY-876 and NV-5440 inhibit GLUT1-, 
GLUT3-, and GLUT4-mediated 2DG uptake in HEK293 in a dose-dependent manner 
(figure 4.8A and B). In our hands, BAY-876 shows a ≥10-fold greater potency with GLUT1 
than GLUT3 and GLUT4 (figure 4.8A), while NV-5440 shows similar affinities for GLUT1 
and GLUT3, but is 5-fold less potent against GLUT4 (figure 4.8B). Molecular docking 
studies reveal that BAY-876, as well as NV-5440, interact with identical residues in 
GLUT1, GLUT3 and GLUT4 (figure 4.8C and D). 
Discussion 
BAY-876 and NV-5440 inhibit the glucose transporter, GLUT1, by acting as 
noncompetitive inhibitors of human erythrocyte sugar uptake, and as competitive inhibitors 
of net glucose exit, suggesting that BAY-876 and NV-5440 interact with GLUT1 at, or close 
to, the endofacial sugar binding site. This conclusion is supported by ligand binding and 
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molecular docking analyses which reveal that these compounds overlap with glucose and 
cytochalasin B (CB, an extensively characterized endofacial ligand of GLUT1) for binding 
to the endofacial sugar binding site of GLUT1. 
Indeed, BAY-876, NV-5440 and CB are endofacial inhibitors that inhibit GLUT1 by a 
common mechanism (29,117,118,186). We demonstrated this by showing that: 1) BAY-
876 and NV-5440 decrease the Vmax for sugar uptake but increase Km for sugar exit from 
cells, indicating that BAY-876 and NV-5440, just like CB (116,117), compete with glucose 
for the sugar exit site, but not the sugar uptake site; 2) BAY-876 and NV-5440 dock within 
the CB binding pocket revealed recently by the CB–bound hGLUT1-e1 crystal structure 
(29). Molecular docking predicts that BAY-876, NV-5440 and CB interact with common 
GLUT1 residues. Each forms hydrophobic interactions with Ile164, Phe379 and Trp388, 
and NV-5440 forms an additional hydrophobic contact with Trp412 and a hydrogen bond 
with Trp388 as shown for the CB–hGLUT1 crystal structure (29). 3) BAY-876 and NV-
5440 inhibit CB binding to the endofacial sugar binding site in a dose-dependent manner 
but in a way that suggests that there are multiple, cooperative endofacial ligand biding 
sites in the transporter complex. Exofacial inhibitors of GLUT1 also inhibit CB binding to 
the endofacial sugar binding site by acting at multiple exofacial binding sites (see figures 
2.7 & 3.4). Collectively, these results suggest that ligand binding to GLUT1 is much more 
complex than is described by the simple, alternating access model for how GLUT1 
functions. 
Like CB (120,239), subsaturating concentrations of BAY-876, BAY-588 and NV-5440 
stimulate erythrocyte sugar uptake (figure 4.3). This action of endofacial inhibitors on 
GLUT1-mediated glucose transport is termed trans-allostery (120), because the 
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stimulating ligands interacts with GLUT1 at the opposite (trans) side of the membrane 
relative to the transported substrate. This trans-allosteric effect is lost as inhibitor 
concentration is raised, resulting in inhibition of sugar uptake (figure 4.3). If GLUT1 
functions as a simple alternating access carrier, as is suggested by published 
interpretations of recent crystal structures of human GLUTs 1 and 3 (16,28-30,119), trans-
allostery should be impossible. Instead, these crystal structures inform us that monomeric 
GLUT1: 1) alternates between outward-facing and the inward-facing conformations; 2) is 
capable of binding multiple exofacial ligands when in the outward-facing conformation, 
but, 3) can bind only a single large ligand when in the inward-facing orientation. This 
present study, however, strengthens the argument that operationally, the glucose 
transporter simultaneously presents exofacial and endofacial sugar binding sites. Given 
the positive cooperativity observed at low inhibitor concentrations, we propose that GLUT1 
functions as an oligomeric complex of alternating access subunits. This hypothesis is 
supported by previous reports that show GLUT1 also exhibits cis-allostery with low 
concentrations of exofacial inhibitors (120,122,124,239) and the report by De Zutter et. al. 
(123) implicating TM9 as the GLUT1 tetramerization interface. 
With an apparent inhibitory constant of ~ 13 nM for inhibiting human erythrocyte glucose 
transport, BAY-876 and NV-5440 are the most potent inhibitors of GLUT1 reported to date. 
We show that the structural analogs of NV-5440 that retain the benzonitrile group inhibit 
GLUT1-mediated sugar transport in human RBCs with similar inhibitory potencies as NV-
5440, whereas NV-5981 in which the benzonitrile group is replaced with a benzaldehyde 
group is more than 200-fold less potent than NV-5440. Likewise, substituting the nitrile 
group in BAY-876 with a tert-butyl group to form BAY-588 reduces its inhibitory potency 
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by at least 40-fold. While BAY-876 and NV-5440 are structurally different, the presence of 
a benzonitrile group confers similar inhibitory potencies on BAY-876 and NV-5440. 
Many benzonitrile-containing drugs have been developed to treat a wide range of disease 
conditions including cancers (e.g. breast (273-275), prostate (276), pancreatic (277), 
myeloid leukemia (278-280), and lung cancer (281)), acne (282,283), heart failure (284), 
hypertension (285), mood disorders (286), arthritis (287) and HIV AIDS (288). The nitrile 
substituents in drugs usually act as hydrogen bond acceptors (e.g. fadrozole hydrochloride 
and letrozole – aromatase enzyme inhibitors used to treat breast cancer (273,274)). There 
are cases, however, where the nitrile group forms no specific interactions with the protein 
target. An example of this is seen with BMS-214662 (a farnesyltransferase inhibitor 
developed for chronic myeloid leukemia), where the nitrile group forms no specific 
interactions with farnesyltransferase, but enhances solubility of the drug by about 10-fold 
more than its bromo analog (280). The nitrile group in BAY-876 shows no specific 
interactions in GLUT1, GLUT3 and GLUT4 (figure 4.8C). Similarly, the nitrile unit in NV-
5440 shows no specific interactions with GLUT3 and GLUT4, but forms hydrogen bonds 
with Gln282 and Trp388 in GLUT1 (figure 4.8D). Regardless of whether the nitrile groups 
in BAY-876 and NV-5440 form specific interactions with GLUT1, or not, our experimental 
data clearly show that nitrile unit confers greater inhibitory potency to the GLUT1 inhibitors. 
Siebeneicher et. al. (167) tested the inhibitory effects of BAY-876 on GLUT1, GLUT2, 
GLUT3 and GLUT4 in a cell-based assay, and reported that BAY-876 is more selective 
towards GLUT1 than GLUT2, GLUT3 and GLUT4 by a selectivity factor of > 100-fold. 
Consistent with this report, our isoform specificity data reveal that BAY-876 is more 
selective towards GLUT1 than GLUT3 and GLUT4, although we only observed a 
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selectivity factor of ≥ 10-fold for GLUT1 (figure 4.8A). To resolve the disparity between the 
selectivity factor observed in this present study and the one previously reported, much 
more data points will be needed at high BAY-876 concentrations, and this will only be 
achievable by automating the sugar uptake experiments used in this study. NV-5440 
shows similar affinities towards GLUT1 and GLUT3 but is 5-fold less selective for GLUT4 
(figure 4.8B). While specificity of these compounds for GLUT1 is important, treatment of 
patients with GLUT1 inhibitors will adversely impact non-diseased tissues, like the brain, 
that depend on GLUT1-mediated glucose uptake for proper function. A better treatment 
regimen, therefore, is to combine GLUT1-mediated glucose transport inhibition, with 
ketogenic diet (which will provide a source of metabolic fuel to healthy tissues while cancer 
cells are starved of glucose (289)). With this treatment strategy, specificity of the inhibitor 
for GLUT1, GLUT3 and GLUT4 becomes less important, instead what is more important 
is the ability of the inhibitors to effectively limit glucose availability to the cancer cells. 
BAY-876, NV-5440 and the nitrile-containing analogs of NV-5440 are very promising novel 
anticancer therapeutics. In vitro and in vivo pharmacokinetic studies on BAY-876 show 
that it has an excellent oral bioavailability and a long terminal half-life (167). Similar 
pharmacokinetic analyses are needed for NV-5440 and its analogs, as well as further tests 
that show how these nitrile-containing inhibitors of GLUT1 impact normal carbohydrate 
homeostasis within a host. This present report provides important mechanistic information 
about how BAY-876, NV-5440 and their analogs inhibit GLUT1 and should serve to 
stimulate more research into finding suitable GLUT1 inhibitors that can eventually be used 
as anticancer therapeutics. 
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Chapter V 
Conclusion and future directions 
Inhibition of GLUT1 and glucose metabolism in cancer is a viable strategy for killing cancer 
cells. There is an increased interest to develop small molecule anticancer drugs that 
specifically target GLUT1, with several groups using different approaches, including high-
throughput and virtual screening to identify compounds that impair the glucose transport 
function of GLUT1. These efforts are beginning to yield dividends with several glycolytic 
enzyme inhibitors at different phases of clinical trials (193,290), and also with the recent 
report of compounds that inhibit GLUT1 at low nanomolar concentrations. 
However, for this strategy to be therapeutically viable in cancer treatment it is important to 
understand the potency and specificity of candidate GLUT1 inhibitors. Once, this is 
established, it becomes feasible to modify any treatment regimen to take into account the 
potential adverse effects of inhibiting GLUT1 on normal brain glucose metabolism, in 
particular, and, more generally, on the overall carbohydrate homeostasis of the patient. 
This study provides a fundamental framework for characterizing candidate GLUT1 
inhibitors for their inhibitory potencies, and sidedness of action on GLUT1 by performing 
specific sugar transport and ligand binding experiments in human erythrocytes. We tested 
21 previously uncharacterized candidate GLUT1 inhibitors for their mechanisms of GLUT1 
inhibition in freshly isolated human red blood cells. We show that WZB117, quercetin, 
EGCG and ECG act as exofacial inhibitors that interact with GLUT1 at, or close to the 
extracellular sugar binding site. BAY-876 and NV-5440 are endofacial GLUT1 inhibitors 
that compete with glucose for binding at the intracellular sugar binding site. Furthermore, 
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STF-31 and the PUG series (PUG-1 – PUG8) failed to inhibit human erythrocyte sugar 
transport (figure 5.1). 
Chan et. al. (166), identified STF-31 by high-throughput screening and reported that STF-
31 inhibited GLUT1–mediated glucose uptake by renal cell carcinomas (RCCs), resulting 
in the selective killing of these cancer cells. We sought to extend this finding by 
investigating the mechanism by which STF-31 inhibits GLUT1. Contrary to the findings of 
Chan et. al. that showed up to 70 % inhibition of human erythrocytes glucose transport 
with 5 µM of STF-31 (166), we found no inhibition of human erythrocyte GLUT1 by STF-
31, either at the reported 5 µM concentration or by a 10-fold higher (50 µM) concentration 
of STF-31 (figure 5.1A). Indeed, recent studies showed that STF-31 is instead an inhibitor 
of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme of the NAD+ salvage 
pathway (291,292). Precisely how STF-31 inhibition of NAMPT decreases GLUT1–
mediated glucose uptake is unknown, but this could be related to cell death initiation by 
STF-31. 
Ung et. al. (185) identified PUG-1 – PUG-8 as GLUT1 inhibitors by virtual screening of 
several chemical libraries of compounds. They followed up their virtual screening by 
testing the effects of these compounds on 2-deoxyglucose uptake in CHO-K1 cells, and 
reported IC50s of 0.45 – 58.6 µM for PUG-1 – PUG-8. Again, we sought to identify the 
mechanisms of GLUT1 inhibition by these compounds but found that they do not inhibit 
GLUT1–mediated sugar uptake in human erythrocytes (figure 5.1B), in GLUT1-
transfected HEK293 cells (figure 5.1C) and in untransfected HEK293 cells (figure 5.1D). 
PUG1 (0.5 µM) and PUG5 (25 µM) stimulate GLUT1-mediated 3MG uptake by human 
erythrocytes by 57% and 98% respectively (figure 5.1 B). This indicates possible cis- or   
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Figure 5.1: STF-31 (A) and PUG-1 – PUG-8 (B–D) do not inhibit GLUT1 
 
Each bar represents the mean ± S.E.M of 3 duplicate measurements, and statistical analysis 
was done by ordinary one-way ANOVA. A, 3MG uptake ± STF-31 in human RBCs. There is no 
significant difference (p > 0.05) between control and STF-31–treated cells. B, 3MG uptake ± 
PUG-1–PUG-8 in human RBCs. PUG-1 (0.5 µM) and PUG-5 (25 µM) significantly increase 3MG 
uptake in human erythrocytes by 57% and 98% respectively (B), (**, p = 0.0051; ***, p < 0.0001). 
The other PUG compounds show no significance difference from control (p ≥ 0.206).  C, 3MG 
uptake ± PUG-1–PUG-8 or WZB117 in HEK293 cells stably expressing GLUT1. WZB117 
significantly inhibit 3MG uptake (**, p = 0.003); PUG-1–8 show no significant difference (p ≥ 
0.685). D, 2DG uptake ± PUG-1–PUG-8 or WZB117 in untransfected HEK293. WZB117 
significantly inhibit 2DG uptake (**, p = 0.011); PUG-1 significantly simulate 2DG uptake by up 
to 70% (*, p = 0.042); PUG-2–8 show no significant difference (p ≥ 0.947) compared to control. 
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trans-allosteric effects by these ligands on GLUT1, and also suggests that the ligands 
interact with GLUT1. However, raising the concentration of PUG1 by 20 fold (10 µM) failed 
to inhibit sugar uptake by human RBCs (figure 5.1B). 
The lack of inhibition of human erythrocyte sugar transport by STF-31 and PUGs 1–8, 
underscores the importance of validating the candidate GLUT1 inhibitors in human 
erythrocytes, as these cells abundantly express GLUT1 as the only glucose transporter. 
Once we established the mechanisms of action of GLUT1 inhibitors in human red blood 
cells, we moved on to test their specificity for class 1 GLUTs (GLUT1, GLUT3 and GLUT4), 
which transport glucose as their primary substrate. This we did in cultured HEK293 cells 
stably expressing these GLUT isoforms. With the exception of WZB117, that inhibits 
GLUT4 more strongly (up to 10-fold more) than GLUT1 in HEK293 cells, we show that the 
inhibitors tested in this study inhibit GLUT1 with greater or equal potency than GLUT3 or 
GLUT4. The fact that these molecules inhibit GLUT1, GLUT3 and GLUT4, indicates that 
their ability to serve as anticancer agents does not derive from their specificity for GLUT1, 
but rather from the extreme sensitivity of cancer cells to limited glucose uptake. 
Consequently, the use of these compounds in cancer therapy may impair glucose uptake 
by astrocytes, neurons and insulin-sensitive tissues (e.g. fat and skeletal muscle cells) 
which depend on GLUT1-, GLUT3- and GLUT4-mediated glucose uptake respectively. A 
way to mitigate against adverse consequences in normal, differentiated cells is to combine 
small molecule inhibition of GLUT1 with application of a ketogenic diet which will serve as 
an alternative source of metabolic fuel for normal tissues with adaptable metabolism while 
cancer cells are starved of glucose (289). 
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BAY-876 and NV-5440 are benzonitrile–containing compounds, and are the most potent 
inhibitors of GLUT1 reported to date. We show that analogs of NV-5440 retaining the 
benzonitrile group inhibited GLUT1 with similar avidity, while analogs of both BAY-876 
and NV-5440 lacking the benzonitrile group are less potent inhibitors of GLUT1, with 
reduced inhibitory potency of 40- to 200-fold. It will be interesting to see if introduction of 
nitrile groups on phenyls of the exofacial inhibitors, WZB117, quercetin, EGCG and ECG, 
will improve their inhibition of GLUT1. 
Furthermore, we report that GLUT1 ligands, regardless of their mechanisms of GLUT1 
inhibition, stimulate glucose uptake at low, subsaturating concentrations, followed by 
inhibition of glucose uptake as inhibitor concentration is raised. We interpret this finding 
as evidence that GLUT1 simultaneously presents multiple ligand binding sites, with the 
possibility of exposing 2 exofacial and 2 endofacial binding sites at any instant (figure 5.2; 
(266)). We reason that at low concentrations, inhibitor binding to a high affinity site 
stimulates glucose transport, but binding of inhibitor to the second lower affinity site, at 
high [inhibitor], leads to inhibition of glucose transport. Glucose uptake stimulation at low 
flavonoid concentrations could also explain the beneficial effects of these compounds 
against diabetes, where increased GLUT1–mediated glucose uptake could lower blood 
sugar concentration. 
This present study, as well as another recent study from our lab reveal that the exofacial 
GLUT1 ligands, maltose (120) and WZB117 (239), can bind to the outward-open 
conformation of GLUT1 in orientations that still expose the catalytic (core) exofacial 
glucose binding site, which may be responsible for cis-allostery observed with these 
ligands (120,239,266). Further studies can explore this finding to identify molecules that   
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Figure 5.2: GLUT1 as a tetramer of alternating access subunits 
 
GLUT1 is considered a dimer of dimers (a tetramer) of alternating access transporters 
in which each dimer must present subunits in opposite conformations (e.g. one subunit 
presents an e2 conformation and the second an e1 conformation or vice versa). If an 
e1 subunit of a dimer undergoes the e1 to e2 conformational change, the adjacent e2 
subunit within the same dimer must undergo the e2 to e1 conformational change. If a 
dimer contains an inhibitor in its e1 subunit (e.L1), that dimer is trapped in an inhibited 
state. If the adjacent dimer does not contain an inhibitory ligand (i.e. its e1 subunit is 
ligand-free), the occupancy state of the neighboring liganded dimer is communicated to 
the uninhibited dimer and transport of sugar via the e2 subunit is accelerated either via 
increased affinity of sugar binding or via increased translocation. 
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preferentially bind at sites (peripheral and intermediate glucose docking sites) that still 
permit glucose binding to the core site, in an attempt to develop small molecules that 
directly bind to GLUT1 to stimulate glucose uptake. This will be useful in treatment of 
diseases including GLUT1 deficiency syndrome, diabetes, and neurological disorders 
(Alzheimer’s and Parkinson’s disease), where glucose uptake into cells is greatly 
diminished. 
We took advantage of the increasing proficiency of in silico ligand docking methodologies 
such as GLIDE (293-295) and homology modeling techniques (241,242) to predict the 
interactions between ligands and GLUT isoforms in this study. This allowed us to predict 
protein–ligand interactions in the absence of crystal structures of the ligand bound to its 
target. However, this method is limited because it treats the protein target as a static 
structure and generates multiple docking poses ranked by their glide scores (GS) which 
are related to but not necessarily predictive of the standard free energy (∆G) for binding 
(293-295). While glide scores are successful in selecting the best or most probable ligand–
protein docking pose, they are less successful in predicting experimental Kd values for 
ligand binding. In this study, we chose the ligand–protein docking poses with the most 
favorable docking scores for ligands for which experimental ligand–protein interactions 
data are unavailable. For glucose–GLUT1 interactions, we chose only docking poses that 
predicted hydrogen bonds that are consistent with previously published biochemical data 
(86,87). We also relied heavily on our sugar transport data to decide how best to interpret 
our ligand docking studies. For instance, GLIDE predicted better glide scores for 
cytochalasin B (CB) docking to GLUT1-e2 (GS = –8.31 to –5.42 kcal/mol) than CB docking 
to GLUT1-e1 (GS = –7.14 to –3.72 kcal/mol). Whereas extensive biochemical and kinetic 
characterization of CB, and even a recent GLUT1–CB crystal structure show that CB 
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interacts only with GLUT1-e1 (29,117,118,186). Therefore, docking analysis must be 
guided by experimental data. Also, in the absence of ligand–GLUT1 crystal structures, 
combination with a method that allows dynamic movement of the protein target (i.e. 
allowing for induced fits by incorporating molecular dynamic stimulations) may better 
predict GLUT residues involved in ligand interaction. 
To ultimately verify the conclusions in this study (oligomeric complexes of allosteric, 
alternating access transporters each presenting multiple exofacial ligand binding sites, 
and antiparallel functional arrangement of exofacial and endofacial substrate binding 
sites), we must visualize structures of GLUT1 with ligands bound. Detergents disrupt the 
oligomeric state of GLUT1 (111,215,296), and detergent–solubilized GLUTs do not bind 
ligands efficiently (215,297). One way to verify functional GLUT1 structures may be to 
isolate GLUT1 from cell membranes by detergent-free techniques, such as by using 
styrene maleic acid copolymers to isolate proteins from membranes surrounded by their 
native lipids (298) producing SMALPs (Styrene Maleic Acid LipoProteins) which retain 
ligand binding function. Cryo-EM can then be used to obtain structures of GLUTs with 
ligands bound. Efforts to achieve this are underway in our laboratory.  
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APPENDIX 
Acute AMPK stimulation of glucose transport in cultured brain capillary 
endothelial cells does not occur via inhibition of GLUT1 endocytosis 
Rationale, Results & Discussion 
Acute metabolic stress dependent activation of AMPK in cultured murine brain capillary 
endothelial cells (bEnd.3 cells) results in a 2- to 3-fold increase in plasma membrane (PM) 
GLUT1 content, and a corresponding increase in glucose uptake (ref: (132); and figure 
A.1). This stimulation of glucose transport does not result from increasing total GLUT1 
mRNA or protein levels (132,151), suggesting that acute AMPK activation controls GLUT1 
trafficking between the intracellular and cell surface membranes in bEnd.3 cells. Here we 
used a reversible cell surface biotinylation technique (figure A.2A – D and A.4A) to test if 
AMPK regulates GLUT1-mediated glucose uptake in blood-brain barrier (BBB) endothelial 
cells by stimulating exocytosis of intracellular GLUT1 to the PM or by inhibiting 
endocytosis of PM GLUT1, or a combination of both. 
Our data (figure A.3) reveal little or no internalization of PM GLUT1 in basal, unstimulated 
bEnd.3 cells. Whereas, we observe up to 30% net internalization of PM TfR in these cells 
(figure A3), suggesting that AMPK does not increase PM GLUT1 levels in bEnd.3 cells by 
inhibiting GLUT1 endocytosis. Assuming changes in cell surface GLUT1 biotinylation 
reveal changes in cell surface [GLUT1] not cell surface GLUT1 lysine accessibility, AMPK 
activation must stimulate GLUT1 exocytosis in order to produce increased PM GLUT1 and 
increased glucose uptake (figure A.4). However, it has been challenging to conclusively 
demonstrate AMPK stimulation of GLUT1 exocytosis using cell surface biotinylation at 
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37ºC where membrane trafficking may be too rapid to capture the time course of GLUT1 
externalization by biotinylation. More definitive experimental proof may require alternative 
approaches such as immunohistochemistry. 
Additionally, we show that while acute treatment of bEnd.3 cells with GLUT1 antagonists 
inhibits glucose uptake (figure A.5A), acute application (0 to 1 hour) of these inhibitors 
does not lead to AMPK activation or increased cell surface GLUT1 levels (figure A.5B – 
C).  
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Figure A.1: BBB endothelial cells increase cell surface GLUT1 levels in response to acute 
metabolic stress of agonist-induced activation of AMPK 
A, Illustration summarizing the observation that AMPK activation either by acute metabolic stress 
or agonist increases cell surface GLUT1 content by 2- to 3-fold. B, A766962 activation of AMPK 
results in up to a 3-fold in cell surface GLUT1 without increasing total GLUT1 protein. C, Blot 
quantitation of B. 
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Figure A.2: Technique of reversible cell surface biotinylation to measure net GLUT1 
internalization 
A, Step-by-step protocol for measuring net PM GLUT1 internalization. The PM is shown as an 
orange circle and GLUT1 as cyan ellipses present both at the PM and inside the cell. (1) AMPK 
activation: cells are treated with or without AMPK agonist (0.1 mM A769662 for 1 hr or 2 mM 
AICAR for 2 hrs at 37 ºC). (2) PM protein biotinylation: cells are transferred to 4 ºC to halt 
membrane trafficking and cell impermeant sulfo-NHS-SS-biotin applied to biotinylate (red dots) 
amino groups of cell surface exposed lysine residues. GLUT1 has at least 4 potentially NHS 
ester accessible lysine residues (ref: (17)), and α–subunit of Na–K ATPase has at least 1 (ref: 
(224)). (3) Unreacted biotin is quenched with excess glycine (100 mM) or Tris (5 mM) at 4 ºC 
and the cells are warmed back to 37 ºC for varying time periods to restore membrane trafficking. 
(4) Cells are transferred back to 4 ºC and treated with the cell impermeable reductant (TCEP; 50 
mM) for 2 x 15 min, to cleave off any biotin label remaining at the PM. (5) Cell are washed 
extensively to remove any residual TCEP, followed by lysis. (6) Clarified lysate [Total protein] is 
determined by BCA and a normalized amount of each sample is loaded onto avidin beads to 
capture biotinylated proteins that were protected from extracellular TCEP by internalization. (7) 
Pulled-down proteins are eluted from avidin beads and quantitated by immunoblotting using 
appropriate antibody. B – D, Optimization of major steps in the reversible cell surface 
biotinylation technique. B, Optimization of the biotinylation step (step 2 in A). Cells were labeled 
with 0.2 – 5 mg/mL sulfo-NHS-SS-biotin for 10 – 120 min at 4 ºC. The extent of PM GLUT1 and 
Na–ATPase biotinylation depends on the concentration of the biotinylating reagent and the 
duration of biotinylation. C, Optimization of the avidin pull-down step (step 6 in A). Ratio of bead 
volume (50 – 200 µL) to the concentration of total protein lysate (50 µg) from cells treated with 
or without 0.5 mg/mL sulfo-NHS-SS-biotin for 30 min, was varied from 1:1 to 4:1, and the extent 
of GLUT1 and Na–K ATPase pull-down was assessed by immunoblot. Figure shows that a ratio 
1:1 ratio of beads to total protein lysate is sufficient to capture PM proteins biotinylated with 0.5 
mg/mL biotin reagent. D, Optimization of TCEP stripping step (step 4 in A). PM proteins were 
biotinylated with 0.5 mg/mL sulfo-NHS-SS-biotin for 30 min (step 2 in A). After quenching 
unreacted biotin, biotinylated PM proteins were cleaved with 50 mM TCEP for 10 – 15 min. 100% 
stripping efficiency was obtained for Na–K ATPase at 10 or 15 min strip, while 91 – 93% stripping 
efficiency was obtained for GLUT1. In subsequent assays, the 50 mM TCEP stripping step was 
performed for 2 x 15 min. 
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Figure.A.3: Net internalization of cell surface GLUT1 and transferrin receptor (TfR) in 
cultured cells (HEK293 cells (A) and bEnd.3 cells (B)) stably expressing GLUT1 
 
The reversible cell surface biotinylation protocol reveals robust net internalization of TfR in 
HEK293 cells (up to 80% internalization after 5 min) followed by a decline in signal to about 20% 
(after 30 min), suggesting re-externalization of internalized biotinylated TfR. In bEnd.3 cells we 
see only about 30% net internalization of TfR after 30 min, suggesting a slower rate of 
internalization in these cells. In both HEK293 and bEnd.3 cells, GLUT1 internalization is 
extremely slow with about 10% and 5% internalized GLUT1 after 30 min in HEK293 and bEnd.3 
cells respectively. 
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Figure.A.4: Measuring GLUT1 externalization by cell surface biotinylation in bEnd.3 cells 
stably expressing GLUT1 
 
A, Modified cell-surface biotinylation protocol for measuring GLUT1 exocytosis. Here, 
biotinylation of PM proteins is performed at 37 ºC. The rationale is that if AMPK activation 
stimulates GLUT1 exocytosis, we should obtain more biotinylated PM GLUT1 in AMPK-activated 
cells versus basal control cells. B, A western blotting readout of the experiment described in A. 
C and D are graphical representation of data presented in B. As shown in B & C, we observed 
about 50% increase in PM membrane GLUT1 in AMPK-activated cells vs unstimulated control 
cells at 2 min, and as the time course progresses this increase is lost. This suggests that the rate 
of GLUT1 externalization is much faster than this technique can resolve. We still observe a 2-
fold increase cell surface [GLUT1] in AMPK-activated cells vs basal control cells when 
biotinylation is performed at 4 ºC (D). 
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Figure A.5: Acute treatment of bEnd.3 cells with GLUT1 inhibitors inhibit glucose uptake 
but is without effect on AMPK or PM GLUT1 content. 
A, 5 min 2-deoxyglucose uptake in untransfected bEnd.3 cells and in bEnd.3 cells stably 
expressing GLUT1 treated with or without 10 µM WZB117 or 10 µM cytochalasin B (CB) for 5 
min. WZB117 and CB inhibit sugar uptake by greater than 75% in both transfected and 
untransfected cells. B, Treatment of bEnd.3-stable GLUT1 cells with 10 µM WZB117 did not 
increase PM GLUT1 but the AMPK agonist, A769662 increased PM GLUT1 by 87%. C, 
A769662, but not GLUT1 inhibitors or 1 hr glucose withdrawal, activated AMPK in bEnd.3– 
GLUT1-transfected stable cells. 
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